3SOF

Had a big run yesterday on the news, then pulled back. Now the gap is filled. Bought 15000 this am.

NEW YORK, Sep 27, 2005 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA, Trade) announced today that it has entered into a $3.2 million, one year contract with the United States Army Medical Research and Material Command (USAMRMC). The agreement, for the rapid identification and treatment of anti-viral diseases, is funded through the United States Air Force (USAF). SIGA's efforts will aid the USAF Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat agents Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention (CDC) Category A biothreat agent, and Adenovirus is a cause of significant respiratory infectious disease, both of which may impair the combat readiness of USAF Personnel.

SIGA's computational approach to the development of countermeasures is designed to interface with USAF programs for the identification of potential agents of bioterrorism, and will provide a key building block in the foundation of a rapid response capability to biological threat agents. War-fighters and special operations forces, in particular, may be called upon to operate in environments containing known or unknown pathogens. Until these pathogens can be accurately identified and neutralized, our war fighters, Special Operations Forces and our nation remain vulnerable to the release of both natural and engineered viral pathogens.

"I am very excited about our relations with the USAF and SIGA's ability to participate in an effort which, I believe, is of crucial importance to our nation," said SIGA's CEO, Dr. Bernard L. Kasten. "I see a clear opportunity to continue working with the USAF in the future and to further advance SIGA's antiviral counter measure programs."

"We welcome the opportunity to work with our USAF colleagues to develop this important biological defense capability", said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA


Edit of the Thread Name, "SIGA,buying on the pullback"
These types of messages with the Ticker Symbol become out of date as time goes passes.
Thank You ,
setravis

SIGA,Gets an extension to 3-21-06. Keep an eye on it. It may have another big run. Lots of recent good news.

On September 1, 2005, SIGA responded to the notice and indicated that as of August 31, 2005, SIGA believed it had regained compliance with the Stockholders' equity requirement and that its stockholders' equity on August 31, 2005 was in excess of $2,500,000. SIGA noted that its stockholders' equity deficiency resulted from SIGA's decision to accelerate the development and related costs of its lead Smallpox anti-viral drug, SIGA-246. The development work is currently being funded through a two years grant from the National Institutes of Health ("NIH"). Approximately $1,000,000 of the $1,700,000 in development work incurred in the first half of 2005 was to be funded during the second year of the grant which began on August 1, 2005. The second year funding was approved by the NIH and SIGA was able to recognize the related revenues subsequent to the filing of the Form 10-Q for the period ended June 30, 2005.

On September 22, 2005, SIGA received an additional notice from NASDAQ, indicating that the Nasdaq Staff believes that SIGA provided a definitive plan evidencing its ability to achieve and sustain compliance with the Rule, and as such, has determined to grant SIGA an extension of time to evidence compliance upon the filing of its periodic report for the quarter ended September 30, 2005. The Nasdaq Staff will continue to monitor SIGA's ongoing compliance with the stockholders' equity requirement and, if at the time of SIGA's next periodic report SIGA does not evidence compliance; it may be subject to delisting.

October 06, 2005 08:00:03 (ET)


NEW YORK, Oct 06, 2005 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA, Trade) today announced that the company's lead smallpox compound, SIGA-246, completely protected golden ground squirrels from lethal doses of monkeypox virus. Monkeypox virus is closely related to human smallpox virus, and causes a similar disease in both monkeys and humans. SIGA-246, administered orally, demonstrated significant antiviral activity against the golden ground squirrel model of monkeypox disease. The study was conducted in the BSL-3 facility at the University of Texas Medical Branch (UTMB). SIGA had announced in October 2004 that it had established the efficacy of SIGA-246 in several mouse models.

"The successful outcome of this study is important," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "It is the first demonstration of SIGA-246 efficacy against monkeypox in a lethal challenge model using a genetically diverse population of wild rodents."

Smallpox virus is considered one of the most significant threats for use as a biowarfare agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. Weaponized smallpox virus may have an incubation period as short as 3-7 days. It is classified as a Category A agent by the Center for Disease Control (CDC). Mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions.

SIGA's CEO Dr. Bernard L. Kasten stated, "The results of this study demonstrate that SIGA-246 is an orally active compound that can prevent the systemic spread of monkeypox virus. The drug performance continues to be very promising as we expedite its development."

I'm in since 28-sep @ 1.0097 on your call, at that time there was really low risk on downside, then that was the reason I liked.... so, (so far) good "pick" and good "Timing" of you ... and thanks.
But,,, now with this last news what dou you think this really mean for SIGA...

 I really like SIGA they have a lot in the works.and the goverment is giving them millions. Theres a fear of bio terrorism. I bought 15000 more yesterday. Once they get notice from the nasdaq that they won't be delisted I think we'll see new highs.

NEW YORK (MarketWatch) -- Siga Technologies shares gained 18.5% to $1.16 on Thursday after the company said SIGA-246, its lead smallpox compound, "completely protected" golden ground squirrels from lethal doses of monkeypox virus in a recent study. The company said the study was conducted in the BSL-3 facility at the University of Texas.


SIGA scientists have developed methods that allow essentially any gene sequence to be expressed in GRAS gram-positive bacteria, with the foreign protein being displayed on the surface of the live recombinant organisms.  Since these organisms are inexpensive to grow and are very stable, this technology affords the possibility of rapidly producing live recombinant vaccines against any unwanted biological agent that might be encountered such as Bacillus anthracis (anthrax) or Smallpox.  Our Chief Scientific Officer, Dennis Hruby, has over 20 years experience working on smallpox-related research and has been leading a SIGA/Oregon State University consortium working on and antiviral drug development project for the past two years.

The market potential for our biological warfare defense products has not yet been quantified beyond the potential to obtain a share of the approximately $9 billion the federal government is committing to support research in the coming year.  The government's purchase of approximately $800 million worth of the existing smallpox vaccine to have an inventory on hand if needed is evidence of market's potential.

Anti-Smallpox Drugs: While deliberate introduction of any pathogenic agent would be devastating, the one that holds the greatest potential for harming the general U.S. population is smallpox.  At present there is no effective approved drug with which to treat or prevent smallpox infection.  To address this serious risk, SIGA scientists have identified two key smallpox proteinases and are using their expertise in the design of proteinase inhibitors to develop an effective antiviral drug that can be used to ensure our future safety.

 ;)
top    SIGA Stats    Symbol Search


Time B/S Shares  Price     

15:34:17.073 B 200  1.2600 

15:34:17.073 B 1,000  1.2600 

15:33:11.620 B 500  1.2500 

15:33:08.517 B 300  1.2500 

15:33:03.669 B 180  1.2500 

15:33:03.669 B 1,020  1.2500 

15:32:57.826 B 1,880  1.2500 

15:32:57.826 B 100  1.2400 

15:28:24.337 B 1,000  1.2400 

15:17:50.660 B 2,243  1.2300 

15:17:50.660 B 200  1.2300 

14:54:20.401 B 300  1.2300 

14:53:04.402 B 100  1.2300 

14:53:04.402 B 600  1.2300 

14:43:24.905 S 500  1.2200 

14:43:24.905 S 500  1.2200 

14:21:52.876 S 100  1.2200 

14:21:52.876 S 500  1.2200 

14:03:40.335 B 1,800  1.2000 

14:03:40.335 B 1,700  1.2000 

Strong close on good volume,look for more upside next week.

SIGA, Having another good day. I believe there is still some upside here, but I will have to take a little profit here, up 35%.

SIGA, Making another run today. There should be no problem with delisting now. I am selling all but 5000 into todays rally.

I won't sell  ... I'm waiting for price above 1.40 ...  1.75 is resistance for me.. the trend is clearly up for 20 sesions now (the general market can't say the same  :-\)....
good luck ..

Bought back in @ .95.

1-05-06  SIGA Reports on Correspondence With Nasdaq


NEW YORK, Jan 05, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA). As previously disclosed, SIGA entered into a Securities Purchase Agreement, dated November 2, 2005, with four investors for the issuance and sale of 2,000,000 shares of SIGA's common stock at $1.00 per share for aggregate consideration of $2,000,000 and certain warrants. The investors were also entitled to purchase additional shares of SIGA's common stock for a gross amount of up to $2,000,000 at an initial price of $1.10 per share for a period of 90 trading days following the effectiveness of a registration statement.

On December 9, 2005, SIGA was verbally notified by The Nasdaq Stock Market that it was in violation of the shareholder approval rules set forth Marketplace Rule 4350(i)(1)(D)(ii) because the share issuance cap found in the Warrant and Additional Investment Right agreements was not in compliance with IM-4350-2, which requires a share issuance cap to apply for the life of the transaction unless shareholder approval is obtained.

Subsequently, on December 13, 2005, SIGA provided The Nasdaq Stock Market with copies of signed amended and restated Warrant and Additional Investment Right agreements, which evidence a share issuance cap which complied with IM-4350-2.

As a result, on December 30, 2005, SIGA received a letter from The Nasdaq Stock Market informing it that The Nasdaq Stock Market had determined, based on the above described actions that SIGA had regained compliance with the Rule and that the matter was now closed.

SIGA, Up 16%. Can't find any news on it. Sold 1/2 @ 1.15.

SIGA : has been trading up for the last three day's and is now testing 1.60 resistance

Breakout today ?? ??? ;D

SIGA Technologies: PharmAthene awarded $213 mln Department of Defense contract for advanced development of Protexia
Briefing.com - September 25, 2006 4:02 PM ET
   

Related Quotes
Symbol   Last Chg
SIGA Trade 1.0599 0.00
Real time quote.
 
PharmAthene announced today that it has been awarded a multi-year contract valued at up to $213 mln from the Department of Defense U.S. Army Space and Missile Command, for advanced development of the co's broad spectrum chemical nerve agent prophylaxis, Protexia. Under the contract, PharmAthene will be responsible for the conduct and oversight of all product development activities. The initial stage of development, for which $34.7 mln has been allocated, includes manufacturing process development, preclinical safety and toxicity testing, submission of an Investigational New Drug Application with the FDA, and initiation of a Phase I clinical trial. This communication is being made in respect of the proposed merger transaction involving SIGA and PharmAthene. In addition, SIGA has filed a preliminary proxy statement with the SEC in connection with the transaction and will mail the definitive proxy statement to SIGA shareholders of record at the record date for the special meeting of the shareholders to be held to provide approvals relating to the proposed transaction.

GREAT NEWS...But such a gap (more 50% gains) + filled black candle -> prudent...Some traders could take benefits..Waiting for if price doesn't filled the gap..A stock to follow for day-trader

news :
PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that it has been awarded a multi-year contract valued at up to $213 million from the Department of Defense (DoD) U.S. Army Space and Missile Command, for advanced development of the Company's broad spectrum chemical nerve agent prophylaxis, Protexia(R).
"We are extremely pleased to have been chosen by the Department of Defense as the recipient of this important biodefense contract," commented David P. Wright, President and Chief Executive Officer of PharmAthene. "The Department of Defense continues to be at the forefront of the development and procurement of novel therapeutic countermeasures to combat chemical and biological warfare and we are very excited to partner with them to carry out advanced development of Protexia."
Under the contract, PharmAthene will be responsible for the conduct and oversight of all product development activities. The initial stage of development, for which $34.7 million has been allocated, includes manufacturing process development, preclinical safety and toxicity testing, submission of an Investigational New Drug (IND) Application with the United States Food and Drug Administration (FDA), and initiation of a Phase I clinical trial. Following the successful completion of the Phase I clinical trial, the government may exercise its option to fund additional development activities beyond the initial $34.7 million, leading to FDA licensure. The contract also provides the Department of Defense with the option to procure an initial 90,000 doses of Protexia.

That's got to be a breakaway gap ;)

I'm thinking you may be right Terliso.  I am back in this one.  50dma should cross the 200dma very soon. ;D   I think it may pop toward the end of the day, if we get some volume.

I just took a position, there's a bullish cross in the weekly chart.... let's see what it does ;)

Terliso,
Looks good on the 3 magics for the weekly chart  and 50sma is about to cross over on the daily as well.
Definately looks like a G-pattern as well, but technically would have been smoother if the big spike was not on a gap up, G does not like when the pull back breaks below the spike candle (but in this case it never filled the gap, breakaway as you say.)  So the G point should be 1.88, if that breaks to the upside with volume we get the G run.  I may join you, will see how the volume looks in the AM.
Cheers
joe

This just popped up on my filter tonight. Long term resistence is near 1.80.

Couple multi-million $$ grants and a hefty DOD contract this month. Nice developments to help break a resistence zone  >:D

Im likely entering along with you terliso tomorrow, and possibly Joe ;). 1.60 would be nice  >:D

-fous

Just bought @ 1.74!

Nice intraday run my fellow traders ;)

lets break the 1.89 G point   ;)  I am in also

limited order not filled at the beginning (1.69),
in @ 1.88

g point has broken  >:D

Took my profits.... SIGA run almost 40% in 2 days, I will catch on the pullback ;)

Good Trading! ;)

News After Hours, SIGA went up to 2.10$ AH on the news of the 16,5 Million but went down to the 1.70's after the news about the cancelled merger came out!
Curious what it will do tomorrow ... :-\



SIGA Terminates Merger Agreement with PharmAthene, Inc.
Wednesday October 4, 5:10 pm ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) disclosed today that it had terminated its Agreement and Plan of Merger with PharmAthene, Inc., pursuant to the terms of that agreement.


In reaching its decision, the SIGA Board of Directors considered many factors, including recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months, which amount includes a grant of $16.5 million from the National Institutes of Health also announced today.

Donald Drapkin, Chairman of the Board of SIGA, commented, "SIGA is excited about its future and committed to the development and successful completion of its lead product candidate, SIGA-246, a smallpox antiviral treatment, as well as its other anti-viral and anti-infective programs."

http://biz.yahoo.com/bw/061004/20061004006001.html?.v=1



SIGA Receives $16.5 Million from the NIH to Advance Development of Its Smallpox Drug Candidate, SIGA-246
Wednesday October 4, 5:05 pm ET
Total Funding Awards Received by SIGA since August 2, 2006 Now Exceeds $27 Million

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced the receipt of a 3 year, $16.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes for Health (NIH), to advance the development of SIGA-246, the company's smallpox drug candidate. The award will support the development of SIGA-246 through the preparation and filing of a New Drug Application with the Food and Drug Administration. The receipt of this award brings the total amount of funding commitments the company has received from various sources since August 2nd to over $27 million.

"We are grateful for the continued commitment of the NIH to the development of SIGA-246," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "The funding we have received from the NIH, as well as their advice and guidance have been critical to the success of our smallpox drug program to date. We look forward to continue working with the NIH as SIGA-246 advances forward."

In July 2006, SIGA announced the successful completion of its first human clinical safety trial. The preliminary results indicated that SIGA-246 is safe and well tolerated in human volunteers at all tested orally administered doses.

SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. It represents a new approach to achieve a novel, orally active, antiviral therapeutic to smallpox. The Centers for Disease Control and Prevention classified smallpox as a Category A agent. It is considered one of the most significant threats for use as a bio-warfare agent due the fact that people in the United States have not been vaccinated against it since 1972. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. At present there is no approved treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions. "We are committed to continue the development of SIGA-246 and hope to provide a solution to this urgent bio-security need," commented Dr. Hruby.

http://biz.yahoo.com/bw/061004/20061004005992.html?.v=1






(http://img241.imageshack.us/img241/7032/sigawt4.jpg)

That's a bad news right there, wonder what the price will do tomorrow...... I got a limit sell order @ 2.10 this morning & I saw the price went to $1.99 for a while but it went down so I  pulled the trigger right away....

Best of luck for those who still holding it ;)

excuse my ignorance   :-\  but I don't see why this would be considered bad news.

I mean it did say that SIGA terminated the merger and not the other way around..........plus the only reason why it did terminate it was because of good clinical results and the recent grants it received.  ARE PEOPLE JUST OVERREACTING TO THIS NEWS???   ??? ???

I hope this is all just an overreaction in after hours.    >:D

Maybe, I'm also not sure if it's bad news...  :-\
Found this on the yahoo forum (yes I know ...  :) )



NOW that the planned MERGER with PharmAthene is OFF, the $25 million in cash that was supposed to be raised by a SIGA stock sale is NO LONGER REQUIRED.

In my view, PharmAthene may have been in cahootz with some hedge funds that have driven the price of SIGA down sharply in order to obtain the maximum number of SIGA shares when it would have tried to raise the $25 million required by the merger plan.

NOW, THESE HEDGE FUNDS WILL HAVE TO COVER THEIR SHORT POSITIONS.

And PharmAthene will have to incur the COSTS AND TROUBLES of an IPO in order to go public, which they were going to achieve through the proposed merger with SIGA.

THIS SUGGESTS THAT IF PHARMATHENE STILL WANTS THE MERGER TO TASKE PLACE, THEY WOULD HAVE TO OFFER MUCH MORE FAVORABLE TERMS TO SIGA SHAREHOLDERS.

In other words, the MERGER IS STILL POSSIBLE (albeit much less likely) BUT THEY WILL HAVE TO DROP THE REQUIREMENT FOR THE $25 million in newly raised cash (at least).

In either case, SIGA will gain as the SHORTS COVER and LEAVE.

Moreover, I do believe that the NIH and DOD would like to see an independent SIGA because of the CONVINCING potential of its ANTI-VIRAL DRUGS and because they want to see a variety of diverse suppliers for their BIOSHIELD contracts -- hence the $16.5 million NIH GRANT to SIGA.

ACTUALLY, SIGA's anti-viral treatments have huge potential in fighting a VARIETY OF ACUTE VIRAL INFECTIONS (e.g., SARS, Ebola, bird-flu, etc.). And they may even be effective against chronic viral infections (e.g., HBV, HCV, etc.).

OBVIOUSLY, when SIGA obtains the expected order CONTRACT from the Federal government for SIGA's anti-smallpox treatment, IT WILL BE SEVERAL TIMES LARGER THAT SIGA's CURRENT MARKET CAP, which is only $49 million.

It will all be history soon!!

I agree...I don't think it's bad news.  To me it sound like good news. :)

I tend not to worry about after hours unless, it's obviously bad news such as earnings miss or drug trial failure.

We shall see.  SIGA could be volitile tomorrow.

SIGA is down 15% on the news....

 

Quote from: Terliso on October 05, 2006, 11:37:20 AM
SIGA is down 15% on the news....

That's why I gave up long ago trying to figure out how the market would react to news. :P

Anyway...as long as it doesn't enter the gap below 1.40...I think it's O.K.

Doubled my position at 1.48.  Also take a look at those three magic lines.

If main shareholders rejected the deal it's because they see something better

Strongly believe the news created a great confusion which will settle down
shortly

GLTA 

Quote from: Terliso on October 04, 2006, 01:55:11 PM
Took my profits.... SIGA run almost 40% in 2 days, I will catch on the pullback ;)

Good Trading! ;)

You are right jorgegr that should be the price to get back in again ;)

support @ 1.40 $ has hold  ;D

up 10 %  ;D

Sold half my position at 1.71 (bought yesterday) and holding again my previous
investment

FOUS made a BIG mistake on selling it for a LOSS !! :D ;D Thats he gets !

ALSO, THE GOLDEN CROSS HAPPENED TODAY !!!1 ;D :D :) >:D

Glad I didn't sell, something must be up, maybe a revised offer from PharmAthene?  ???

Quote from: REALDEALS21 on October 06, 2006, 02:36:19 PM
FOUS made a BIG mistake on selling it for a LOSS !! :D ;D Thats he gets !

ALSO, THE GOLDEN CROSS HAPPENED TODAY !!!1 ;D :D :) >:D

I made no mistake, i simply made a decision not to expose my money to the risk involved in this trade.

Nice rebound though ;)

-fous

Quote from: fous on October 06, 2006, 03:18:38 PM

Quote from: REALDEALS21 on October 06, 2006, 02:36:19 PM
FOUS made a BIG mistake on selling it for a LOSS !! :D ;D Thats he gets !

ALSO, THE GOLDEN CROSS HAPPENED TODAY !!!1 ;D :D :) >:D

I made no mistake, i simply made a decision not to expose my money to the risk involved in this trade.

Nice rebound though ;)

well said fous,
applause
maxi

-fous

Quote from: rickjust on October 06, 2006, 03:26:12 PM

I made no mistake, i simply made a decision not to expose my money to the risk involved in this trade.


well said fous,
applause
maxi

Yes, well said, fous.  Applause.

Even though I made a different decision than FOUS on this trade
i think his reason is correct. He is responsible not only for his own money
but also of all those following his guidelines, and therefore his main
concern is and should be to preserve his portfolio as far as possible from
losses.

Looking at his portfolio's performance is enough to qualify his expertise.

OK boys and girls,  let´s take a break and  have a nice weekend. 

Quote from: jorgegr on October 06, 2006, 04:16:43 PM
Even though I made a different decision than FOUS on this trade
i think his reason is correct. He is responsible not only for his own money
but also of all those following his guidelines, and therefore his main
concern is and should be to preserve his portfolio as far as possible from
losses.

Looking at his portfolio's performance is enough to qualify his expertise.

OK boys and girls,  let´s take a break and  have a nice weekend. 

I second that, well said!


Curious what SIGA has left for us next week! :)

Thanks for your comments guys its greatly appreciated.

As jorg said, lets take a break. Time to enjoy the weekend away from the work week  ;)

-fous

Hey guys- been watching this one too ;)

I think you may soon have a tiger by the tail here!!

Tough call- enter with a close above $1.80 or try and enter on a pullback.

This stock has multi bag possibilities- insider buying with news would set SIGA off.

Watching for entry

GOLDEN CROSS HAPPENED TODAY ! TOMORROW WILL BE THE FOLLOW THRU !!!  :D ;D :)

SIGA is in consolidation mode IMO  ;)

11-Oct-2006

Other Events


Item 8.01. Other Events.

On October 10, 2006, SIGA was notified by NASDAQ that its previously disclosed market value of listed securities deficiency had been cured.   ;D

Getting ready for a pop soon ... ?



(http://img276.imageshack.us/img276/5295/siga1ky6.jpg)

I´m ready for the pop  ;)  >:D

have a nice weekend
Oliver

Up a dime today !  :D

Hopefully volume can pick up so we break thru 1.95-2  resistance.

BREAKOUT OF $2 ! :) ;) :D ;D

Quote from: la-onda on October 13, 2006, 05:53:13 PM
I´m ready for the pop  ;)  >:D

have a nice weekend
Oliver

There it is!  :)

Good day for SIGA ...  :)




(http://img483.imageshack.us/img483/925/sigawh8.jpg)

this stock is flipping out this am.

just watching the time and sales on it.

not in..just observing

glta

Wow...up 190% pre-market.   :o 

Yessss!  ;D  >:D

Question is what to do now, hold or ...




SIGA Technologies Drug Blocks Smallpox
Wednesday October 18, 8:49 am ET
SIGA Tech Shares Soar As Lead Drug Candidate Succeeds in Preventing Smallpox in Primate Study

NEW YORK (AP) -- Biotechnology company SIGA Technologies Inc. said Wednesday its lead drug was successful in giving complete protection against smallpox in a Centers for Disease Control and Prevention study on monkeys.

ADVERTISEMENT

The drug candidate, called SIGA-246, prevented symptoms when delivered at the same time as the virus and 24 hours after delivery of the virus. It prevented lesion formation and reduced the virus to non-threatening levels without any obvious toxicity.

The Food and Drug Administration granted the drug "fast-track" status in December. The most recent study was funded by the Department of Health and Human Services, the CDC and the Department of Defense.

There has not been a natural occurrence of smallpox since 1977. There is currently no approved treatment for the disease. Since the Department of Homeland Security has categorized the disease as a material treatment, the drug candidate would be eligible for addition to the national stockpile.

"This drug holds great promise as a therapy for poxvirus infections," said SIGA Chairman Donald Drapkin, in a statement.

He said the amount of virus used in the study was equivalent to the level present in late stages of the disease in humans, which demonstrates the drug could be used to prevent the disease possibly up to several days after initial exposure.

The news caused shares to rise $4.05 to $6.02 on the INET electronic exchange, indicating the stock may open at more than triple Tuesday's closing price of $1.97. Over the past year, Siga shares have traded on the Nasdaq between 86 cents and $2.33.


http://biz.yahoo.com/ap/061018/siga_smallpox.html?.v=1

 ;D ;D ;D  Sold 1/2 expect the daytraders to be on this one today.

SIGA Technologies says SIGA-246 is first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial
Briefing.com - October 18, 2006 7:31 AM ET
 

Related Quotes
Symbol   Last Chg
SIGA Trade 1.97 0.00
Real time quote.
 
Co announces that its lead drug, SIGA-246, is the first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial conducted at the federal Centers for Disease Control and Prevention. In this study, once-daily, oral administration of SIGA-246 protected cynomolgus monkeys from smallpox disease following intravenous high dosing with smallpox virus. The drug prevented symptoms of disease whether delivered at the same time as the virus or 24 hours later, supporting the drug's use for both post-exposure prophylaxis and treatment. SIGA-246 completely prevented lesion formation and reduced viral load to non-threatening levels in treated animals with no obvious toxicity.

How is that for volume!!!  :o :o

Quote from: bocasva on October 16, 2006, 12:59:56 PM
Hopefully volume can pick up so we break thru 1.95-2  resistance.

Quote from: bocasva on October 18, 2006, 09:17:56 AM
How is that for volume!!!  :o :o

Quote from: bocasva on October 16, 2006, 12:59:56 PM
Hopefully volume can pick up so we break thru 1.95-2  resistance.

almost 6 million in pre-market, "not bad" ... :D

Darn...I almost bought more after it broke that resistance yesterday.... ::)

I'd be a very rich man if I actually did all those things in the stock market that I wish I had. :D

bought 6900 shares at 1.74 on Oct 4th, glad I didn't sold it ...  ;D

sold 1/2 at 5.20, I can't be a pig.....I'll let the other 1/2 ride freely >:D

I sold at 5.12 cheers to all bagholders

I sold 1/2 too.

As for the other half.  If SIGA can get something better than a black candle, this one can go up from here; otherwise, 38% fib retracement at 3.92ish.

Whoops...Chart ::)

Just sold all at 5$ for a 187% profit! ;D :D >:D

I'm out, will keep it on the radar. Applauds to all that traded SIGA.
I'm buying CYTR, presentation tomorrow @ 3:40 et.

SIGA CEO coming up on CNBC

Quote from: Se7en on October 17, 2006, 03:20:09 PM

Quote from: la-onda on October 13, 2006, 05:53:13 PM
I´m ready for the pop  ;)  >:D

have a nice weekend
Oliver

There it is!  :)

Ohhhh man I just woke up just now & made 160% in a day...  thank you SE7EN ;)

I saw you posted the "There it is" yesterday & decided to buy back again 2 minutes before the closing that day & I got in @ 1.99. applause Se7en :D ;D ;)

Quote from: Terliso on October 18, 2006, 11:38:06 AM

Quote from: Se7en on October 17, 2006, 03:20:09 PM

Quote from: la-onda on October 13, 2006, 05:53:13 PM
I´m ready for the pop  ;)  >:D

have a nice weekend
Oliver

There it is!  :)

Ohhhh man I just woke up just now & made 160% in a day...  thank you SE7EN ;)

I saw you posted the "There it is" yesterday & decided to buy back again 2 minutes before the closing that day & I got in @ 1.99. applause Se7en :D ;D ;)

hehe, nice to hear that my little message was good for something!!  ;D


Applaud to all of you guys! :)

first birthday of my daughter Johanna & 165% SIGA profit  >:D
Awesome

applaud to everybody  >:D
cheers
Oliver

I guess most of us here that SIGA is now our biggest gainer so far this year ;) :D

For me its CSHD and SIGA, both over 250%

I think SIGA will try 5.75 todya or tomorrow.  ;D

Look at this Before & After chart it dwarfed the previous prices....

what would be a good reentry price ?
any suggestions?

cheers
O.

Quote from: la-onda on October 18, 2006, 02:18:25 PM
what would be a good reentry price ?
any suggestions?

cheers
O.

Well SIGA ended up with a black candle. :P

Well see if SIGA stays in the gap above 4.35??

If not the 38% fib retracement is around 3.92ish.

fyi
SIGA Announces $9.0 Million Private Placement
Thursday October 19, 8:53 am ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today that on October 18, 2006 it entered into a Securities Purchase Agreement for the issuance and sale to institutional investors of 2,000,000 shares of the company's common stock at $4.54 per share and warrants to purchase 1,000,000 shares of the company's common stock. The warrants are exercisable at any time and from time to time through and including the seventh anniversary of the closing date at an exercise price equal to 110% of the closing price of the company's common stock on October 18, 2006.

4.54$ should act as a support, in again @ 4.5$  >:D

down 8% on heavy volume.... ???
any suggestions?


cheers
O.

Quote from: la-onda on October 19, 2006, 10:51:15 AM
down 8% on heavy volume.... ???
any suggestions?


cheers
O.

wait
maxi

Would appreciate some comments about the fact that this company will issue and sell
2.000.000 shares @ 4,54 and warrants to purchase 1.000.000 shares, therefore
is  that PPS a resistance and investors would wish to buy lower or what's the
experience in these cases ???

TIA

jorgegr 

SIGA needs to find support, I still have my remaining 1/2 in.  How about a buyout from a bigger player?

I still have 1/2 too.  Should have sold the rest when I knew CEO was going to be on CNBC.. :-\

Anyway...after such a huge run-up...a stock like this can go either way.  This one dropped..not unexpectedly after a black candle like yesterday.  The 38% fib retrace is at 3.92sih...which it got close today and the 50% is around 3.45.

By no means do I believe this stock will close this gap any time soon...but it may trade sideways for a time.  Speculation will drive this until news comes out.

just FYI some SIGA facts:
Quotation (I am agreeing with all the information I am posting here  ;) ):

SIGA Technologies has demonstrated 100% protection against human smallpox virus in a primate trial. That is the news that sent this stock much higher & on volume. What everyone is failing to see with an open objective mind is that this platform is going to work on other bacterial strains. The platform has been proven. SIGA's platform developes drugs that prevent symtoms of disease wether it is done at the same time as the virus or 24 hours after. SIGA pipe line will be good for many post-exposer treatments

May 2005 analyst presentation (please read carefully!):
http://www.investologyinc.com/reports/paid/SIGA%20052305.pdf


Knobias report (very detailed basic information):
http://www.knobias.com/institution/customers/companies/reports/pdf/1954257282/1954257282-UNIFIED.pdf

Quotaton part 2:
Here is some DD I performed for my own use which some of you may find usefull. Read the most recent press releases first then take a look at the following information.

1. Smallpox is classified by CDC as a Category A agent (most dangerous). "Category A agents are believed to pose the greatest potential threat for adverse public health impact and have a moderate to high potential for large-scale dissemination."

2. Vaccine available but no treatment exists. "Smallpox can be prevented through use of the smallpox vaccine. There is no proven treatment for smallpox, but research to evaluate new antiviral agents is ongoing."

3. Competition. Cidofovir (used to fight HIV) and VIG may have some benefit. "Early results from laboratory studies suggest that the drug cidofovir may fight against the smallpox virus;"

But has significant side effects and efficacy is unclear.

"Complications include renal toxicity, neutropenia, fever, anemia, headache, hair loss, uveitis and/or iritis, and abdominal pain; monitor neutrophil counts; IV prehydration with NS and coadministration of probenecid can minimize nephrotoxicity; monitor serum creatinine and urine protein 48 h prior to treatment (adjust dose accordingly)"

Also: "There are two medications that may help persons who have certain serious reactions to the smallpox vaccine; vaccinia immune globulin (VIG) and cidofovir. VIG has been extensively used in the past and felt (but not shown in controlled studies) to be effective. Cidofovir may be effective based on studies in animals. Treatment with these medications may require the vaccine recipient to be in the hospital. They are investigational and may cause a number of serious side effects themselves."

4. Since August 2, 2006 SIGA has recieved over 27 Million in funding to advance its platform including 16.5 Million from NIH to "support the development of SIGA-246 through the preparation and filing of a New Drug Application with the Food and Drug Administration" for Smallpox.

for all links please check:
http://messages.finance.yahoo.com/Healthcare/Biotechnology_and_Drugs/threadview?m=tm&bn=26191&tid=7866&mid=7866&tof=8&frt=2

Quotation part 3:
5. On 14 March, 2006 SIGA announced a non-binding merger with PharmAthene which would give SIGA a 32% stake in the combined company:

On 25 September, 2006 PharmAthene announced that it had recieved a $213 Million multi-year contract for its nerve agent drug Protexia. Post-merger, SIGAs share of this revenue would have been $68.16 Million (213 x 32%.
After the $213 Million announcement on 25 September, SIGA's share price rose 88% to $1.99.

Despite the favorable impact the Protexia announcement had on SIGA share price 9 days earlier, on OCT 4, 2006 SIGA cancelled the merger with PharmAthene due to "recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months, which amount includes a grant of $16.5 million from the National Institutes of Health..."

6. In December 2005, the FDA granted SIGA-246 Fast Track Status.

About Fast Track:
"Under the FDA Modernization Act of 1997, designation as a Fast Track Product means that the FDA will facilitate the development and expedite the review of a drug if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs for such a condition.
This fast track designation gives...the opportunity to submit a Biologics License Application (BLA) in sequential sections, and have these sections reviewed as they are submitted, thus saving development time. A BLA is the biologic products equivalent to a New Drug Application and is the final stage before a drug is approved for the market by the FDA. Fast track status also opens the possibility for receiving a priority review of the BLA where the review time would be halved to just 6 months."

please check the link for sources:
http://messages.finance.yahoo.com/Healthcare/Biotechnology_and_Drugs/threadview?m=tm&bn=26191&tid=7868&mid=7868&tof=6&frt=2

7)
Siga-246 will be purchased by the USA goverment.
The New York-based company said the Department of Homeland Security has designated smallpox a "material threat" to national security, so Siga-246 "will be eligible for purchase for the Strategic National Stockpile under Project Bioshield."
http://www.thestreet.com/_yahoo/newsanalysis/biotech/10315799.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA


I will hold my shares (Average price now @ 4.3$) analyst coverage and/or upgrade will come soon, lots of good news will be communicated in the near term future IMO

any other suggestions?

cheers
Oliver

Thank you for your detailed info la onda, you changed my mind. Altho will speculate on buying a little lower. (applaud)

jorgegr

Well i missed the double bagger lol. Lets see if i cant make at least 20% on this sucker this time. Im in at 4.10. I see the potential for a similar chart to ACOR for SIGA. Who  knows we might still have another bag to make ;)

-fous

I'm also back in @ 4.13$.

Quote from: fous on October 20, 2006, 12:05:12 PM
Well i missed the double bagger lol. Lets see if i cant make at least 20% on this sucker this time. Im in at 4.10. I see the potential for a similar chart to ACOR for SIGA. Who knows we might still have another bag to make ;)

-fous

Quote from: Se7en on October 20, 2006, 01:02:55 PM
I'm also back in @ 4.13$.

Seeing you guys back in, makes me more confident about holding on to this tiger.
GLTA

Was able to get in again at 4.04. Seems bulls are fighting for control now

I don't think its time to get in yet, the 9sma is being left behind because of the gap up it needs to catch up first before deciding to get in.....the 9sma must catch up not the price so it's better to wait for now ;) :D ;D

it will be interesting if SIGA will act as ACOR  ;D

have a nice weekend
cheers
Oliver

 ;)

good one boatguy  ;D

Seems Terliso was right we bought too soon.

jorgegr

I'm back in 15,000 @ 3.57.

Quote from: stocks2watch2 on October 23, 2006, 01:49:02 PM
I'm back in 15,000 @ 3.57.

congrats stocks2watch2,
better entry price as mine (4.17$ average)

cheers
Oliver

why I am so confident, that I will have huge profit with SIGA shares again part 1

why I am so confident, that I will have huge profit with SIGA shares again part 2

why I am so confident, that I will have huge profit with SIGA shares again part 3

>:D >:D >:D

cheers
Oliver

please check also the video:
http://www.kval.com/news/4448787.html?video=YHI&t=a

Smallpox Breakthrough

Story Published: Oct 20, 2006 at 6:12 PM PST
By Cathryn Stephens
Watch the Video
It's potentially a major breakthrough in bioterrorism defense. A Corvallis biotech lab has developed the first drug ever to show 100% percent protection against the smallpox virus.
It's a disease that was eradicated decades ago, but smallpox is considered one of the top biowarfare threats today. This new drug could wipe out that threat.
SIGA-246 promises to safeguard the population from a smallpox bio-warfare attack, according to company officials in Corvallis.

"We think it's huge," said Dennis Hruby, the chief scientific officer with SIGA Technologies. "It was a horrible dread disease, and having a drug on the shelf that will prevent this from ever happening again I think is a gigantic insurance policy that we're all going to be very happy about." Hruby says the drug proved 100% effective in a Centers for Disease Control and Prevention test, protecting monkeys from the smallpox virus with no side effects.
"For this kind of drug you want a really safe drug because you're talking about a drug to prevent a disease that doesn't exist and so safety has to be very high on the list," said Hruby.
Inside the SIGA lab in Corvallis there are 50 researchers, including 16 PhD's. Along with the smallpox project, they're also researching drugs to treat Ebola and Dengue Fever.
"I get pressure all the time, move the company back east, move to San Francisco. This has just been an outstanding place to work, next to Oregon State, it's easy to recruit good people, it's a really good environment," said Hruby.
Hruby believes SIGA's smallpox drug will be just as effective on humans, both as preventative and as treatment, should it be needed. The main buyer of the drug would be the federal government. "In a real world scenario what's going to happen is if you have a population you're not going to know who's been exposed, who hasn't and for how long, so what you'd like to do is treat simultaneously with drug and vaccine and protect everybody," said Hruby.

Testing on SIGA-246 is continuing, but the U.S. government will likely be able to stockpile it before it receives final FDA approval under the Department of Homeland Security's Project Bioshield.
SIGA hopes to submit its new drug application for approval by the the Food and Drug Administration in early 2009.

http://www.kval.com/news/4448787.html


>:D

cheers
O.

last but not least:
Healthy development
CASEY CAMPBELL/Gazette-Times
At Siga Technologies' Corvallis research labs, Eric Stavale works on a possible treatment for the Dengue virus. Siga got a big cash infusion last week after announcing progress on an experimental smallpox treatment.
Siga Technologies finds quick payoff from test of smallpox remedy

By BENNETT HALL
Gazette-Times business editor

It's been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.
Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.
"In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product," said Dennis Hruby, Siga's chief scientific officer and a microbiology professor at Oregon State University.
Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.
Siga claims its drug, a once-daily pill called Siga-246, showed "100 percent protection" against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.
Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant.
The news of a successful test triggered a financial windfall for Siga, which employs 50 people at its Corvallis research labs.
On Wednesday, the day the test results were announced, the company's stock price more than doubled, shooting up to $4.54 a share after languishing at around $1 for most of the last year.
On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

"It gave us the opportunity to bring in some cash quickly at a nice price," said chief financial officer and acting CEO Tom Konatich, who's been with the biotech firm for eight years. "Our balance sheet right now is about as strong as it's been during my tenure."
The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.

Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.
"Siga's a significantly different company today than it was in February and March," Konatich said by phone from the company's New York headquarters Friday. "We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug."

Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.

"It's in the hundreds of millions of dollars, if not more," he said.

Other potential markets await overseas, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization's advisory council, which he hopes will help spread the word about Siga's research.

Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is also pursuing drug candidates for a range of other exotic viruses.

"There's two things: There's biodefense, and there's emerging diseases," Hruby said. "Hopefully, we'll never need it for biodefense. But it's nice to have a drug like this on the shelf."

http://www.gazettetimes.com/articles/2006/10/23/news/business/1mon01siga.txt

Great info la-onda! <applaud>

It was a good day for SIGA, hopefully the bleeding has stopped now ... :)




(http://img196.imageshack.us/img196/4137/sigahb9.jpg)

You guys ready to pick-up SIGA?  :D ;D hehe

Look at that histogram, bringing this up again ---> most of the time every uptick or downtick on WEEKLY histogram indicates a change of a trend (MACD Lines above zero, weekly chart) ;)
http://www.3stocksonfire.org/trading/index.php?topic=5852.0

Trade it good!! :D

sure looking a lot better ;)

im in at 3.67 :)

SIGA breaking down- easy here! :-\

SIGA is now sitting @ 9sma & there is no bounce happening yet... hmmmmm, I suspect SIGA might go lower below 9sma. $2.90 should be a good entry point (half of the big white candle) ;)

----Daily chart might be looking bearish but weekly chart is still bullish ;)

yeah, i guess my 3.65 was too high :(

Quote from: for3J1M on October 26, 2006, 02:10:30 PM
yeah, i guess my 3.65 was too high :(

Well, there is still the chance that the 13ema will act as support if this stock is truly to act like ACOR did recently.  That stock came close but never quite touched the 13ema.  For SIGA the 13 ema is at 3.23.  If it goes below that and gets to 2.90 as Terliso pointed out, its probalby a screaming buy ;)

Quote from: for3J1M on October 26, 2006, 02:10:30 PM
yeah, i guess my 3.65 was too high :(

my 375 doesn't look so prudent now.  :-\
holding for now.
maxi

Bounced off the 3.23 support, I bought 15,000 more. I think we at least go back to 4.54 soon.

Quote from: tokyopua on October 26, 2006, 02:32:01 PM

Quote from: for3J1M on October 26, 2006, 02:10:30 PM
yeah, i guess my 3.65 was too high :(

Well, there is still the chance that the 13ema will act as support if this stock is truly to act like ACOR did recently.  That stock came close but never quite touched the 13ema.  For SIGA the 13 ema is at 3.23.  If it goes below that and gets to 2.90 as Terliso pointed out, its probalby a screaming buy ;)

Nice strong bounce this morning from 13ema, setting up for a Piercing Pattern candlestick pattern.  The only negative in comparison to the ACOR chart is that the 13 ema actually did get pierced.  On the positive side, the last few times SIGA tried to rally it never rose above the high of the previous day.  It has already done that today, which I view as a bullish move that points to potental rounding and eventual higher prices.

Applauds on that gutsy move Stocks2watch2, thats a nice chunk of change to lay down!

Quote from: tokyopua on October 26, 2006, 02:32:01 PM

Quote from: for3J1M on October 26, 2006, 02:10:30 PM
yeah, i guess my 3.65 was too high :(

Well, there is still the chance that the 13ema will act as support if this stock is truly to act like ACOR did recently.  That stock came close but never quite touched the 13ema.  For SIGA the 13 ema is at 3.23.  If it goes below that and gets to 2.90 as Terliso pointed out, its probalby a screaming buy ;)

Applause, you've got it right. We just need a strong close and we are on back to higher prices next week.

Quote from: stocks2watch2 on October 23, 2006, 01:49:02 PM
I'm back in 15,000 @ 3.57.

Quote from: stocks2watch2 on October 27, 2006, 09:46:37 AM
Bounced off the 3.23 support, I bought 15,000 more. I think we at least go back to 4.54 soon.

Stock2watch2, I hope you are not risking your $100,000 in just one stock.

hi do you guysthink this is  a good entry price  i missed the first run and want to buy. i think it will have a nother big up day and i dont want to miss it again.i hope its dropping because its lunch time.  thanks

-- I still don't think jumping in SIGA is now
-- SIGA is now trading @ 50% fibonacci retracement it may hold it may not
-- 61.8% Fibonacci retracement is down @ $2.73 closing below that level the stock will turn bearish I don't think that will happen too.
-- Half of the candle from last week (weekly chart) @ 2.90 is the best entry point.

Goodluck!! ;)

thanks terliso.  i picked up a little at 3.43 i'm buying more just don't no when.also  i don't think it would of dropped back if the nasdaq didn't drop. jmo

Terliso;
Do you think it's going to hold and stay around here for a while??

fyi
Yahoo quotation:
SIGA points of review:

1)SIGA-stock surge on 18 October 06 with massive (39,349,000) volume that included institutional investors buying.
SIGA followed with 6 pull back\consolidation days. The time frame of margin selling has past. Friday Oct. 27 the stock market closed all indexes down, the NASDAQ -28.48 roughly. SIGA closed up The same day signaling buying consideration for the coming week.

2)The spark that ingnited SIGA --->SIGA Announces Smallpox Treatment Breakthrough. Video of the breaking news comes out in the news: http://www.kval.com/news/4448787.html
f you have not watched this video you should (check my last posts) Under "Bio Shield" the government may be able to stockpile SIGA-246 without the FDA. The FDA green light for human use may be in 2009.

3)Why the news is important: The money involved--->CEO of SIGA "various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one. It's in the hundreds of millions of dollars, if not more," he said."
According to the Congressional Budget Office, the 5.6 billion under "BIO Shield" will be to acquire drugs against the 5 pathogens,
& in the ammountts, specified below:
Smallpox----->$1.9 billion
Anthrax------>$1.4 billion
Btulinum toxin------>$1.8 billion
Ebola------>$260 million
Plague----->$220 million
SIGA is not just working for a piece of the pie on Smallpox but, is advancing an Ebola effort.
Friday 27 Oct.o6 Advent Financial Update report Gave SIGA a 12 month price target of $10.20 & raised it to "buy" from "neutral" (check my 2nd yahoo quotation)

4)The proposed merger with PharmAthene has been cancelled: SIGA has recently obtained since 2 Aug. 06 $27 million. $16.5 million
grant money from NIH. Siga Pulls Out of PharmAthene Merger based on this feeling SIGA will do better on its own.

5)Next q. earnings: 8-10 November 06 range based on past report release dates. Will SIGA have a good quarter?
CEO: Tom Konatich, who's been with the biotech firm for eight years. "Our balance sheet right now is about as strong as it's been during my tenure."

The answer seems clear SIGA is on the correct path.

If SIGA stock musters enough buying interest to break through $3.80 in the next few days it could set the stage for a very nice rally, back above $5.00
If there is additional news watch out for the break to Advent Financials target of $10.20.


Advent Financial Update:

The fundamental factors that we factor into our analysis and valuation have considerably strengthened for SIGA in recent weeks as a number of important developments took place:

- The proposed merger with PharmAthene has been cancelled thus removing the related uncertainties and unknowns that complicated or prevented a complete analysis of SIGA.

- SIGA-246 fully protected monkeys from a variant of the smallpox virus that it prevented from
becoming infective by blocking the action of a viral enzyme that is necessary for the assembly of an envelope protein (p37) without which the virus is unable to get out of the host (invaded) cells. As a result, the virus becomes trapped inside the cell and is unable to spread to other cells; the virus is no longer infective! This specific viral enzyme is also present in the smallpox virus against which SIGA-246 should also protect. Moreover, the studies in monkeys confirmed the results of earlier studies in rodents in which SIGA-246 fully protected rodents against all varieties of the poxvirus that were tested. SIGA-246 has thus successfully completed both of the efficacy tests required under the "twoanimal rule."

- SIGA-246 appeared safe and to be well tolerated in a Phase I trial on healthy volunteers that was completed in June 2006.

- The Company is now preparing to submit the Phase I trial results to the FDA as part of seeking authorization to proceed with the Phase III trials that are necessary for obtaining the data for statistical proof of efficacy and safety that is required by the FDA.

- The Company has recently obtained close to $21 million in additional funding for completing the development of SIGA-246 and submitting an NDA for it to the FDA.

Factoring the above developments into our valuation model for SIGA and using conservative
assumptions, we now estimate at 80% (up from our previous 35% - see our December 9, 2005 update) the probability that it will be approved in early 2008 and will generate revenues of $400 million and fully diluted EPS of $1.30 in FY09.

Assuming this stock will have a P/E of 10 by the end of FY09, its price will then be $13.00 (fully diluted). To calculate a 12-month Price Target for SIGA, we discount back by two years its future value of $13.00 in FY09 using an annual discount factor of 0.129 that combines the current 3-year, risk-free 4.80 % Treasury yield (source: Bloomberg.com - October 20, 2006) and a 100% - 80% or 20% risk factor. The resulting 12-month Price Target is $10.20. Discounting back by three years, we calculate a risk-adjusted Present Value of $ 9.04 for this stock, up from our previous $4.50 (see Dec 9, 2005 update) for this stock that has traded in the $2.00 to $5.50 range in recent days.

Conclusion
We believe that SIGA may begin selling its first product, the smallpox antiviral SIGA-246 and
achieve EPS of $1.30 on revenues of $406 million in FY09. We raise our rating on SIGA to Buy from Neutral and our 12-month Price Target to $10.20 from our previous No Price Target.

https://secure.reuters.com/ecommerce/Catalog/ReportDetail.aspx?id=38164454&search=

have a nice weekend
Oliver

Please read the 22 slides Advent Financial Report:
http://adventfinancialinc.com/research_reports/SIGA%20Update%2010.pdf

cheers
O.

Thx for the excellent information la-onda! <applaud>

nice day for SIGA  ;D

la-onda thanks for the great post on the 27th. lets hope for a nice run into earnings.

Do you all think this has  bottomed?  I still haven't  boght more. I'm not good at  finding the highs  and lows. I would like to buy more. I thought it was going to take off after yesterdays  run.

Quote from: for3J1M on October 31, 2006, 11:28:11 AM
la-onda thanks for the great post on the 27th. lets hope for a nice run into earnings.

Do you no when they release earnings?

I couldn´t find the exact earning date, SIGA was consolidating today IMO

SIGA was consolidationg today IMO

I just hope we stay in the 3.50 3.60 range and dont drop any lower. Earnings probaly wont make much difference anyhow. What we need is more news on any progress or grants. I bet we would double or more on a good pr.

I agree earnings may not make much difference.  Earnings expectations are not what got SIGA here.  I think SIGA can double without another announcement.  Alot of stocks with a huge piece of news jump up huge then consolidate for 1 to 3 weeks before resuming the climb.  Of course nothing is guaranteed.  An overnight double is a big jump and I'm not surprised it is taking a little while to consolidate.  However I think it is looking good technically.

Good luck,
Jason

10 Q out:

http://biz.yahoo.com/e/061101/siga10-q.html

....
Results of Operations

Three months ended September 30, 2006 and 2005

Revenues from grants and research and development contracts for the three months ended September 30, 2006 and 2005 were $2.0 million and $2.9 million, respectively. For the three months ended September 30, 2006 we recognized $907,000 from NIH SBIR grants supporting two of our lead programs. Revenues from NIH SBIR grants supporting these programs during the same period in 2005 were $2.7 million. $1.1 million of the revenues recognized from these grants and contracts during the three months ended September 30, 2005, related to expenditures that SIGA incurred during the quarter ended June 30, 2005, prior to approval of the second year of these grants. The decline of $1.8 million was partially offset by an increase of $834,000 in revenues recognized in connection with a $3.2 million, one year contract with USAMRMC. The agreement, for the rapid identification and treatment of anti-viral diseases, was entered into on September 22, 2005 and is funded through the USAF (the "USAF Agreement"). The decline was also offset by $119,000 recorded in connection with a $500,000, one year, Phase I SBIR grant from the NIH to support the development of our Bacterial Commensal Vector technology for the delivery of smallpox vaccine, ending on February 28, 2007. On August 30, 2006, we received a three year, $6.0 million award from the NIH to support the development of our antiviral drugs for Lassa fever virus. On August 1, 2006, we received a three year, $4.8 million SBIR Phase II continuation grant from the NIH to support the development of our smallpox drug candidate, SIGA-246. On September 26, 2006, we entered into a three year, $16.5 million contract with the National Institute of Allergy and Infectious Diseases of the NIH, to further advance the development of our smallpox drug candidate. Revenues from these new grants and contracts will be recognized as services are performed.

Selling, general and administrative expenses ("SG&A") were $802,000 and $415,000 for the three months ended September 30, 2006, and 2005, respectively. The increase of $387,000 or 93% is primarily due to legal and accounting expenses of $258,000 incurred during the three months ended September 30, 2006 in connection with our merger agreement with PHTN which was terminated in October 2006, and a credit of $200,000 in legal expenses recorded during the same period in 2005. The increase in legal and accounting fees were partially offset by a decline of $100,000 in payroll expenses from the quarter ended September 30, 2005.

Research and development expenses ("R&D") increased $391,000 or 22% from $1.8 million for the three months ended September 30, 2005 to $2.2 million for the three months ended September 30, 2006. The increase is primarily due to $345,000 incurred during the three months ended September 30, 2006 under our agreement with the USAF and an increase of $200,000 in payroll expenses related to the expansion of the Company's research and development work force. In addition, on April 1, 2006, we completed the renovation of a new laboratory space in Corvallis, Oregon. Depreciation expense and lab supplies expenditures for the three months ended September 30, 2006, increased by $220,000 and $105,000, respectively, from the same period in 2005. These increases were partially offset by a decline of $80,000 in amortization expense and a decline of $375,000 in expenditures related to two of our lead programs.

During the three months ended September 30, 2006, and 2005 we invested $442,000 and $600,000, respectively, in the development of our lead drug candidate, SIGA-246, an orally administered anti-viral drug that targets the smallpox virus. For the three months ended September 30, 2006, we invested $176,000 in our internal development resources and $266,000 on external manufacturing and clinical testing activities. For the three months ended September 30, 2005, we invested $168,000 in our internal development resources and $464,000 in pre-clinical testing of SIGA-246. From inception of the SIGA-246 development program to-date, we have invested $5.9 million related to this initiative, of which $1.4 million and $4.5 million were spent on internal development resources, and clinical and pre-clinical work, respectively. These resources reflect SIGA's research and development expenses directly related to the program. They exclude additional expenditures such as the cost to acquire the program, patent costs, allocation of indirect expenses, and the value of other services received from the NIH and the Department of Defense ("DoD").

$326,000 and $349,000 of our R&D expenses during the three months ended September 30, 2006 and 2005, respectively, were used to support the development of ST-294, a drug candidate which has demonstrated significant antiviral activity in cell culture assays against arenavirus pathogens. For the three months ended September 30, 2006,

we invested $110,000 in internal development resources and $216,000 in pre-clinical testing. For the three months ended September 30, 2005, we spent $189,000 on internal human resources and $160,000 on pre-clinical testing of ST-294. From inception of the ST-294 development program to-date, we have spent a total of $2.8 million related to this program, of which $1.5 million and $1.3 million were expended on internal human resources and pre-clinical work, respectively. These resources reflect SIGA's research and development expenses directly related to the program. They exclude additional expenditures such as the cost to acquire the program, patent costs, allocation of indirect expenses, and the value of other services received from the NIH and the DoD.

R&D expenses related to our USAF Agreement were $172,000 and $360,000 for internal human resources and external R&D services, respectively, during the three months ended September 30, 2006. During the same period in 2005, we spent $26,000 and $16,000 on internal human resources and external R&D services, respectively. Costs related to our work on the USAF Agreement, during the term of the agreement to-date were $1.7 million, of which we spent $717,000 and $903,000 on internal human resources and external R&D services, respectively. These resources reflect SIGA's research and development expenses directly related to this agreement. They exclude additional expenditures such as patent costs and allocation of indirect expenses.

Patent preparation expenses for the three months ended September 30, 2006 and 2005 were $36,000 and $8,000, respectively.

A gain of $351,000 was recorded during the three months ended September 30, 2006, reflecting the decline in fair market value of common stock rights and common stock warrants sold in November 2005, from June 30, 2006 to September 30, 2006. The warrants and rights to purchase common stock of SIGA were recorded at fair market value and classified as liabilities at the time of the transaction.

Other expenses, net, were $48,000 for the three months ended September 30, 2006 primarily reflecting interest expense related to the three $1.0 million notes payable to PHTN. During the same period in 2005 we recorded net other income of $2,000.

Our product programs are in the early stage of development. At this stage of development, we cannot make reasonable estimates of the potential cost for most of our programs to be completed or the time it will take to complete the project. Our lead product, SIGA-246, is an orally administered anti-viral drug that targets the smallpox virus. In December 2005 the FDA accepted our IND application for SIGA-246 and granted it Fast-Track status. Fast Track programs of the FDA are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

We expect that costs to complete our SIGA-246 program will approximate $15 million to $20 million, and that the project could be completed in 12 months to 36 months. There is a high risk of non-completion of any program, including SIGA-246, because of the lead time to program completion and uncertainty of the costs. Net cash inflows from any products developed from our programs are at least one to three years away. However, we could receive additional grants, contracts or technology licenses in the short-term. The potential cash and timing is not known and we cannot be certain if they will ever occur.

The risk of failure to complete any program is high, as each, other than our smallpox program that entered phase I clinical trials in 2006, is in the relatively early stage of development. Products for the biological warfare defense market, such as the SIGA-246 smallpox anti-viral, could generate revenues in one to three years. We believe the products directed toward this market are on schedule. We expect the future research and development cost of our biological warfare defense programs to increase as the potential products enter animal studies and safety testing, including human safety trials. Funds for future development will be partially paid for by NIH SBIR grants, the contract we have with the U.S. Army, additional government funding and from future financing. If we are unable to obtain additional federal grants and contracts or funding in the required amounts, the development timeline for these products will slow or possibly be suspended. Delay or suspension of any of our programs could have an adverse impact on our ability to raise funds in the future, enter into collaborations with corporate partners or obtain additional federal funding from contracts or grants.

Nine months ended September 30, 2006 and 2005

Revenues from grants and research and development contracts for the nine months ended September 30, 2006 and 2005 were $4.9 million and $6.2 million, respectively. Revenues recorded for the nine months ended September 30,

2006 declined $1.3 million or 22% from the same period in the prior year. For the nine months ended September 30, 2006 we recorded $2.2 million from NIH SBIR grants and an agreement with Saint Louis University, supporting two of our lead programs. Revenues from NIH SBIR grants supporting these programs during the same period in 2005 were $5.6 million. The decline of $3.4 million was partially offset by $2.1 million of revenues recognized in connection with our $3.2 million, one year contract with USAMRMC. The agreement, for the rapid identification and treatment of anti-viral diseases, was entered into on September 22, 2005 and is funded through the USAF. The decline was also offset by $278,000 recorded in connection with a $500,000, one year, Phase I SBIR grant from the NIH to support the development of our Bacterial Commensal Vector technology for the delivery of smallpox vaccine, ending on February 28, 2007. On August 30, 2006, we received a three year, $6.0 million award from the NIH to support the development of our antiviral drugs for Lassa fever virus. On August 1, 2006, we received a three year, $4.8 million SBIR Phase II continuation grant from the NIH to support the development of our smallpox drug candidate, SIGA-246. On September 26, 2006, we entered into a three year, $16.5 million contract with the National Institute of Allergy and Infectious Diseases of the NIH, to further advance the development of our smallpox drug candidate. Revenues from these new grants and contracts will be recognized as services are performed.

Selling, general and administrative expenses ("SG&A") for the nine months ended September 30, 2006 and 2005 were $3.2 million and $2.1 million, respectively. The increase of $1.1 million or 56% is mainly attributed to professional fees and non-cash consulting charge recorded for the nine months ended September 30, 2006, and a credit of $200,000 in legal expenses recorded during the same period in 2005. During the nine months ended September 30, 2006 we recorded legal, accounting and consulting expenses of $752,000, $164,000 and $82,000, respectively, for due diligence services, fairness opinion and legal . . .

I was worried about the drop now it looks like it will stabalize. I bought more at 3.25

Quote from: Terliso link=topic=2905.msg75294#msg75294 date=1161972009
-- Half of the candle from last week (weekly chart) @ 2.90 is the best entry point
quote]

hopefully thats as close to 2.90 as we get. good call terliso!  alvin58 did you buy more?

Rumor is that there is a contract in the workings soon !!!!! ;D

yahoo board quotation:

"rumour" link:
http://www.fbo.gov/spg/USAF/AFDW/11CONS/Awards/FA7014-07-C-0002.html

PR out today or tomorrow IMO  >:D

Quote from: la-onda on November 02, 2006, 11:42:47 AM
yahoo board quotation:

"rumour" link:
http://www.fbo.gov/spg/USAF/AFDW/11CONS/Awards/FA7014-07-C-0002.html

PR out today or tomorrow IMO  >:D

Do you think this is real? It says the contract award date was october 28  that was on a Saturday.

It is real, I have contacted IR.
If it is finally approved, a PR will be released  >:D

cheers
Oliver

Quote from: la-onda on November 02, 2006, 05:17:54 PM
It is real, I have contacted IR.
If it is finally approved, a PR will be released  >:D

cheers
Oliver

Great  I just thought it was odd that it had a Saturday date on it.
Thanks   Al

Quote from: la-onda on November 02, 2006, 05:17:54 PM
It is real, I have contacted IR.
If it is finally approved, a PR will be released  >:D

cheers
Oliver

Good job la-onda, though it's only a contract for only $1,443,693, but still better than nothing!:)

This news was in many boards all day long, but agree with se7en the amount is not so relevant and in fact the market did not overreacted after cpmmented on a yahoo board and also confirmed by la-onda who contacted IR. IMHO this stock was following the 9EMA and today changed to the 13EMA. The numerous experts we have here will tell the next probable moves.

Nevertheless there is another gem in todays news, confirming that the US Government can buy and store SIGA's drug/vaccine without the previous FDA release due to the current regulations and this could become a worldwide trend on countries fighting terrorism, trying to prevent contamination attacks.

jorgegr

im looking to avg. down. anybody have ideas on the bottom? was 3.10 it or are we going lower into next week?

up 11 % so far  >:D

can  anybody find news?

Quote from: la-onda on November 07, 2006, 10:28:59 AM
up 11 % so far  >:D

looking good :)  Volume picked back up to

3.75 still haunting us.....I believe it will be broken sooner or later

Hey guys,

Just bought SIGA at 3.65.   :D

This was because I accidentally sold GIGM yesterday at 4.40 pm pacific time when I accidentally  put a limit sell order to sell GIGM instead of a stop limit sell order.  :-[ Sure enough my order was executed and therefore missed out on the 1/2 point return today.  Hopefully SIGA will make it up to me........please!! >:D >:D

Good luck all!

We continue surfing the 13EMA and love that Full STO crossing

Quote from: bocasva on November 07, 2006, 10:43:58 AM
3.75 still haunting us.....I believe it will be broken sooner or later

3.75 broken for good and should act as support from now on, 4 is the next battle to win

SWEET...great volume ;D

Yup I'm loving it!!   :D :D

Looking very strong at the close!! This is getting exciting guys!!

Quote from: stocks2watch2 on October 27, 2006, 09:46:37 AM
Bounced off the 3.23 support, I bought 15,000 more. I think we at least go back to 4.54 soon.

;D

4.33 AH >:D >:D >:D

on fire

4 was nothing, taken out easier than I thought....that's what we call a short masacre, I mean, a short squeeze ::)

 ;D ;D wow, thats what i call a close. i kept raising my selling price, finally sold some at 4.25. my heart couldnt take it anymore!! great posts everyone!! la-londa great picture. now lets go to the moon.!!!!

It took me 1 1/2 hours to read this entire thread, but it was worth it  :). I wish I've read it earlier. Anyway, here's my perspective on the stock:

1) SIGA rejected $68 M when it backed off from the merger with PharmAthene. The only reason to do this is because management thinks the company is worth a lot more.
2) Current market cap is $135 M.
3) The government is supporting SIGA's research and tests with money.
4) The SIGA-246 test on monkeys was 100% successful and without side effects.
5) The government plans to acquire $1.9 B of smallpox related drugs. SIGA is the leading treatment.
6) There was a private placement, but it wasn't big, just $9 M, and it was bought by hedge funds at $4.54.
7) Technical analysis is very bullish, with the stock coming back after a period of consolidation
8) There's an element of emotion here, since smallpox shows up in every history book as the deadliest disease ever.
9) Vulnerability of 223 million Americans that were never vaccinated against smallpox

I could go on with bullish information (most of it taken out from this thread), but I think you get the point. I believe SIGA can double from current levels, reaching a market cap of $270 M, easily. 

There are risks, however. There are always risks. The company may dilute shareholders value by issuing and selling shares in the open market. The drug can be effective on monkeys, but not effective on humans. It can take a long time for the drug to be approved. SIGA doesn't have an history of financial stability or profits to be supportive if the share price starts declining.  Warren Buffet would never buy this, that's for sure.

But, you're either a speculator or you're not. As I view it, a speculator MUST buy SIGA now. It may go up 100 or 200% on speculation alone. Because there's room to dream here. You're not attached to fundamentals, you're allowed to dream.

Bulls have the ball now, and I bet they will score. If they don't, there are always protective stop losses to use. I guess a buy tomorrow below today's high may deliver a 100% plus return with no more than 15% risk.

I already cashed in a 187% profit on this one, another 100% wouldn't be bad!  ;D

Thx for your take on SIGA David!

Applaud David....... :D ;D

Excellent analysis on SIGA.........so does that mean that you are buying this for the 3sof tomorrow morning?

Thank you to everyone who kept this thread alive........or else I wouldn't have jumped in.  I liked how the candlestick was looking today so I decided to jump in.  Again, great work everyone!!

Thai

Quote from: stocks2watch2 on November 07, 2006, 03:58:22 PM

Bounced off the 3.23 support, I bought 15,000 more. I think we at least go back to 4.54 soon. ;D

we came pretty close 4.42!!

Quote from: bocasva on November 07, 2006, 10:43:58 AM  3.75 broken for good and should act as support from now on, 4 is the next battle to win

bocasva, i hope so!  4 is holding so far.  i would like to add more if we drop under 4!

Chart still looks good guys!!   :P As you can see from the chart yesterday, it made its move once it retraced to it's breakout point  in the late afternoon.  As you can see, it has just retraced back to the breakout point again and hopefully we can see the same kind of result as we did during the last closing moments of yesterday's trading day.  Keep your fingers crossed. >:D >:D >:D

Was hoping SIGA would close above $4, but no such luck :-\

SIGA will probably go down in the morning. (unless news) but I think 3.75 should provide good support and possible entry point 8)

We shall see.

Just for the record, I bought SIGA at the open at $4.05 and sold 1/2 an hour before the close at $3.90 for a 3.7% loss (-0.24% for the total equity - anyway, the 3 Stocks on Fire Portfolio was up 2.87% today  :)). I had the plan of selling if the stock were about to close below $4.

Here's my reasoning:

QuoteI actually was quite uncomfortable holding SIGA during today's session. I should have said "sell with a 5% profit" hehe, but I didn't, and I always follow what I say when the markets are closed.

I was reading some articles about smallpox and acknowledged that the disease is extinct since 1978. Officially there are only two locations that kept the virus for studies: one lab in the US and another in Russia. The concern is that the USSR had a secret biological weapons programme and created many more locations with the variola virus, and later those virus got to rogue states and terrorist groups.

I just think that if they had it, they would have already used it, since it would be so simple and there's no limit to their evil. Government has $1.9 B for smallpox, but $700 M plus already went to Wyeth's vaccine, Dryvax. Those $1.9 B are until 2013, I don't think there will be much more.

The bullish case was getting more and more difficult to defend in my head, and when I saw the stock come back down to $4 after that 10% morning rally, I knew I would take a loss on SIGA.

It was a small 3.7% loss on 6.66% of capital, this means 0.24% of total capital. I like to take small losses and large profits, so the global result is an above average return.

Good luck to everybody that continues holding SIGA  :)

Thanks David!  I like how you keep to your game plan and just move on............I think that's one of the most important things to learn about trading stocks.   ;)

Unfortunately, I haven't learned yet   :P 

I'll continue to hold since I am risk free at the moment. 

Thai

Quote from: thai626 on November 08, 2006, 05:29:52 PM
Thanks David!  I like how you keep to your game plan and just move on............I think that's one of the most important things to learn about trading stocks.   ;)

Unfortunately, I haven't learned yet   :P 

I'll continue to hold since I am risk free at the moment. 

Thai

I agree with you Thai, it's one of the most important and most difficult to implement. Allow me to recommend you an excellent book on the subject: The Disciplined Trader, from Mark Douglas (http://www.amazon.com/Disciplined-Trader-Developing-Winning-Attitudes/dp/0132157578/sr=8-1/qid=1163026944/ref=pd_bbs_sr_1/104-9523553-3423120?ie=UTF8&s=books). It's not an easy read, but I've read it 7 or 8 times and I love it !

Im sorry but i feel u made a big mistake. The money is coming from the govy.They didnt pay for research to not buy.Also look at angn and acor on the charts.After the long white candlestick off the rebound they had 1 day like this then took off.JMHO,Good luck all.

Quote from: etercnoc on November 08, 2006, 07:16:14 PM
Im sorry but i feel u made a big mistake. The money is coming from the govy.They didnt pay for research to not buy.Also look at angn and acor on the charts.After the long white candlestick off the rebound they had 1 day like this then took off.JMHO,Good luck all.

I beg to differ on this issue.  David had a game plan and he followed his game plan limiting his loss.  For all we know, this stock could tank tomorrow and we'll be the ones looking like a fool :-\ .  You never know in the world of the stock market.  Anything can/will happen no matter how strong your feelings are! 

I agree with you however that the comparison between ACOR and SIGA look very similar even up to the day after a nice long white candle.  I'm just hoping that we can see the same white candlestick tomorrow   >:D

Good luck all!

Thai

Yea , i understand. Im sorry i was not trying to disrespect anyones opinion.I guess i should have worded my statement differently.Hope we all can smile from making money  ;D and we will see what siga and the market brings us in the AM.Have a good evening.

Bought some more @ 4.02$.

I wonder when they are going to announce that 'little' contract, it's almost a week now?! ::)



SIGA Passes Another Milestone with Smallpox Drug SIGA-246
Thursday November 9, 1:17 pm ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of two independent primate trials of its smallpox drug SIGA-246. Last month, SIGA announced that SIGA-246 provides complete protection against human smallpox virus in nonhuman primates. The current trials involve infection with high doses of monkeypox virus, which may be lethal in primates if left untreated. SIGA-246 again afforded complete protection against disease symptoms. As with the primate trial last month and the human safety trial announced earlier this year, the current trials also demonstrate that SIGA-246 should be safe as well as effective.

ADVERTISEMENT
The first monkeypox virus study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) and conducted at the Lovelace Respiratory Research Institute in Albuquerque, NM. In this study, all monkeys in the two groups receiving SIGA-246 (different dosages) were completely protected from disease.

The second study was conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and was funded by the Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch. In the second study, two groups of nonhuman primates received SIGA-246 orally starting either one day post-infection or three days post-infection. Again both treatment groups were completely protected from disease.

"Taken together with the recent breakthrough results from the smallpox virus study, the data continue to support the use of SIGA-246 as the first drug available to prevent and treat disease caused by pathogenic poxviruses without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. He added, "These are very important results for two reasons. First, in many respects monkeypox infections in non-human primates are more aggressive than infection with smallpox virus (normally a human pathogen), so protection by SIGA-246 represents a higher hurdle. Second, SIGA will likely use SIGA-246's performance against monkeypox infection in monkeys, along with the results in all of the several animal species tested to date, to satisfy FDA's efficacy requirements, so success here bodes well."

SIGA previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. SIGA-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with results from additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to SIGA-246.

The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.


http://biz.yahoo.com/bw/061109/20061109005761.html?.v=1 (http://biz.yahoo.com/bw/061109/20061109005761.html?.v=1)





Siga: Studies Show Smallpox Drug Is Safe
Thursday November 9, 2:41 pm ET

Siga Pharamceuticals Says 2 Federal Studies Show Smallpox Drug Is Safe and Effective

NEW YORK (AP) -- Biotechnology company Siga Technologies Inc. said Thursday results from two independent studies of its smallpox drug show that it is safe and effective.

The trials were conducted by the National Institute of Allergy and Infectious Diseases and the U.S. Army Medical Research Institute of Infectious Diseases. They focused on primates that had high levels of monkeypox infection, which can be fatal if left untreated. In both studies, the subjects were completely protected from the disease.

ADVERTISEMENT
The study validates a previous study, the company said, in which the drug candidate provided complete protection against human smallpox in non-human primates.

Studies have shown that the treatment drug is safe to administer to humans in a once-a-day pill form. The drug, called Siga-246, has been granted Fast-Track status by the Food and Drug Administration.

Shares of Siga rose 14 cents, or 3.8 percent, to $4.03 in afternoon trading on the Nasdaq. The stock has traded between 86 cents and $5.50 over the last 52 weeks.


http://biz.yahoo.com/ap/061109/siga_clinical_trial.html?.v=1 (http://biz.yahoo.com/ap/061109/siga_clinical_trial.html?.v=1)

Quote from: Se7en on November 09, 2006, 06:30:31 PM
Bought some more @ 4.02$.

I wonder when they are going to announce that 'little' contract, it's almost a week now?! ::)

There it is, not only 1, but 2!!!  ;D

Up 9% in pre-market!



SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force
Friday November 10, 7:30 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
ADVERTISEMENT


"We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.

SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.



http://biz.yahoo.com/bw/061110/20061110005112.html?.v=1

man this stock has volume...and is very volatile intraday....yesterday i got some at 4.03 i sold for now premarket 4.35 ...8% i have to take in this short period as it is the way i do trading. Lets see later what happens ? heading to 5 dollar ?

I don't know guys, this news that Se7en published isn't all that relevant, after all it is a $2.3 M deal in a $140 M market cap (at least according to the latest share count, but it can be higher now).

But I really don't know what to think of this stock, as I said, it allows you to dream, but it is also very risky, since it has no fundamental base to it. Just speculation here, so, at least in the short term, anything can happen.

Longer term I doubt it will sustain current prices.

Good luck  :)

Quote from: David Randolph on November 10, 2006, 08:16:12 AM
But I really don't know what to think of this stock, as I said, it allows you to dream, but it is also very risky, since it has no fundamental base to it. Just speculation here, so, at least in the short term, anything can happen.

..........just daytrading this ...not staying in for long....i seems a lot of traders are in there....

I got in @ 3.82 yesterday... SIGA is in a strong uptrend trend, if it can close above $3.92 this session we might see above $5.50 next week...

I'm trading SIGA based purely on technicals ;)

Quote from: Terliso on November 10, 2006, 11:39:19 AM
I got in @ 3.82 yesterday... SIGA is in a strong uptrend trend, if it can close above $3.92 this session we might see above $5.50 next week...

I'm trading SIGA based purely on technicals ;)

i am joining you terlisa am back in 4.04 ...waited for a dip

cool beans...I waited too and bought in at $4.06.

I like the close above $4.00 and the weekly chart as well.  :)

consolidation after the contract announcement
13 EMA as support

chart update:

Chart Update:

are we going to see a gap up tomorrow?  possibly $5???  I hope so!


LONDON, Nov 14 (Reuters) - British vaccine maker Acambis Plc (ACM.L: Quote, Profile, Research) said on Tuesday it had been unexpectedly dropped from consideration by the U.S. government for a new smallpox vaccine contract that analysts believe could be worth up to $1 billion.

Acambis shares plunged as much as 37 percent in early trading to a six-year low of 97-1/4 pence.

Acambis had been competing with Denmark's Bavarian Nordic (BAVA.CO: Quote, Profile, Research) to supply the U.S. government with a weakened version of the smallpox vaccine suitable for vulnerable members of the population such as the elderly.


THE 21st CENTURY IN PICTURES

War and Conflict
View Slideshow
At 0830 GMT, Bavarian Nordic shares were up 20.5 percent at 494 Danish crowns. Bavarian Nordic was not immediately available for comment.

"We are surprised that the U.S. government would eliminate Acambis from the ... process," Acambis Chief Executive Gordon Cameron said in a statement. "We believe that our proposal would have met the requirements of the U.S. government, especially given Acambis' track record in the biodefence field."

Acambis had already supplied the U.S. government with more than $500 million worth of standard smallpox vaccine as the country moved to build up stocks amid fears of bio-terrorist attack. Analysts had assumed Acambis would win at least half of the new contract. "This is obviously a significant disappointment," Goldman Sachs analysts wrote in a research note. "In our view, management credibility has suffered a significant setback and highlights the imperative of strategic alternatives."

Acambis said it had been informed that its proposal for the new contract was "no longer in the competitive range for award".

"Acambis plans to request a meeting to gain further clarification, following which it will consider its options," the firm said. (additional reporting by Michael Flaherty in New York and Kyle McLaughlin in Copenhagen)

Well the Acambis news was out Before market Tuesday morning. 

UPDATE 3-Acambis loses U.S. smallpox deal, shares slump
Tue Nov 14, 2006 6:21am ET146

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061114:MTFH47811_2006-11-14_11-21-42_L14654127&type=comktNews&rpc=44

SIGA Technologies Presents Its Smallpox Drug (SIGA-246) to the World Health Organization (WHO)
Business Wire - November 16, 2006 7:30 AM ET
   

Related Quotes
Symbol   Last Chg
SIGA Trade 4.03 +0.01
Real time quote.
 
SIGA Technologies, Inc. (NASDAQ: SIGA) announced that, on November 16, 2006, its Chief Scientific Officer, Dr. Dennis E. Hruby, will make a presentation on the progress of SIGA-246 to the World Health Organization's Smallpox Advisory Committee on Variola Virus Research. Dr. Hruby is attending by invitation and will serve as a temporary advisor to the Committee which is meeting in Geneva, Switzerland. This is the second year in a row that Dr. Hruby has been invited to make a presentation to the WHO on the development status of SIGA's smallpox antiviral drug (SIGA-246). "Given the central role of the WHO in safeguarding the health and well-being of the global citizenry, we appreciate the opportunity to update them on the recent significant advancements in developing SIGA-246 since we introduced the compound to the WHO last year," commented Dr. Hruby.

In October 2006, SIGA announced that SIGA-246 completely protected non-human primates from lethal doses of smallpox (variola virus). SIGA-246 is the first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial, which was conducted at the federal Centers for Disease Control and Prevention (CDC). Recently, SIGA also announced that oral dosing with SIGA-246 completely protected non-human primates from lethal doses of monkeypox virus even when treatment started 3 days after infection and at doses equivalent to the potential human dose. Monkeypox virus is closely related to human smallpox virus and causes a similar disease in both monkeys and humans. "These monkeypox studies are important in that the disease in non-human primates recapitulates smallpox disease seen in humans, and this model will be used as one of the definitive animal models the FDA will use to evaluate this drug. These results also confirm that SIGA-246 can be used both to treat smallpox and in the event of a monkeypox or related outbreak, such as the multi-state monkeypox outbreak in June 2003," stated Dr. Hruby. These primate trials and the human safety trial announced earlier this year demonstrate that SIGA-246 should be a safe and effective antiviral.

Smallpox virus is considered one of the most significant threats for use as a biowarfare agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. Weaponized smallpox virus may have an incubation period as short as 3-7 days. It is classified as a Category A agent by the CDC. Mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions.

saw that - nice.  SIGA is getting real global exposure.  Is tarting to look better, but I think they may shake the tree a little more before the next leg up...

It looks like it wants to hold around 4.00. At least the volume is still there.

everyday siga opens high and closes in red. dont feel good about this.

Motly fool article

Why We Love Wild Penny Stocks
By Tim Hanson (TMF Mmbop) and Brian Richards (TMF Brich)
November 16, 2006

Penny stocks have huge potential -- that's their blessing and their curse.

The potential rewards are enormous. Just take a look at the returns from SIGA Technologies (Nasdaq: SIGA) or Ocean Bio-Chem (Nasdaq: OBCI) since the beginning of September -- the stocks have each more than doubled.

Those $1 and $2 doubles look like easy gains, considering that Seaboard (AMEX: SEB) would have to add another $1,500 in value to double its share price, and Alleghany (NYSE: Y) would need to throw another $330 on the fire to eke out another double.

Everybody loves pennies
It's the potential of quick gains in stocks like SIGA and Ocean Bio-Chem that keeps investors coming back. We typed "penny stocks" into Google and the search engine spit out "about 1,760,000" hits. We did the same for more time-tested terms such as "blue-chip stocks" and "dividend-paying stocks" and got just 309,000 and 191,000 hits, respectively.

Sure, we expected a discrepancy, but the size of the gap was startling. It became even more interesting when we broke down those hits with Google Trends. According to Trends, penny stocks are particularly alluring to investors in Orlando, Las Vegas, Tampa, and Calgary -- the locales where the term is most often searched.

hi,
this not an article this is an advertisement. they print this same article every few months , only the stock names change. it is to subscribe to their service.
thanks,
maxi

Quote from: rickjust on November 17, 2006, 10:33:38 AM
hi,
this not an article this is an advertisement. they print this same article every few months , only the stock names change. it is to subscribe to their service.
thanks,
maxi

Thanks I thought they were bashing siga. I never liked motley fool and surely wouldn't want to subscribe to there service. thanks again, AL

advisor fyi alerts

11/15/06    Institutional holdings of SIGA increased significantly

look at the bottom of the page
http://moneycentral.msn.com/detail/stock_quote?Symbol=SIGA&FYI=True#Alerts

stopped out at 3.82.  Shame  :'(

hi,
i am about to get out . bought at 406 . can anyone give me a reason to stay in short term.

Quote from: rickjust on November 17, 2006, 11:00:20 AM
hi,
i am about to get out . bought at 406 . can anyone give me a reason to stay in short term.

I'll hold, waiting for some big news and a big pop!

Quote from: rickjust on November 17, 2006, 10:33:38 AM
hi,
this not an article this is an advertisement. they print this same article every few months , only the stock names change. it is to subscribe to their service.
thanks,
maxi

Your right that they do this as there way of advertising, but at the same time it's there way of bashing a stock. They are as bad or worse than stockleman IMO. I think this did have an effect on todays trading.

Quote from: rickjust on November 17, 2006, 11:00:20 AM
hi,
i am about to get out . bought at 406 . can anyone give me a reason to stay in short term.

out 377 >:(  11% LOSS

Quote from: Terliso on November 10, 2006, 11:39:19 AM
I got in @ 3.82 yesterday... SIGA is in a strong uptrend trend, if it can close above $3.92 this session we might see above $5.50 next week...

I'm trading SIGA based purely on technicals ;)

Let's play fair guys.... I got stop out @ 3.80 loss -0.52% plus commission 9.95 each :(

Bad trading!!!

Maxi, Scotsman and Alister,

Applauds for following up on your trades in such a timely manner.  That's really great!  It's a great help to everyone when we can give each other that kind of input.

Quote from: Terliso on November 17, 2006, 01:32:58 PM
Let's play fair guys.... I got stop out @ 3.80 loss -0.52% plus commission 9.95 each :(

Alister,
You went beyond fair, reportig the commission, too!  :D

Quote
Bad trading!!!

On the contrary. 

Your entry at the 50% retracement was very, very good.  Pattern support got broken just before 11:00 AM, then horiztal support at 3.81 got taken out on the print of 3.80, where you sold for a very minor loss.

That's EXCELLENT trading!

Where is support now?  We don't know.  ???

It could be anywhere in that channel that broke out to the upside on November 7, or it could be a lot lower.

"When in doubt...get out" isn't a bad idea.

The channel broke out above validated resistance (#5) at about 3.55.  That put about 4.45 IN PLAY, which MADE within a few pennies (the high was 4.48).

Math for the Bull Channel:

4.00 - High of the channel
3.10 - Low of the channel

4.00 - 3.10 = 0.90 Points + 3.55 breakout = Target: 4.45.

That "could be" it on the upside for awhile.  You might want to watch, and see if another Bullish pattern emerges.

Good luck, everybody!

hi,
i wanted to pull the trigger on thursday before close when i could see even after news it couldn't break 412. i said no i will wait until morning and i will sell it . morning came , and i did not pull the trigger even though my finger was on it and every fiber of my being wanted out , lol. sold 377.

so i decided to try an analysis on the weekly chart based on pivot, support and reistance calculations which i normally use on day charts . i will see how this pans out this week and maybe continue with other stocks, here goes:
what went wrong with siga ? well, nothing if you got in at $1.50 or even $3.20. plenty , if you are in at 5 bucks or like myself, 406 and selling for a loss, looking for a pop on news .
    the news came...........  and came........and came again , no pop. more of an ignition , then a fizzle, like one of those roman candles that fails to ignite fully.
      all the news of the world couldn't move this stubborn stock this week. finally, on friday they ran out of things to  say and the stock fell over. but as you can see below in the weekly chart it is still bullish and there might be a good entry point down the road with some more consolidation. come on, they've got the cure for smallpox!
my calculations are as follows based on the previous week high , low , close.
this weeks pivot =3.88
high: 4.19 +  low: 3.70 + close: 3.76 =11.65  divide by 3 =3.88

support 1. : 3.57
3.88+3.88=7.76 -4.19=3.57

support 2: 3.39
3.88 - .49  ( 4.06 - 3.57 = .49) = 3.39

resistance 1: 4.06
3.88 + 3.88 = 7.76 - 3.70 = 4.06

resistance 2:  4.37
3.88 + .49 = 4.37

so i am going to watch this week and update this next weekend to see how it reacted to these calculations .
thanks,
maxi

p.s. notice the ema 20 comes in at 359 just 2cents above my support. the 5ema comes in at 3.89 one penny above my pivot

Maxi,

As the kids say, "You GO, Boy!"

What a lot of hard work you did on your calculations!  Great.  Applause.

Quote from: rickjust on November 18, 2006, 04:36:33 PM
i wanted to pull the trigger on thursday before close when i could see even after news it couldn't break 412. i said no i will wait until morning and i will sell it . morning came , and i did not pull the trigger even though my finger was on it and every fiber of my being wanted out , lol. sold 377.

Isn't that a pain in the %#@#?

Quote
the news came...........  and came........and came again , no pop. more of an ignition , then a fizzle, like one of those roman candles that fails to ignite fully.
      all the news of the world couldn't move this stubborn stock this week. finally, on friday they ran out of things to  say and the stock fell over.

In addition the to chart patterns/support levels that I post in the Previous Picks folder, that stood out, on the fundamental side: a lack of response to "good news" didn't translate as "good news" for the price of the stock,

Thursday's rally to 4.19, above the recent 4.17 high, was a fakeout, that fizzled on Friday, then the triangle broke.

I'm not sure if I've got this recent pattern drawn correctly.  It could be TWO separate patterns, which I'll try to post Monday's open.

Both this chart, and the TWO separate patterns have short-term Bearish implications, though.

Wouldn't it be great fun, if we all could put our heads together, and catch a nice rally in SIGA, like that nice channel breakout on November 7, that put a target of 4.45 IN PLAY?  It MADE.

Quote from: Melf Elf on November 18, 2006, 05:17:45 PM
Maxi,




Wouldn't it be great fun, if we all could put our heads together, and catch a nice rally in SIGA, like that nice channel breakout on November 7, that put a target of 4.45 IN PLAY?  It MADE.

thanks melf ,
i will be watching . i don't thinl k it is " game over" for this one just yet
maxi

Quote from: rickjust on November 18, 2006, 05:24:36 PM

Quote from: Melf Elf on November 18, 2006, 05:17:45 PM
Maxi,




Wouldn't it be great fun, if we all could put our heads together, and catch a nice rally in SIGA, like that nice channel breakout on November 7, that put a target of 4.45 IN PLAY?  It MADE.

thanks melf ,
i will be watching . i don't thinl k it is " game over" for this one just yet
maxi

I ² that and I'm still in by the way!  :)




(http://img295.imageshack.us/img295/4224/siga3ms8.png)

Quote from: Melf Elf on November 18, 2006, 05:17:45 PM
I'm not sure if I've got this recent pattern drawn correctly.  It could be TWO separate patterns, which I'll try to post Monday's open.

Forget that idea.  It seems to confuse the issue, rather than add any clarity.

If the Triangle pattern is going to play out (the bottom of it is the yellow line in this chart), then roughly 3.20 is IN PLAY.

Math:

4.48 - was the high
3.81 - was the low

4.48 - 3.81 = 0.67 Points

The breakdown occurred on Friday, crossing below about 3.87, so...
3.87 - 0.67 = Target: 3.20

Alternatively, a possibility is that the triangle will morph into a downward sloping channel, a "fractal" (repeating pattern) of the one that broke out on November 7.

If that's the case, we need Data Point #4, another "hit" to the bottom of the channel, which basis the daily chart, comes in on Monday, November 20, at 3.56.  Depends on what hour the low would come in, basis this Hourly Chart.

We also could have a Bullish Falling Wedge, and the low already is in, at Friday's 3.70 low (we'd simply move the trendline for Data Point #4 up under the 4.70 low).

If we've got another Channel, or the Bullish Falling Wedge, the breakout above the down trendline (#1 and #3) for Monday, November 20, is a print of 4.08.

Interestingly, the 34/55 RSIs came into Bullish Synchronicity of Friday.  I'll put up that chart and explain the implications in the next post.

The 34/55RSIs last came into Bullish Synchronicity on November 2.  The high that day was 3.65, so that became the "buy pivot," meaning that a print of 3.66 the next day would be a "buy signal."

The high the next day, November 3, only was 3.42, so no "buy signal" was issued.  But, SIGA closed up a penny, to 3.35, so the 34/55 RSIs remained at Bullish Synchronicity, meaning that the 3.42 high of November 3 became the new "buy pivot."  A print of 3.43 in the next session, Monday, November 6, would be a "buy signal."

3.43 got printed on November 6, so the "buy signal" was issued.  If we look back at the hourly chart, that's when the Channel was forming, so that was a good indication ("lead indicator") that the resolution would be an upside breakout of the channel.

The channel broke out the next session, November 7, crossing about 3.55, putting the 4.45 target IN PLAY (I posted the math back in another post).

If we had taken the 3.42 "buy signal," and held SIGA to the 4.45 target, the gain would have been 30.1%.  Not bad.

So, we're now back at Bullish Synchronicity at Friday's close.  Friday's high was 3.99, so that's the "buy pivot," meaning that a print of 4.00 on Monday, November 20 is a "buy signal."  And, we know that a print of 4.08 is a breakout above the down trendline (#1 and #3) on the hourly chart.

What I'd really, really like to see, is for SIGA to go down and put in Data Point #4 for a channel, near 3.56, NOT print the 4.00 "buy signal," and give us a lower "buy pivot," like it did back on November 2 and November 3.

This thing didn't come out on YHOO, but it was published on the SEC site on Friday, 2 PM:

http://www.sec.gov/Archives/edgar/data/1010086/000116923206004592/d69918_s-3.txt

Dilution.

Besides dilution, my fundamental concern on SIGA is this:

QuoteI was reading some articles about smallpox and acknowledged that the disease is extinct since 1978. Officially there are only two locations that kept the virus for studies: one lab in the US and another in Russia. The concern is that the USSR had a secret biological weapons programme and created many more locations with the variola virus, and later those virus got to rogue states and terrorist groups.

I just think that if they had it, they would have already used it, since it would be so simple and there's no limit to their evil. Government has $1.9 B for smallpox, but $700 M plus already went to Wyeth's vaccine, Dryvax. Those $1.9 B are until 2013, I don't think there will be much more.

Good luck to people still holding, I was out with a 3.7% loss at $3.90.

Quote from: David Randolph on November 19, 2006, 08:32:55 AM
This thing didn't come out on YHOO, but it was published on the SEC site on Friday, 2 PM:

Thanks, David. 

It looks like SIGA sold off on that 2PM news, but it bounced a little in the final hour.  Still below the triangle breadown, though.


                                                   Proposed Maximum     Proposed Maximum
Title of Each Class of             Amount to be      Offering Price     Aggregate Offering      Amount of
Securities to be Registered         Registered          Per Unit              Price          Registration Fee
-------------------------------------------------------------------------------------------------------------
<S>                                <C>                 <C>                 <C>                  <C>
common stock, par value $.0001
per share .....................    3,272,400(1)        $  3.98(2)           $  13,007,790        $  1,391.83
-------------------------------------------------------------------------------------------------------------

That 3.98 is interesting, since Monday's "buy pivot" is 4.00 , and a breakout above the down trendline is 4.08,, so to get either of those two numbers, or both, buyers would have to show willingness to play more than that 3.98.

We'll see how that news plays out in the chart.  Interesting.

Oh No!  :o  Almost everyone sold their shares except me!

I got in at 3.65 so I will risk a little longer and put in a stop order at 3.50.

I hope SIGA recovers next week as the weekly chart shows a pennant similar to the pennant before the last run up.   >:D

Good luck everyone!

Thai

Good morning - The one thing that confuses me is how volumes returned to the levels shown prior to the huge run up and we never saw significant moves up or down accompanied by big volumes -

IMO we will likely see continued consolidation until the now democrat controlled house takes a stand on commitment to Homeland Defense - the other thing that could move it up from here on is likely going to be positive reports on human testing - good luck with that since as pointed out the disease hasn't been around for 50 years -

I got in at 1.26 - sold enough to now be playing on house money - I will ride out GLTA that are in this - if nothing else it will be interesting.

Ed

Buy from technical, sell the technical ;)

I have to correct you on this. That was not dilution. This was just the registration of the stocks that they had issued earlier in their PIPE deal. Please read the following:

"Estimated   solely  for  the  purpose  of  computing  the  amount  of  the
      registration  fee, in accordance with Rule 457(c) under the Securities Act
      of 1933, as amended.  The maximum offering price per share is $3.98, which
      was the average high and low prices for SIGA's common stock as reported on
      the NASDAQ Capital Market on November 15, 2006."

Quote from: David Randolph on November 19, 2006, 08:32:55 AM
This thing didn't come out on YHOO, but it was published on the SEC site on Friday, 2 PM:

http://www.sec.gov/Archives/edgar/data/1010086/000116923206004592/d69918_s-3.txt

Dilution.

Besides dilution, my fundamental concern on SIGA is this:

QuoteI was reading some articles about smallpox and acknowledged that the disease is extinct since 1978. Officially there are only two locations that kept the virus for studies: one lab in the US and another in Russia. The concern is that the USSR had a secret biological weapons programme and created many more locations with the variola virus, and later those virus got to rogue states and terrorist groups.

I just think that if they had it, they would have already used it, since it would be so simple and there's no limit to their evil. Government has $1.9 B for smallpox, but $700 M plus already went to Wyeth's vaccine, Dryvax. Those $1.9 B are until 2013, I don't think there will be much more.

Good luck to people still holding, I was out with a 3.7% loss at $3.90.

Thanks for the correction wontfinddaname  :)

I agree that this registration is old news, related to the October 18th private placement:

SIGA Announces $9.0 Million Private Placement (http://biz.yahoo.com/bw/061019/20061019005548.html?.v=1)

Anyway, there was dilution here.

PS: Thanks for registering wontfinddaname, now keep up :)

Thanks for the welcome, David. This board is great. I'm really sick of the craziness on the yahoo boards.

About the article.  Well, this stock never went up because people were afraid of a live current smallpox virus breakout - like the bird flu.  It is all because of biodefense protection.  This is one of the largest biological warfare scares - which makes potential big funding from the US military and potentially other world power militaries.  So I think the US isn't the only potential funding.   I honestly think if this SIGA 246 is so good and doesn't have any side effects then the US military will find money to buy it.



Jason

Quote from: wontfindaname on November 19, 2006, 03:48:51 PM
Thanks for the welcome, David. This board is great.

wontfinddaname,

Yes, welcome, and applause for your input.

Quote
I'm really sick of the craziness on the yahoo boards.

Reading yahoo boards made me want to try to be a good elf, because I realized that "hell" probably is having to read those horrible things that some of those people say to each other, for all of eternity.
:o  >:D

hello all,
wonderful & continuous discussion about SIGAs potential.
I have sold 15% of SIGA @ 4.06 to minimize my portfolio risk.
SIGA potential is much too high IMO, I will continue to hold.
cheers
Oliver

The problem with SIGA  is its not a stock with growing #s q over q that you can trade by the chart.I look st it as when not if they will get a huge $ order and if this is at 3 or 3.60 it wont matter.SIGA will open at 8 or better and then again u missed the  big profit.Thats just my thoughts and thanks for the great board.Everyone here does a great job.

Quote from: rickjust on November 18, 2006, 04:36:33 PM

support 1. : 3.57
3.88+3.88=7.76 -4.19=3.57

support 2: 3.39
3.88 - .49  ( 4.06 - 3.57 = .49) = 3.39

resistance 1: 4.06
3.88 + 3.88 = 7.76 - 3.70 = 4.06

resistance 2:  4.37
3.88 + .49 = 4.37

so i am going to watch this week and update this next weekend to see how it reacted to these calculations .
thanks,
maxi

p.s. notice the ema 20 comes in at 359 just 2cents above my support. the 5ema comes in at 3.89 one penny above my pivot

siga bounces off 360 pretty strong . 3cents above my first support at 357 a penny above 20ema

maxi

Quote from: Melf Elf on November 19, 2006, 08:26:41 AM
What I'd really, really like to see, is for SIGA to go down and put in Data Point #4 for a channel, near 3.56, NOT print the 4.00 "buy signal," and give us a lower "buy pivot," like it did back on November 2 and November 3.

The bang off the bottom of the channel was 3.60.,  SIGA is back to UNCH, and Data Point #4 for the channel is in now.

That looks good, if it holds up this afternoon.

Quote from: Melf Elf on November 20, 2006, 12:15:23 PM

Quote from: Melf Elf on November 19, 2006, 08:26:41 AM
What I'd really, really like to see, is for SIGA to go down and put in Data Point #4 for a channel, near 3.56, NOT print the 4.00 "buy signal," and give us a lower "buy pivot," like it did back on November 2 and November 3.

The bang off the bottom of the channel was 3.60.,  SIGA is back to UNCH, and Data Point #4 for the channel is in now.

That looks good, if it holds up this afternoon.

I hope so Melf.....I hope so!   ;)

However, my stop order is still intact at 3.50.  Let's see what the rest of the day holds for us.  >:D

Thai

This could be interesting for SIGA ...  :)


Senate to Take Up Biological Threats
Firms Could Get Funding Sooner

By Renae Merle
Washington Post Staff Writer
Wednesday, November 15, 2006; Page D01

The Senate is moving to take up legislation as soon as this week revamping a struggling multibillion-dollar effort to counter bioterrorism threats with a national stockpile of new vaccines and other drugs.

The legislation creates a central authority within the Health and Human Services Department to manage the effort, sets aside an additional $1 billion for research and gives the federal government the flexibility to provide cash infusions to the small firms doing most of the work.
   


Supporters of the bill, which is more than a year in the making, are cautiously optimistic that it will pass. Sen. Harry M. Reid (D-Nev.), who is slated to take over as majority leader, listed it among his priorities for Congress's lame-duck session.

"From a policy standpoint, there is nobody shooting at it," said Sen. Richard Burr (R-N.C.), one of the bill's sponsors.

If passed, the legislation would have to be reconciled with the House version, which was passed in September. The initiative is intended to salvage the Bush administration's Project BioShield, a $5.6 billion program to counter biological and radioactive weapons.

The two-year effort has been marked by delays and operational problems. Some companies, for example, have floundered as they conducted research and testing because the bulk of government payments typically do not arrive until firms are ready to produce approved drugs.

Meanwhile, Project BioShield's most significant investment, a nearly $1 billion effort by VaxGen Inc. to develop an anthrax vaccine, is in limbo after the Food and Drug Administration refused to let the company conduct human tests and Health and Human Services threatened to end the company's contract.

Project BioShield "didn't work because a majority of the companies choose not to participate and the ones that did, they were not financed through the valley of death," Burr said.

The new legislation aims to correct those problems, but it still may face some questions. Sen. Patty Murray (D-Wash.), who said she supports the intent of the bill, nonetheless raised safety concerns.

"We need to debate compensating those who may suffer adversely from new vaccines or treatments and expand protections for high risk populations like children, pregnant women, and the elderly," Murray said in a statement.

Under the current proposal, the bill would create the Biomedical Advanced Research and Development Authority to oversee the effort. The bill also attempts to pump more government money into the private market sooner. Under current law, participating companies are not paid until they deliver the drugs, even though Health and Human Services has the authority to give companies a 10 percent prepayment, which would have to be repaid if the company failed to deliver the product. But the agency has never exercised that option.

The legislation would speed up the development cycle by allowing Health and Human Services to pay companies up to 5 percent of the value of their contract when they reach certain milestones, providing them with a welcome cash infusion. The Senate version would also allocate $1 billion over three years for research not funded by a Project BioShield contract or the National Institutes of Health. The House version of the legislation sets aside $160 million per year for two years.

"The federal government is now their venture capital partner," Burr said.

Lance Ignon, VaxGen's vice president for corporate affairs, applauded the notion of the government playing a larger role in sharing the financial risk. Under the current program, "we have all of the financial risk," he said.

The change would not be a "panacea" in VaxGen's case, he said, but could be helpful to the company and the industry in general.

"The success of our nation's bio-defense effort will rest in large measure on the ability to form true partnerships between government and industry based on mutual respect," Ignon said. That includes an "understanding of the almost inevitable setbacks one encounters in drug development."


http://www.washingtonpost.com/wp-dyn/content/article/2006/11/14/AR2006111401247.html (http://www.washingtonpost.com/wp-dyn/content/article/2006/11/14/AR2006111401247.html)

hi,
still looks bearish but hanging between support 357 and the pivot price 388
here is a chart
maxi

Monday's high was 3.85, so that was the Buy Pivot for yesterday's trading, and the Buy Signal was a print of 3.86.  The high only was 3.82, so no Buy Signal was issued.

For today, November 22, yesterday's high of 3.82 becomes the Buy Pivot, and a print of 3.83 is the Buy Signal.

The 34RSI has fallen ¼ pont below its "shadow," the 55 RSI.  Readings are:

34RSI - 60.53
55RSI - 60.78

Those still are at Bullish Synchronicity since the readings are so close, and they're right at the 55EMA, but that's looking weak.  And, the MACD is below its signal line, and falling.

So, "Push has come to shove" here.

The 3.83 Buy Signal needs to get printed, or SIGA simply could "slip slide away" to the 3.20-ish target IN PLAY from the Triangle break SIGA had last week (the break below the yellow trendline on the intraday chart, posted over the weekend), or it could slide even lower than that.

Al-Qaeda Attempts to Lay Hands on Nuclear Weapons


Politics: 14 November 2006, Tuesday.

Al-Qaeda and other Islamic extremists want to acquire chemical or radiological weapons in order to attack a Western country, a senior British official has said on condition of anonymity due to the sensitive nature of his work.

Britain's Foreign Office has evidence that terrorist groups have attempted to purchase chemical, biological, radiological and nuclear materials, the official has said.

The warning comes after last week MI5's head Eliza Manningham-Buller said the authorities have identified 30 major terrorist plots being devised in the UK and involving over 1,600 individuals.

"We know the aspiration is there, we know the efforts to get the materials are there, we know the efforts to get the technology are there", a spokesperson of Britain's Foreign Office said.

The senior official said that an attack with radiological or chemical weapons would be based on unsophisticated technology and would cause mass panic rather than mass casualties.

The official added that Britain's Foreign Office is more concerned about legitimate substances and biological weapons that could be used to create weapons such as anthrax or smallpox.[/u]



http://www.novinite.com/view_news.php?id=72583

Since we are still pulling back on no news, what do you think will the driver for any pop (small or large) in the next month? I don't think a large contract will be coming until early next year. I don't think they can license ST-426 for 90 days after the cancellation of the merger with Pharmathene. So, I don't see any buyout or licensing deal till January at the earliest. Analyst upgrades perhaps?

Quote from: wontfindaname on November 22, 2006, 05:20:42 PM
Since we are still pulling back on no news, what do you think will the driver for any pop (small or large) in the next month? I don't think a large contract will be coming until early next year. I don't think they can license ST-426 for 90 days after the cancellation of the merger with Pharmathene. So, I don't see any buyout or licensing deal till January at the earliest. Analyst upgrades perhaps?

They had every right to cancel the merger so I don't see how this can effect the licensing thing!?
A buyout is always possible but I'm more expecting a deal with the government, the big question is when but it can be sooner (or later) than we all think ...
A couple of upgrades also wouldn't hurt! :)

QuoteIf the Merger is not consummated, PharmAthene and SIGA have agreed to negotiate, in good faith and exclusively for 90 days, the terms of a definitive license agreement for SIGA-246, SIGA's lead biodefense compound. As a result, SIGA could become less attractive to new merger partners or investors generally if the Merger is not completed.

The above was taken from a proxy statement filed on June 30, discussing the terms of the merger agreement. As the merger was not consummated, there is a 90 day period for which SIGA has to wait before striking a license deal with other companies.

Quote from: rickjust on November 18, 2006, 04:36:33 PM
support 1. : 3.57
3.88+3.88=7.76 -4.19=3.57

support 2: 3.39
3.88 - .49  ( 4.06 - 3.57 = .49) = 3.39

resistance 1: 4.06
3.88 + 3.88 = 7.76 - 3.70 = 4.06

resistance 2:  4.37
3.88 + .49 = 4.37
so i am going to watch this week and update this next weekend to see how it reacted to these calculations .
thanks,
maxi
p.s. notice the ema 20 comes in at 359 just 2cents above my support. the 5ema comes in at 3.89 one penny above my pivot

just updating the chart.

Quote from: wontfindaname on November 22, 2006, 05:45:55 PM

QuoteIf the Merger is not consummated, PharmAthene and SIGA have agreed to negotiate, in good faith and exclusively for 90 days, the terms of a definitive license agreement for SIGA-246, SIGA's lead biodefense compound. As a result, SIGA could become less attractive to new merger partners or investors generally if the Merger is not completed.

The above was taken from a proxy statement filed on June 30, discussing the terms of the merger agreement. As the merger was not consummated, there is a 90 day period for which SIGA has to wait before striking a license deal with other companies.

Helpul info, thanks...

Quote from: wontfindaname on November 22, 2006, 05:45:55 PM

QuoteIf the Merger is not consummated, PharmAthene and SIGA have agreed to negotiate, in good faith and exclusively for 90 days, the terms of a definitive license agreement for SIGA-246, SIGA's lead biodefense compound. As a result, SIGA could become less attractive to new merger partners or investors generally if the Merger is not completed.

The above was taken from a proxy statement filed on June 30, discussing the terms of the merger agreement. As the merger was not consummated, there is a 90 day period for which SIGA has to wait before striking a license deal with other companies.

thx, didn't know that but it says with 'other companies', I think this has no influence on a possible  contract with the government or am i seeing this wrong?

Yes I was talking about licensing out the drug to other companies. Government contract is not affected by this. However, knowing the pace at which the govt works, I don't foresee them giving SIGA a 500 million contract before the end of the year.

Quote from: rickjust on November 20, 2006, 11:46:07 AM
support 1. : 3.57
3.88+3.88=7.76 -4.19=3.57
support 2: 3.39
3.88 - .49  ( 4.06 - 3.57 = .49) = 3.39
resistance 1: 4.06
3.88 + 3.88 = 7.76 - 3.70 = 4.06
resistance 2:  4.37
3.88 + .49 = 4.37
so i am going to watch this week and update this next weekend to see how it reacted to these calculations .
thanks,
maxi

hi,
siga held onto my support level at 357 hitting one penny above on two of the four days last week.
4 out of 4 days with a lower top. 3 out of 4 with a lower or even bottom. didn't break the pivot at 388. high this past week being 385
this weeks pivot : 369
support1: 353
support2: 342
resistance1: 380
rest2: 4.07
wekkly chart still looks strong
thanks
maxi

Quote

SIGA mentioned, could add some fuel ...

Caution on Bioterror

By Marc Lichtenfeld
Senior Columnist
11/28/2006 7:17 AM EST
Click here for more stories by Marc Lichtenfeld

Next week the Senate is expected to revamp Project Bioshield, a $5.6 billion spending plan meant to shore up the nation's defenses against a bioterror attack.


The original law, enacted in June 2002, was supposed to provide inducements for biotech companies to work on vaccines and antidotes for threats such as anthrax and Ebola. However, the structure of the bill actually served as a disincentive.
That's because companies weren't going to get paid until the products they developed were approved for use. Large biotechs such as Amgen (AMGN - commentary - Cramer's Take - Rating) and Genentech (DNA - commentary - Cramer's Take - Rating) had little interest in the government's program. After all, they had businesses to run.

At the same time, several smaller firms were salivating over the possibility of large contracts and eagerly signed up. The problem has been that participating companies have had a difficult time successfully developing products and getting through the period before a treatment is successfully launched, when cash is going out but none is coming in.

The newest bill, sponsored by Sen. Richard Burr (R., N.C.) will, among other things, add $1 billion to the program to fund companies prior to product approval. That should ease the financial strain for firms developing products that the government deems essential to protecting our nation's health.

Below are some of the publicly traded companies that are researching ways to protect the American public from bioterror threats. Just keep in mind that many of these companies have very low market caps, are thinly traded, have little or no revenue or track records and should be considered very speculative.

--------------------------------------------------------------------------------------------------------------------------------------------

Page 2 




Nevertheless, it's not difficult to imagine a threat sending these stocks soaring, so you should be aware of which ones could participate in a rally caused by fears of bioterror.
Mixed Results
Two of the most frightening potential bioweapons are anthrax and smallpox, both of which can be fatal to humans. Recall that the former was used five years ago when a series of anthrax-laced letters were sent through the mail, to deadly effect. Research efforts haven't been without promise, but a great deal of work remains to be done before treatments or vaccines are widely available.

VaxGen (VXGN - commentary - Cramer's Take) has been the recipient of the largest contract under Project Bioshield, but recently things have taken a damaging turn.

Should the company successfully deliver the 75 million doses of anthrax vaccine stipulated in the contract, it will gross $877.5 million. However, VaxGen has failed in its efforts so far, and earlier this month the Food and Drug Administration ordered a clinical halt on its phase II tests. The company has until Dec. 18 to resolve the issues with the FDA, or the government could terminate the contract.

Emergent Biosolutions (EBS - commentary - Cramer's Take), which went public two weeks ago, already has an approved anthrax vaccine. Its contract with the government calls for the purchase of 10 million doses at a cost of $243 million.


Page 3 



   
If you plan on investing here, know that you'll be one of only a handful of stockholders. The Gaithersburg, Md.-based company is tightly controlled by CEO Fuad El-Hibri, who owns more than 81% of the outstanding stock. Aside from its anthrax fighter, Emergent is also working on a vaccine against botulism.
Meanwhile, Human Genome Sciences (HGSI - commentary - Cramer's Take - Rating) has received a $165 million contract from the Department of Health and Human Services for 20,000 doses of ABthrax. Roughly 90% of the total funds are expected in 2008 upon delivery of the drug.

As for smallpox, Acambis (ACAM - commentary - Cramer's Take) has two offerings for treating the virus. One is a vaccine called ACAM2000, and the company expects to sell 10 million doses for $30 million to the U.S. government this year.

The other product recently was dealt a setback after the U.S. said it wouldn't be considered for a potential $1 billion contract. Acambis plunged 40% in one day.

The company was working on the second product with Baxter International (BAX - commentary - Cramer's Take - Rating), the distributor of ACAM2000. Bavarian Nordic, whose stock trades in Copenhagen, is now believed to be the favorite for the contract.

A company still doing research is Siga Technologies (SIGA - commentary - Cramer's Take - Rating), whose SIGA-246 smallpox antiviral is in preclinical studies. The company claims SIGA-246 is the first drug ever to demonstrate 100% protection against human smallpox in a primate trial.

Understand that smallpox is considered by health authorities to have been eradicated, but samples of the virus remain held in labs. Were a case to appear today, it would be "the result of an intentional act," the Centers for Disease Control and Prevention says on its Web site. "A single confirmed case of smallpox would be considered an emergency."



Page 4 




Also high on the list of the government's worries are hemorrhagic fever viruses such as Ebola. An Ebola vaccine, being developed by Dutch biotech company Crucell (CRXL - commentary - Cramer's Take - Rating), recently entered phase I trials with 48 healthy volunteers. Currently, no cure or vaccine for Ebola is on the market.
Nuclear Threat
As if biological agents weren't menacing enough, the government also has to contend with the horrific possibility that terrorists could one day use a radioactive device against the U.S. or its interests.

"Everyone is talking about nuclear," says Dr. Jean Patterson, chairwoman of the Department of Virology and Immunology at the Southwest Foundation for Biomedical Research. Patterson, an expert on bioterrorism, says that the threat of a nuclear attack is now at the forefront of law enforcement officials' concerns.

While a so-called dirty bomb would be deadly to those in the immediate vicinity and likely cause widespread panic, the threat of radiation poisoning is low, according to most experts. In fact, most deaths would be attributed to the explosion of the device rather than the radiation.

Still, with North Korea saying it's making bombs and worries in the West that Iran wants to do the same, protecting American lives from atomic weapons has become a very high priority.

One of the defensive-minded companies is Hollis-Eden Pharmaceuticals (HEPH - commentary - Cramer's Take - Rating), which hopes to receive a contract from the HHS early next year for a drug to treat acute radiation syndrome. No dollar figures have been provided. The drug, Neumune, is also set to begin phase I/II trials for health-care-associated infections.

Separately, Akorn (AKN - commentary - Cramer's Take - Rating) has received a $21.9 million contract for 450,000 units of Ca-DTPA and Zn-DTPA, which treats internal contamination from radioactive elements.

To call many of these names speculative is an understatement, to say the least. In a number of cases, the government might be a company's only customer. Nevertheless, if the unthinkable happens or is even threatened, you'll know which stocks might see a rush of activity. Tread carefully, and let's hope that these companies' products are never needed.

http://www.thestreet.com/_yahoo/newsanalysis/biotech/10324397_4.html

Long term I think this stock is da bomb, but at least for this week, I don't foresee any major changes. I think it might drop a nickel or so and then maybe come back to the 3.60 level at the best. Next week, after the senate hearings, I think we should see some positive price movement.

I just got stomped out at 3.50.  Dang it!  It didn't bounce like I was hoping it would. >:(

O well......On to the next trade.

Quote from: Melf Elf on November 22, 2006, 04:28:44 AM
For today, November 22, yesterday's high of 3.82 becomes the Buy Pivot, and a print of 3.83 is the Buy Signal.

So, "Push has come to shove" here.

The 3.83 Buy Signal needs to get printed, or SIGA simply could "slip slide away" to the 3.20-ish target IN PLAY from the Triangle break SIGA had last week (the break below the yellow trendline on the intraday chart, posted over the weekend), or it could slide even lower than that.

No Buy Signal was issued, and SIGA has been "slip sliding away" to the 3.20-ish target IN PLAY.

The bottom of the channel, basis the daily chart, comes in today at 3.30.  Today's low is 3.30, thus far, so we'll see if that holds, or if SIGA is going to head lower toward the target.

The channel drops at the rate of five cents per day, so a direct hit to the bottom of the channel at 3.20 would come in on Thursday, November 30.

I'll post the updated daily chart before the open tomorrow.

SIGA currently is BID 3.33...ASK 3.34

Quote from: Melf Elf on November 28, 2006, 01:51:31 PM
The bottom of the channel, basis the daily chart, comes in today at 3.30.  Today's low is 3.30, thus far, so we'll see if that holds, or if SIGA is going to head lower toward the target.

3.30 held as the low of the day.  That was a direct hit to the bottom of the channel, and the fact that buyers stepped in exactly at 3.30, validates it as support.

Problems:

1. Volume was 1.1 Million shares yesterday.  Volume has been well under that for the past several sessions, so there was more selling, as SIGA printed new lows for the move.

2. Although buyers stepped in right at the bottom of the channel, which is good, there wasn't much of a bounce higher.  SIGA closed at the low end of the day's range, at 3.38.

Instead of a "Let's Take This Baby Higher" response off the tag of the channel, the session ended "on a dumb note," so speak, limping back to a 3.38 close.

3. It's a DECLINING channel, so SIGA "could" continue to "walk its way down the channel," continuing to go lower, yet still remain within the confines of the channel. 

Quote
No Buy Signal was issued, and SIGA has been "slip sliding away" to the 3.20-ish target IN PLAY.

The channel drops at the rate of five cents per day, so a direct hit to the bottom of the channel at 3.20 would come in on Thursday, November 30.

That's a possibility, to hit the 3.20 target AND bang off the bottom of the channel, simultaneously, on Thursday...

Another possibility is to tag the bottom of the channel again today, at 3.25 , then reverse higher.  3.25 also is the bottom of the Kumo (Cloud).

We'd like to see some sign of an upside reversal, rather than "limping home" to the 3.38 close yesterday.  It's certainly possible that SIGA could rally right from the get-go today, but then I'd want to see yesterday's 3.60 and the top of the channel get taken out, if that were to occur.

On the downside, if we get something like a tag of 3.25, then a rally back to UNCH, at 3.38, that would be an indication that the stock wants to go higher now.

A nice Bullish Hammer off the bottom of the channel.  Something like that.

BE CAREFUL if this channel breaks to the downside.  Players know that it's there, and they could get panicky if it breaks.  There are a lot of bagholders in this stock who have significant paper losses, particularly in those early high volume candles, beginning with the GIANT "Gap To Crap" candle to 5.50, and that gap down to 2.04 yawns below.

Good luck if you own it, or if you play it.

wow. you called that one. We did hit 3.25. Let's hope it holds there. Or even if it breaks, let's hope that it just happens today and shakes out all the weak hands simultaneously.

Quote from: wontfindaname on November 29, 2006, 10:48:07 AM
wow. you called that one. We did hit 3.25.

wontfindaname,

Yeah, players clearly are keying off that channel.  SIGA banged off 3.25 very quickly, and if this 5-Minute candle is accurate, it's a Bullish Island Reversal to the upside.  Needs follow-thru, of course.

Quote
Let's hope it holds there. Or even if it breaks, let's hope that it just happens today and shakes out all the weak hands simultaneously.

There "could be" a downside break of the channel that ends up being a Bear Trap Fakeout, but be careful if it does break, and please use a stop loss to limit your risk.  As you know, this is a very volatile stock, and with that HUGE gap below, this could get out of control on the downside on a channel break.

Good luck!

Good luck!

Quote

Quote

Quote from: Melf Elf on November 29, 2006, 11:09:56 AM
[There "could be" a downside break of the channel that ends up being a Bear Trap Fakeout, but be careful if it does break, and please use a stop loss to limit your risk.  As you know, this is a very volatile stock, and with that HUGE gap below, this could get out of control on the downside on a channel break.

3.24 got printed, so that's a technical break of the channel, but it's only by one penny, so far, and it "could be" a downside fakeout.  But again, be careful here.

The 11:03AM high was 3.31.  We're back to 3.31 right now.  That  needs to get taken out to the upside for SIGA to look at all bullish here.

SIGA currently is BID 3.30...ASK 3.31

Good luck, everyone!

Great work Melf Elf, immediately after it printed 3.24, some buying came in! Back at 3.27 now ..

Quote from: Se7en on November 29, 2006, 12:25:32 PM
Great work Melf Elf, immediately after it printed 3.24, some buying came in! Back at 3.27 now ..

Thanks, Se7en.  Yeah, there can't have been many trades at the 3.24.  Players are stepping in at the bottom rail of the channel, but they'll step right back out if that gets broken by very much.

The two local highs are at 3.31, so a print of 3.32 "should" bring in some buying interest.  We don't want to see SIGA close down here, or go limping home like a wounded dog at the closing bell.

The open was 3.42, so in order to qualify for a "true" Bullish Hammer off the bottom of the channel, SIGA needs to close at 3.36, or better.  That would give it a tail that is twice as long as the "real body," which is the Open and the Close.

Good luck!

hi ,
breaking down here,
below 325

Quote

,

support1: 353
support2: 342
resistance1: 380
rest2: 4.07

maxi

Quote

Quote

support 2 broken 342. now  resstance on my 5min chart previous post

It seems like a real battle, for the latest 2hrs there was always 10 or 20k at the bid if it was at 3.23 - 3.25!

Quote from: Se7en on November 29, 2006, 03:22:44 PM
It seems like a real battle, for the latest 2hrs there was always 10 or 20k at the bid if it was at 3.23 - 3.25!

Yes, and unfortunately, The Bears won the day, closing it out at the 3.23, below the channel (3.25) and below the Kumo (Cloud), also at 3.25.

UGH.  :P

Our 3.20 target from the intraday triangle breakdown MADE.  That was the session low.  The bottom of the channel comes in today at the 3.20, so if SIGA opens UNCH, it "technically" will be back inside the channel, but it's also in "technical default," for having closed below the channel yesterday.

SIGA really needs to take the Bull by the horns (literally), and rally outta here!

If 3.20 gets broken, SIGA "could" double bottom at the November 2 low of 3.10 (or 3.09...3.08, for a little fakeout), but it's pretty tough to defend staying long if that breaks, with that big gap yawning below.

Good luck to those long.  Please use a stop loss to protect yourselves.  "Don't let a small loss turn into a disaster."

Quote from: thai626 on November 28, 2006, 10:32:46 AM
I just got stomped out at 3.50. Dang it! It didn't bounce like I was hoping it would. >:(

O well......On to the next trade.

Thai,

Applause for using a stop.  Sorry that you got "stomped out,"  but that made me laugh.  It really should be called "stomped out."  It's much more descriptive of how we feel, than "stopped out."

Nice reaction so far today, up around 7% with a high of 3.49!

Quote from: Se7en on November 30, 2006, 11:18:06 AM
Nice reaction so far today, up around 7% with a high of 3.49!

Se7en,

SIGA did what it had to do, off the bottom of the channel.

It gapped up and ticked above the 3.31 that we were looking at yesterday, came back and filled the opening gap exactly, at 3.23, then took off to the upside, leaving the 3.20 target MADE, as the exact low for the move down.

Nice job, technically!

It's "On Fire" here.  Somebody just bought 27,500 shares on a gap up from 3.53 to 3.58 (see chart below), so there's some buying interest coming in.

It would be good for SIGA to settle down now, and form a base for a rally back to resistance.

Good luck!

Melf, I think you posted the wrong chart!  ;)

Melf Elf - Great to see your technical comments!  I always enjoy reading your technical posts because they make alot of sense the way you put it.  

Thanks,
Jason

Quote from: Se7en on November 30, 2006, 11:45:39 AM
Melf, I think you posted the wrong chart!  ;)

Se7en,

Oops...I sure did!  :D

Sorry about that.  Here's the correct chart.

Quote from: mitchjas on November 30, 2006, 11:46:59 AM
Melf Elf - Great to see your technical comments!  I always enjoy reading your technical posts because they make alot of sense the way you put it. 

Thank you, Jason.  I often feel that my comments are much too technically detailed, and possibly confusing (if not outright B-O-R-I-N-G), so I especailly appreciate knowing that they make sense to you.  Thanks again.

hi,
just hit my buy limit 342
maxi

Melf


   Thanks for the great charts. Where do you get them from?Thanks again.

Also do we need to close over 3.52 to break the down channel? ???

Quote from: etercnoc on November 30, 2006, 12:32:48 PM
Thanks for the great charts. Where do you get them from?Thanks again.

etercnoc,

This chart is from Metastock, which I purchased years ago.  I pay Reuters $35.00 a month for end of day data on stocks and indices.  It's only about $25 a month if you just want stocks. 

The charts with the black background are from Scottrade.  Those are free.

Quote from: etercnoc on November 30, 2006, 01:09:18 PM
Also do we need to close over 3.52 to break the down channel? ???

The top of the channel comes in today at 3.61, slightly above today's 3.58 high.  We'd need a close of 3.62, or better, for a channel breakout.

Good luck!

I'm thinking this one is getting closer to a buy here.  I'd like to see a reverse candle at the open to 3.2.  If Melf's bottom channel holds there, then I think timing is right for a break.  I'm gonna bid a half position near the channel bottom and then save the rest for a breakout buy if it occurs.

Good luck.
Bula

Looks like the bottom is falling out on this one today. I'm still holding though.

Quote from: wontfindaname on December 04, 2006, 01:20:36 PM
Looks like the bottom is falling out on this one today. I'm still holding though.

touched exactly the lower bollinger band and the 50 MA is also just underneath!

wow, this is starting to look ugly! we need some news! >:(

The bottom rail of the channel that we've been discussing came in today at 3.10, which was the November 2 reaction low off the "Gap To Crap" high of 5.49.   

The 50 DMA is rising about five cents a day, so it's at about 3.00 today.

The low so far today is 3.03, so the channel broke, but it might have been with purpose: to tag to 50DMA, then rally, showing some sign of a washout to the downside.

So far, SIGA has come back to BID 3.14....ASK 3.15, but we really want to see something better than that, like a nice bullish hammer today, with a long tail, show a sign of an upside reversal.  Or, something bullish-looking tomorrow, like a Bullish Engulfing candle, etc.

Otherwise, as we also discussed, this simply could keep walking down the channel, tand then fail to the downside.

Good luck!

Quote from: Melf Elf on November 29, 2006, 04:26:26 AM
Problems:
3. It's a DECLINING channel, so SIGA "could" continue to "walk its way down the channel," continuing to go lower, yet still remain within the confines of the channel. 

That's proved to be a BIG problem.

SIGA keeps "slip sliding away," yet remains within the confines of the channel, keeping hope alive.

UGH.

The bottom of the channel now is at 3.05, just above yesterday's 3.03 low. The 200DMA was at 2.9923 yesterday.  It's rising four or five cents per day, so it should be in that 3.03-3.05 area, as well.

SIGA really, really, really needs to reverse to the upside here!

Please remember to use stops, if you're long.  This is only one stock.  "Don't let a reasonable loss turn into a disaster....live to play another day."

Good luck!

Bula...I forgot to say hi to you the other day.  Nice to see you posting again.

Quote from: Melf Elf on December 05, 2006, 05:14:12 AM
[The bottom of the channel now is at 3.05, just above yesterday's 3.03 low. The 200DMA was at 2.9923 yesterday.  It's rising four or five cents per day, so it should be in that 3.03-3.05 area, as well.

This morning's low is 3.04

Quote

SIGA really, really, really needs to reverse to the upside here!

Something like this...   8)

It needs to hold up.

i know it too early too celebrate but this looks alot better than 3.07  :)
great post Melf Elf- keep them coming!!

Melf Elf, where is the top of the channel? Would be nice to close above that ....

Quote from: for3J1M on December 05, 2006, 12:05:39 PM
i know it too early too celebrate but this looks alot better than 3.07  :)

for3JiM,

Right.  We'll hold back on the party hats until we see how this rally holds up.  :D

There was a nice volume increase on the rally off the 3.04 low, back to UNCH, then players saw the possibility of a reversal of the bottom off the channel and the 50DMA, and BIG volume came in on the spike to 3.39.

Very nice.

SIGA might need to go back and fill that gap, at 3.16-3.18, but it "shouldn't" do much more than that on the downside.  Enough is ENOUGH, with all of the "slip sliding" that we've witnessed.

Time to rally, dang it!  :D

Quote from: Se7en on December 05, 2006, 12:16:19 PM
Melf Elf, where is the top of the channel? Would be nice to close above that ....

Se7en,

The top of the channel comes in today at 3.436, so a close at 3.44, or better, would take that out.  That doesn't need to occur today, but soon.

Good luck, everyone!

Quote from: Melf Elf on December 05, 2006, 12:22:54 PM
Se7en,

The top of the channel comes in today at 3.436, so a close at 3.44, or better, would take that out.  That doesn't need to occur today, but soon.

Good luck, everyone!

SIGA has hit the home stretch, now at BID 3.43...ASK 3.44...  :D

Good effort, but she Double Topped at 3.45, and closed at 3.39, which had been the high on the day until the late after breakout into the 3.40s (those last two trades with the (T) won't count).

Volume was at least 3 times average daily volume, so that was good to see on the upside reversal.  Overall, a good day.

Quote
It's "On Fire" here.  Somebody just bought 27,500 shares on a gap up from 3.53 to 3.58 (see chart below), so there's some buying interest coming in.

It would be good for SIGA to settle down now, and form a base for a rally back to resistance.

Our 3.20 target from the triangle breakdown had MADE at that point, and 3.58 was the lows of the flag (the next pattern on this chart).

"Former support at 3.58 became exact resistance," as it should in a downtrend, so 3.58 is Key Resistance now.

Unfortunately, rather than "settle down" and "form a base for a rally" after that print of 27,500 shares at 3.58 resistance, SIGA continued to "walk down the channel," and it made a new low of 3.03, at the 50DMA.

UGH.  :P

On the strength of yesterday's reversal off the bottom of the channel, AND at the 50 DMA, AND on good volume, SIGA "should" be able to rally back to Key Resistance, at 3.58.  If it can't, and if it starts looking wimpy, giving back most of yesterday's gains, it likely is going lower.

It needs to do something like rally to 3.58, establishing a neckline for a Bullish Inverse H&S, pull back for a Right Shoulder, then breakout convincingly, above 3.58.

If that were to occur, 4.14 would be IN PLAY.

But, we're ahead of ourselves here....SIGA first needs to get to 3.58!     :D

Quote

Quote

I am finally out  :'(

Quote from: la-onda on December 11, 2006, 12:07:04 PM
I am finally out  :'(

Applause for using a stop on it, Oliver.

Quote from: Melf Elf on December 05, 2006, 05:14:12 AM
Please remember to use stops, if you're long.  This is only one stock.  "Don't let a reasonable loss turn into a disaster....live to play another day."

also put on my watchlist
Biotech News: SIGA Technologies Inc. is Added to Watch List

Monday Dec 11 2006 12:52:36 EST

Dec 11, 2006 (M2 PRESSWIRE via COMTEX) --

Say "ahhh" instead of "ow!" If development-stage SIGA Technologies (NASDAQ: SIGA) has its way, painful vaccinations could become a thing of the past. The company is working on technology to administer vaccines directly through the mucus-lined surfaces -- mouth, nose, lungs, and gastrointestinal and urogenital tracts -- that are the usual entry points for most infectious agents. It focuses on vaccines, novel anti-infectives, and antibiotics for infectious diseases; its lead candidates are vaccines for bio-defense. In 2006 SIGA made breakthrough progress on a smallpox treatment, which completely prevented the disease in preliminary primate trials. The advancement led to funding from the National Institutes of Health.

Shares were down 7% in anticipation of the revamp to Project Bioshield.

Next week the Senate is expected to revamp Project Bioshield, a $5.6 billion spending plan meant to shore up the nation's defenses against a bioterror attack.

The original law, enacted in June 2002, was supposed to provide inducements for biotech companies to work on vaccines and antidotes for threats such as anthrax and Ebola. However, the structure of the bill actually served as a disincentive.

That's because companies weren't going to get paid until the products they developed were approved for use. Large biotechs such as Amgen and Genentech had little interest in the government's program. After all, they had businesses to run.

At the same time, several smaller firms were salivating over the possibility of large contracts and eagerly signed up. The problem has been that participating companies have had a difficult time successfully developing products and getting through the period before a treatment is successfully launched, when cash is going out but none is coming in.

The newest bill, sponsored by Sen. Richard Burr (R., N.C.) will, among other things, add $1 billion to the program to fund companies prior to product approval. That should ease the financial strain for firms developing products that the government deems essential to protecting our nation's health.

Below are some of the publicly traded companies that are researching ways to protect the American public from bioterror threats.

A company still doing research is Siga Technologies, whose SIGA-246 smallpox antiviral is in preclinical studies. The company claims SIGA-246 is the first drug ever to demonstrate 100% protection against human smallpox in a primate trial.

Understand that smallpox is considered by health authorities to have been eradicated, but samples of the virus remain held in labs. Were a case to appear today, it would be "the result of an intentional act," the Centers for Disease Control and Prevention says on its Web site. "A single confirmed case of smallpox would be considered an emergency."

http://new.quote.com/stocks/story.action?id=MTO345u4404

I called Investor Relations today and left a message enquiring why the stock price is plummeting. Tom Konatich (acting CEO) called me back later in the day to reassure me that nothing has changed and that they don't see any fundamental reasons for the drop. He said that he thinks it may be tax selling and that they might consider putting out some information soon to reassure the investors.

Do anyone of you experienced traders know anything about typical trends during December tax loss selling, especially for microcaps like Siga on the downtrends after a major breakout? Any chance for an early Santa Claus rally?

SIGA is in a free fall, maybe closing the gap, who knows ...  ???

I'm  keeping an eye on it and will try to get back in, still think this one has much potential!

Se7en, i agree.    i am also watching closely.  their annual meeting is december 19th. do you think that will help us turn around or a least find a bottom?

I have to say that day by day, I'm losing hope that this stock will retrace at least some of its losses. The current downtrend has lasted a month already with only one up day in the middle. What do you think the bottom is on this one? What is the potential upside without any news?

Quote from: wontfindaname on December 14, 2006, 05:39:17 PM
I have to say that day by day, I'm losing hope that this stock will retrace at least some of its losses. The current downtrend has lasted a month already with only one up day in the middle. What do you think the bottom is on this one? What is the potential upside without any news?

Siga is following the lower BB band...which is never good.  I usually never let a stock fall to the half way point between the bands. 

Anyway...it will probably fill the gap.

By filling the gap, do you mean fall back down to 2?  >:(

The doji is a bit encouraging though.

Interesting ending to the day. Combined with yesterday's doji, I'm curious as to where this will lead us next week. I'm really hoping we can end the year trading at 3+. It will ease my margin requirements and also give us a higher springboard on any positive news next month.

Another solid day. After the doji, we've had two straight up days. Both days, we had a big buyer at the last minute to paint the tape a little. I don't know what that means though. There seems to be significant resistance in the mid 2.80s that the buyer was rightfully afraid of. Even today, if it wasn't for the resistance, we might have closed upwards of 3.

The stockholder's meeting is tomorrow. Let's see what that brings us. GLTA longs.

SIGA up 30% on news!


FDA Approves Orphan Drug Designation for SIGA's Smallpox Drug, SIGA-246
Wednesday December 20, 2:30 pm ET
The Designation is for Both Treatment and Prevention of Smallpox

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today that the Office of Orphan Products Development (OOPD) of the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIGA-246, SIGA's smallpox drug, for the prevention and treatment of smallpox. In December 2005, the FDA awarded SIGA-246 fast track status to expedite the drug's review.

ADVERTISEMENT
Orphan Drug designation will entitle SIGA to seven years of marketing exclusivity in the United States if SIGA-246 becomes the first drug of its kind to obtain marketing approval from the FDA. Historically, the approval time for orphan products as a group has been considerably shorter than the approval time for other drugs.

"This is an important step in bringing SIGA-246 to market. The drug has made significant progress since the approval of its Investigational New Drug application just a year ago. In July 2006, we successfully completed the first planned human clinical safety trial, and, in October, the drug demonstrated 100% protection against human smallpox virus in a primate trial. We believe that SIGA-246 holds great promise and will be the first drug available to prevent and treat the disease without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Smallpox has been designated by the Department of Homeland Security as a "material threat" to our national security, qualifying SIGA -246 for purchase for the Strategic National Stockpile under Project Bioshield. Currently, there is no effective and safe smallpox therapy available without the risk of significant complications, and the U.S. government has expressed strong interest in the development of novel smallpox therapies. Existing techniques to prevent or ameliorate smallpox have unacceptably high rates of complications, including encephalitis, myocarditis and death, and can take days or weeks to confer protection.


http://biz.yahoo.com/bw/061220/20061220005778.html?.v=1 (http://biz.yahoo.com/bw/061220/20061220005778.html?.v=1)

on fire >:D >:D >:D

MONSTER NEWS....2 YEARS EARLYER APPROVED!!

AWESOME!!!

THAT'S MEAN HUGE CONTRACT ON HORRIZONT....

nice!  ;D

is there any entry strategy for SIGA from TA side?

FDA APPROVES ORPHAN DRUG DESIGNATION FOR

SIGA'S SMALLPOX DRUG, SIGA-246



THE DESIGNATION IS FOR BOTH TREATMENT AND PREVENTION OF SMALLPOX



New York, December 20, 2006 -- SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that the Office of Orphan Products Development (OOPD) of the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIGA-246, SIGA's smallpox drug, for the prevention and treatment of smallpox.  In December 2005, the FDA awarded SIGA-246 fast track status to expedite the drug's review.

Orphan Drug designation will entitle SIGA to seven years of marketing exclusivity in the United States if SIGA-246 becomes the first drug of its kind to obtain marketing approval from the FDA.  Historically, the approval time for orphan products as a group has been considerably shorter than the approval time for other drugs.


"This is an important step in bringing SIGA-246 to market.  The drug has made significant progress since the approval of its Investigational New Drug application just a year ago.  In July 2006, we successfully completed the first planned human clinical safety trial, and, in October, the drug demonstrated 100% protection against human smallpox virus in a primate trial.  We believe that SIGA-246 holds great promise and will be the first drug available to prevent and treat the disease without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Smallpox has been designated by the Department of Homeland Security as a "material threat" to our national security, qualifying SIGA -246 for purchase for the Strategic National Stockpile under Project Bioshield.  Currently, there is no effective and safe smallpox therapy available without the risk of significant complications, and the U.S. government has expressed strong interest in the development of novel smallpox therapies.  Existing techniques to prevent or ameliorate smallpox have unacceptably high rates of complications, including encephalitis, myocarditis and death, and can take days or weeks to confer protection.

touched 5$, holy cow!!!  :o

TARGET FOR TOMORROW???

Quote from: MrChina on December 20, 2006, 05:03:49 PM
TARGET FOR TOMORROW???

$10...just kidding. :D

It closed right at open of the black candle.  $5.50 would be plausible.  If it gets above that...the sky's the limit ;D

I have to say I'm glad I held my 15000 shares even against common sense. I checked my portfolio on the phone on Ameritrade mobile around 3:50 and nearly got into an accident. Hopefully, this will rise more till Chrismas and give me a nice present!

15000 shares!!! Yowza!  Thats some serious profits right there!!!  I was pretty happy with my 500 shares.  Picked em up at 3.35 today, when the news came out.  My thinking is this has to be the real deal for SIGA, but looking at the chart, all signs point to being very careful here.  The only difference between this and the recent gaps has been that this news was released during market hours.  It still didn't come close to the volume of the big october gap (although admittedly it all happened in the last hour and a half of trading).

Oliver, its so hard to judge these things from the TA side, when you get a rocket fueled move like this.  It was looking so strong, (and I was sitting at my computer just begging the market to close so it couldn't sell off!!).  4.50 should provide support, 4.20 area should provide support, 3.75-3.80 should provide support, but really who knows until we see a bit of the action tomorrow.  My concern is every other recent big move has been followed by a significant retrace, so if it looks to be gapping down tomorrow, I wil probably sell half at the open.  The candle midpoint is 3.85 (calculated from open and closing prices), so some may look for entry there, but if this news is seen as significant, it could also easily drive the stock well past $5.  I would look to scale entries in and see how the chart develops.

this is crazy!!!! ??? anybody? im thinking of buying more here?

Crazy it is!! 

LOL, after I got it at 4.25 I was already salivating a good profit when it hit 4.6 so I was putting a 5.48 sell order when it drops again and got shaken out at 4.31.

I'm waiting to see if I can pick it up again between 3.75 and 3.85 but it's so volatile today; a lot of short players and profit takers today on this one so it could go even lower.

50% fib retracement it 3.87

Quote from: la-onda on December 20, 2006, 03:42:15 PM
is there any entry strategy for SIGA from TA side?

Oliver,

Yes, you can look for patterns on the 1-Minute chart and play breakouts like we had above #5 of this channel (see chart), at 3.77, at 2:59PM yesterday afternoon, and we also can play pullbacks to the top of the pattern, like the second arrow (below the trendline), at 3.78, at 3:06PM yesterday.

Put your stop below the "last low" of the pattern, or in the case of buying the 3.78 successful pullback to the top of the pattern, put your stop right below 3.78 when the stock moves higher.

There also were two short trades this morning, on the rally failure to the gap, and on the break of 4.25-4.26 support.

Now, let's have some T2T discussion.

That kind of daytrading requires tremendous discipline, to wait for the trade, execute it in fast market conditions, and to pull the trigger and stop it out if the stop gets hit.  No, "Gee, I think I'll hold on, and hope this thing comes back."  We saw what happened with that on the last horrible selloff.

These are "Kamikaze stocks," for those who need an adrenelin rush.  :D

There's nothing at all wrong with that, of course, as long as we know what we're doing.  These stocks can hurt us badly.  In late trading yesterday, there was no let up in the panic buying in the 4.80s, 4.90s, and above 5.00.  Let's picture how those players felt when SIGA dropped to 3.95 this morning, and their positions were down 20%, or more.

UGH.  :P

They now are saying, "Gee, I hope this thing goes back to 5.00, so I can get out!"

UGH.  :P

Again, playing these momo stocks can be exciting, but unless we commit to having a trading plan, and to knowing how we're going to play it, these trades can result in devastating losses.

I'd avoid "throwing money" at them.

Just a suggestion.

Quote from: kslifka on December 21, 2006, 10:35:24 AM
50% fib retracement it 3.87

kslifka,

FWIW, this morning's pattern break below 4.25-4.26 put 3.87 IN PLAY.

4.65 - This morning's high on the rally to the gap
4.26 - (I use the more conservative of the 4.25 and 4.26 lows)

4.65 - 4.26 = 0.39 points

4.26 - 0.39 = Target: 3.87

Be careful, guys.   ;)

The thing that strikes me as weird is that volume yesterday was no where near the volume on the earlier breakout even with what I see as being much better news.

Quote from: Melf Elf on December 21, 2006, 11:17:18 AM
50% fib retracement it 3.87

kslifka,

FWIW, this morning's pattern break below 4.25-4.26 put 3.87 IN PLAY.

3.87 MADE.

Quote from: Melf Elf
3.87 MADE.

Well done, Melf and kslifka. Applause

Quote from: nutsterrt on December 21, 2006, 12:11:36 PM

Quote from: Melf Elf
3.87 MADE.

Well done, Melf and kslifka. Applause

nutsterrt,

That was interesting, how kslifka's retracement was the same as the target.

3.87 didn't hold, probably because of this Symmetrical Triangle that broke to the downside (Bearish Continuation pattern).  The break put 3.78 IN PLAY.  The low, so far, is 3.81, so fairly close.

Math:

4.22 - High of the pattern
3.95 - Low of the pattern

4.22 - 3.95 - 0.27 points

The breakdown occurred at 4.05 - 0.27 = Target: 3.78

Bought SIGA at 4.00.  Stop: 3.91, below the 1:25 PM low, prior to the rally to 4.16.  Risk: a loss of 2.3%

Looks like an Inverse H&S.  Breakout is above 4.16.

Yeah you gotta be real careful when playing these volatile suckers (I have been at it lately, and mostly fairly well - dunno if it is luck or careful 1min chart studying  ???)

I was lucky to see SIGA a couple minutes after it broke yesterday and averaged into a position around 3.30.  I really wanted to sell some yesterday at the end of the day, as I had a strong feeling we would see a pullback today, but pattern daytrading rules forbade it.  So I sold half at 4.50 at the open, holding the other half to see what the day brought, after the first reaction low at 4.25 showed support here, I immediately set a stop on the remainder of my position a little below that, at 4.19, to give it a bit of lee-way.  Sure enough, SIGA broke down on volume through 4.25 and took out my stop.

It brings me to thinking about these kind of highly volatile momentume plays as being incredibly difficult to figure out.  The only way I can work them is by aiming to sell half whenever I think "whoa there she goes, this is crazy" as it runs up, and then protect the rest with a stop that I keep moving as the patterns I see develop.  The problem being that (as we all know) the patterns evolve in ways that are not entirely evident at the time, and chances are, in a volatile stock like these ones, wherever you set your stop, you WILL be stopped out on the remainder, as the swings are so wide that unless you are willing to risk 20%+ of your current value, and put it WAY lower than you will think it will go (just look at ESCL today - people playing that who set stops below $10 for example, thinking there's NO WAY that'll trigger, got hammered).  I have also been working on using aggressive stops and protective stops in combination  when a stock is running hard, like ESCL did yesterday.  However, my aggressive stop ALWAYS gets hit (and often my protective stop too).  Seems better to sell some whenever you think things are going a little bit too well, they probably are.

Speaking of intraday invers H&S breakouts - have a look at MAMA - there she goes again!!!

Quote from: Melf Elf on December 21, 2006, 02:38:26 PM
Bought SIGA at 4.00.  Stop: 3.91, below the 1:25 PM low, prior to the rally to 4.16.  Risk: a loss of 2.3%

Looks like an Inverse H&S.  Breakout is above 4.16.

Aw-w, they got me.  Stopped out at 3.90.  Loss: 2.5%.

That went on much too long for a Right Shoulder, but I stuck with the plan, looking for a Bull Flag morph.

Quote from: ScottishTrader on December 21, 2006, 03:19:19 PM
It brings me to thinking about these kind of highly volatile momentume plays as being incredibly difficult to figure out. 

Scotsman,

No kidding!  :D

I thought my trade would be okay.  Curses!  :D  >:D

Quote from: ScottishTrader on December 21, 2006, 03:19:19 PM
Yeah you gotta be real careful when playing these volatile suckers (I have been at it lately, and mostly fairly well - dunno if it is luck or careful 1min chart studying  ???)

I was lucky to see SIGA a couple minutes after it broke yesterday and averaged into a position around 3.30.  I really wanted to sell some yesterday at the end of the day, as I had a strong feeling we would see a pullback today, but pattern daytrading rules forbade it.  So I sold half at 4.50 at the open, holding the other half to see what the day brought, after the first reaction low at 4.25 showed support here, I immediately set a stop on the remainder of my position a little below that, at 4.19, to give it a bit of lee-way.  Sure enough, SIGA broke down on volume through 4.25 and took out my stop.

It brings me to thinking about these kind of highly volatile momentume plays as being incredibly difficult to figure out.  The only way I can work them is by aiming to sell half whenever I think "whoa there she goes, this is crazy" as it runs up, and then protect the rest with a stop that I keep moving as the patterns I see develop.  The problem being that (as we all know) the patterns evolve in ways that are not entirely evident at the time, and chances are, in a volatile stock like these ones, wherever you set your stop, you WILL be stopped out on the remainder, as the swings are so wide that unless you are willing to risk 20%+ of your current value, and put it WAY lower than you will think it will go (just look at ESCL today - people playing that who set stops below $10 for example, thinking there's NO WAY that'll trigger, got hammered).  I have also been working on using aggressive stops and protective stops in combination  when a stock is running hard, like ESCL did yesterday.  However, my aggressive stop ALWAYS gets hit (and often my protective stop too).  Seems better to sell some whenever you think things are going a little bit too well, they probably are.

Speaking of intraday invers H&S breakouts - have a look at MAMA - there she goes again!!!

ScottishTrader...Do you have Ameritrade???  I had that daytrading flag come up too.  I called TDAmeritrade...and they said the daytrading rule doesn't apply unless you have less than $25,000 in your account.

So I missed on selling yesterday too >:(

Some large buying orders coming in, back above 4$ at the moment ...

Not to rain on anyone's parade, but the following 8-K came out after the bell and appears to be putting a dent in SIGA:

On December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the "Complaint") against SIGA Technologies, Inc. ("SIGA") in the Delaware Chancery Court. PharmAthene's complaint alleges that it has the right to license exclusively development and marketing rights for SIGA's drug candidate, SIGA-246, pursuant to, among other things, the recently terminated merger agreement between the parties. PharmAthene's complaint further alleges that SIGA failed to negotiate the terms of such license in good faith and otherwise failed to grant such license, and it seeks to compel SIGA to enter into such license and pay unspecified damages. SIGA believes that the complaint lacks merit and intends to contest vigorously the alleged claims.

Hm, imo SIGA did nothing wrong by terminating the deal, they had every right to!


ARTICLE XII

TERMINATION

12.1 Termination.



(b) This Agreement may be terminated by SIGA upon the execution of a Superior Agreement (as defined below) by SIGA. SIGA shall not execute a Superior Agreement unless (i) the SIGA Board of Directors has received a Superior Proposal, (ii) in light of such Superior Proposal, the SIGA Board of Directors has determined, in good faith by resolution duly adopted after consultation with outside counsel, that it is necessary for the SIGA Board of Directors to withdraw, amend or modify its approval or recommendation of this Agreement or the Merger in order to comply with its fiduciary duties to the stockholders of SIGA under applicable Law, (iii) SIGA has provided written notice of the determination described in clause (ii) above to Pharmathene, which notice has attached to it a copy of the definitive agreement or agreements containing all of the terms and conditions of such Superior Proposal (the "Superior Agreement"), (iv) at least five (5) business days following receipt by Pharmathene of the notice referred to in clause (iii) above, and after taking into account any revised proposal made by Pharmathene following receipt of the notice referred to in clause (iii) above, such Superior Proposal remains a Superior Proposal and the SIGA Board of Directors has again made the determination referred to in clause (ii) above (it being understood and agreed that any change to the financial or other material terms of such Superior Proposal shall require a new notice to Pharmathene under clause (iii) above and a new five (5) business day period under this clause (iv)), and (v) SIGA has not breached Section 7.13 in any material respect.

12.2 Termination Fee.

(a) If this Agreement is terminated pursuant to Section 12.1(b), SIGA shall pay Pharmathene upon demand a termination fee equal to three percent of the value of SIGA, as determined in accordance with the terms of this Agreement.

(b) All termination fees shall be paid by SIGA by wire transfer of immediately available funds to such account as shall have been designated by Pharmathene.

FREE FALL TODAY?

Looks like we're back in business now, nice.  :D

I think it's really hard to judge anything during this week between x-mas and newyears. Volume is low, so stocks are easily moved.

Still like SIGA, though.

does SIGA fits in Aussie's STEPS?

Showing a lot of strength over the last few days. I think this will build a lot of confidence for whoever wants to buy in!

iAT this level it's interesting....

Just went below the 50 SMA and 20 EMA today. Might be a good buying opportunity. It could be risky though. The last day and a half has seen some heavy selling. I'm guessing the reason could be the overall market has been quite choppy and hasn't provided clear direction. So, a lot of money might be waiting on the sidelines for things to settle down.

Back above the 50MA on takeover rumours ...

http://www.tradethenews.com/story/151571 (http://www.tradethenews.com/story/151571)




(http://img114.imageshack.us/img114/1078/sigais1.png)

Anyone still following this one here? Chart seems interestingly poised. Extremely low volume today. The stock has been pretty anemic over the last few days and has generally followed the NASDAQ lower. Hopefully, the IXIC will rally tomorrow and have us green going into the weekend.

The problem with the SIGA chart is it says clearly that it can't sustain any serious buying pressure.  Every time they release some good news it goes (or gaps) up like crazy and then just sells off, and you really don't know when the next news event that will cause it to jump will be.  But each time, pretty much everyone who bought in after the news event is under water.  I would call it a "jump n dump".  SIGA really needs to show some kind of uptrend before it looks bullish to me.  Otherwise it is just way too risky.

TA-wise currently it, looks to be sitting at the base of a descending triangle.  I suppose you could get a low-risk entry around 3.40 and hope that 3.36 support holds, and that uptrend starts forming, but right now I'm not too keen to play that kind of game.

Longer term it needs to break $5 on a closing basis (currently a long way off) to show that it has really broken out of this cycle.

Hope this helps.

Thanks Scottish. The reason I'm hopeful on this one is because the downside risk is a lot less than it was last month. For the past few days, the 50SMA, 20EMA and the 10EMA have been lying on top of each other and the stock has been hugging these curves as well. In fact today the 20EMA and the 50SMA are going to be intersecting. So, coupled with yesterday's low volume (the lowest it has been in the past few months) I think something is brewing. If anything, yesterday would have been the day for the shorts to push the stock down and they didn't.

Currently, Siga is conducting new animal efficacy tests, which should be released anytime. Plus, I believe Pharmathene's complaint will be thrown out soon as well.

Overall, I think this might not be a bad time to open up a position in this.

Doji day. The market was really brutal to most stock. Siga held up quite well. A whole lot of technical indicators went off today and yesterday (EMA & SMA crossing, doji). The volume was again really low. This leads me to believe that this stock has really bottomed out. The only other dues we might have to pay might be the 76.4% retracement of the monster move on Dec 20th from 2.75 to 4.95, which comes in at 3.27 (which we already hit when the Pharmathene lawsuit news came out on Dec 23rd AH).

We've bounced off 3.37 three times in the last three weeks. Every time that happened, we had a strong move upwards on the next day. However, the last time that happened, the 61.8% Fib retracement became the resistance. We have to see whether we can get past that this time.

Of course, I could be wrong and might be taken to the cleaners too. GLTA.

i think your analysis is reasonable - whenever you see a stock that doesn't get hit by a market wide smackdown like today, yoou gotta ask why.  Really all you need to do is set a stop loss you are comfortable with and ride it to see where it goes.  If you think it won't go much below 3.36, set you stop just below there.  You could be right and we amy see some positive movement.  My point before (I didn't mean to sound too bearish) is that I would like to see a bit of positive action BEFORE I jump back in this one.

Anyway, good luck with it!!

SIGA moving pre-market...don't know why yet??

hm, looks good, yesterday AH there was already some movement but not so big as now, something must be up ...  :)

You got in wontfindaname.  Good call, applauds.  No idea whats going on, but you read the situation to perfection.  currently up 25%+  Congrats  ;)

Thanks. I still don't know what is causing this and when I need to get out. Waiting for the PR. I think this must be the Pharmathene lawsuit being dismissed. I expect a PR around 2:00 PM because that's when they usually release it.

Nice call, wontfindaname.

The breakout of this Descending Triangle is at 3.665, so a gap up opening above that will put 4.09 IN PLAY (the top of the pattern), and 4.38 IN PLAY (measured move) if you're looking for targets to take profits, and to defend against a "Gap To Crap" opening.

Good luck!

Could it be the WHO report that came out. It states that SIGA246 is 8000 times better then any other.Im just guessing thats whats causes this.I feel this has a long way to go over the next year or so.

Quote from: etercnoc on January 19, 2007, 10:12:39 AM
Could it be the WHO report that came out. It states that SIGA246 is 8000 times better then any other.Im just guessing thats whats causes this.I feel this has a long way to go over the next year or so.

Isn't this report already a few days old, would be strange if the reaction to it is so late, must be something else imo ...

Yea you may be right.Looks like its fading off now.Guess we will just have to wait and see.  ;DHAVE A GOOD DAY

Has anyone called investors relations at SIGA?
Maybe theres a new deal with major pharma or buyout offer.
Something caused this gap on volume and this 3.80s settle.

I did. They think it might be the WHO report which is finally garnering some attention.

Quote from: wontfindaname on January 19, 2007, 02:44:25 PM
I did. They think it might be the WHO report which is finally garnering some attention.

Did they say something else, other news coming or ...?

They didn't mention any other news.

However, from a post on the Yahoo board, somebody posted that they spoke to the CEO earlier this week and they were told that papers were filed against the Pharmathene complaint 10 days ago and they can expect it to be dismissed soon. Also, new animal efficacy tests were scheduled to begin on Jan 9th, the results of which should be out soon.

An interesting note from today's trading is that we bounced off of the 76.4% retracement of today's gain at 3.66.

Still holding here and I think(hope) we will be rewarded soon ...  :)

Here's the link to the WHO report (chapter 7) for those who haven't seen it yet.


http://www.who.int/csr/resources/publications/WHOCDSEPR2007_1.pdf (http://www.who.int/csr/resources/publications/WHOCDSEPR2007_1.pdf)

7. Candidate antiviral drugs
7.1 Dr Dennis Hruby reviewed data available on the discovery and development of ST-246, a new candidate antiviral drug. The drug is 8000 times more potent than Cidofovir, can be delivered orally and is relatively easy to synthesize. It is effective against all tested orthopoxviruses, preventing the wrapping of intracellular mature virus (IMV) by intracellular membranes and thereby the formation of extracellular virus particles. The target of the drug is F13 (according to the nomenclature used for the vaccinia Copenhagen strain), a protein essential for the production of extracellular enveloped virus.

7.2 ST-246 is highly effective when given 4–72 hours post infection with a range of
orthopoxviruses in small rodents. It can be used prophylactically and therapeutically and can even be given simultaneous with vaccination, without interfering with the immune response to the vaccine.

7.3 Studies for gaining regulatory approval of the drug are now in progress. The drug has a long biological half life of approximately 18 hours which suggests that a once-a-day
oral regimen might be sufficient. Current information suggests that its bioavailability is good and that there are no adverse side effects. In vitro tests show that the antiviral effects of ST-246 are reproducible across different variola virus strains. Drug resistance to ST-246 can occur with an estimated frequency of 2.5 x 10-6. ST-246 is considered superior to Cidofovir preparations, which are in a more advanced state of drug approval.

7.4 Initial studies indicate that ST-246 is inherently stable and so strategies for creating stockpiles can be developed.

7.5 Dr John Huggins then gave an overview of the current status of antiviral drug development using the current monkeypox and non-human primate variola virus disease models. ST-246 was clearly seen as the drug of choice but Cidofovir could be used as the test case for licensure issues, particularly because its safety in humans did not need to be established. Cidofovir had a proven efficacy with respect to orthopoxvirus infections and protocols had been submitted to the US FDA for consideration under the Special Protocol Assessment Provision. If successful, this will enable the drug manufacturer (Gilead Sciences) to submit a proposal for regulatory approval for this indication. This will be done in parallel with further work on ST-246.

7.6 It was noted that ST-246 was a non-toxic inhibitor of variola virus spread that can be given orally. Clinical safety will be determined in humans and efficacy studies will be performed in non-human primate models of variola virus and monkeypox virus to support an application for orphan drug status of the compound. However, oral drugs may not be well tolerated in severely ill individuals and hence alternative formulations of ST-246 may need to be developed, which can be administered via different routes.
The fact that ST-246 was highly specific in inhibiting the spread of orthopoxviruses was emphasized, as was that this could result in its wider deployment as a potent antiviral compound. Overall, ST-246 looked like an excellent drug candidate that has provided solid protection against challenge by different orthopoxviruses, including variola virus, in all models examined.

Also PharmAthene has moved on and is going public with another company.Looks like to me we should start getting alot of good news reports soon.Market cap has along was to go ,JMHO

Quote from: Melf Elf on January 19, 2007, 09:23:23 AM
The breakout of this Descending Triangle is at 3.665, so a gap up opening above that will put 4.09 IN PLAY (the top of the pattern), and 4.38 IN PLAY (measured move) if you're looking for targets to take profits, and to defend against a "Gap To Crap" opening.

It was a "Gap To Crap" opening.  4.09 MADE at the open.  4.38 still is IN PLAY.

Quote
The breakout of this Descending Triangle is at 3.665,

The low of the day, after the "Gap To Crap" high of 4.22, was 3.66, right at the top of the pattern.

During the past two sessions, the top of the pattern has been support.  I like that.

SIGA is indicated at BID 3.88...ASK 3.89.

I don't like it well enough to pay that price, but I'll pay 3.78, if they'll let me have it.

Bought SIGA at 3.78.  Stop: 3.59.  Risk: a loss of 5%.

Glad to see you aboard Melf, good luck to all of us! :)

Quote from: Se7en on January 24, 2007, 09:47:51 AM
Glad to see you aboard Melf, good luck to all of us! :)

Se7en,

Thanks.  Yes, good luck to all of us!  ;)

I've been impressed that SIGA has been using the top of the pattern as support, rather than filling the big gap from the "Gap To Crap" last Friday.

I planned to buy it this morning on a print of 3.77, a tick above yesterday's high.

When I saw it indicated at BID 3.88 - ASK 3.90, I figured that I had a chance to get it at 3.78, in case 3.77 was hit on the BID, and that it would bang off there, and go higher.

It took a long time to get filled at 3.78.  They filled me in 3 different batches, maybe 15-30 seconds apart, so that looked like a good indication that I probably got in near the low of the day.

At worst, I thought we'd fill 3.74, from yesterday's close.

NOPE.  We retraced it all, and went red.

Right now, it's looking like I bought near the top of another "Gap To Crap!"  :D

Curses!  >:D  :D

3.62 and 3.63 are the lows of the past two days' test of the top of the pattern, so I'll stop it out under there.  We "could" find support a little below there, but I don't want to sit here guessing, with that gap yawning below us. 

We made a "higher high" this morning, above yesterday's candle, so if we now go down and take out those 3.62 - 3.63 lows, I'll take the 5% hit.  I won't like that.

It would be nice if we could rally back to the high 3.70s/3.80s at the close.

hi ,
just put an order in for 373.
5min chart looks healthy, macd and cci about to cross over , needs some volume push though. i haven't been filled yet . 373 may have past me by.
i am pacient these days . i will wait
maxi
p.s. just got filled

Quote from: Melf Elf on January 24, 2007, 10:39:21 AM
[We made a "higher high" this morning, above yesterday's candle, so if we now go down and take out those 3.62 - 3.63 lows, I'll take the 5% hit.  I won't like that.

When SIGA went down to 3.63 this morning, if any of you had asked me what I thought would happen, my response would have been, "You're about to see me take a 5% hit on this trade."

You see why I never try to predict anything!  :D

Quote
It would be nice if we could rally back to the high 3.70s/3.80s at the close.

We didn't get that close, so I really should have abandoned this trade when that didn't occur, rather than sit and "hope" to get saved by the market.  That usually doesn't happen.

But, this trade might turn out alright.  A printed a new high on the day of 3.78  right near the close, so SIGA might want to do something on the upside next week.

In the short-term hourly chart, we now have the chance of a little "W"-bottom breakout with a print next week of 3.84, that would put 4.03 IN PLAY.

Math:

3.83 - Middle, or "pivot" of the "W"

3.63 - Lows (I use the more conservative of the 3.62 - 3.63)

3.83 - 3.63 - 0.20 + 3.83 = Target 4.03.

4.38 still is IN PLAY from last Friday's Symmetrical Triangle "Gap To Crap" breakout, so we've got a chance at seeing the 4.00s again.

Good luck to us next week!  ;)

Quote from: Melf Elf on January 24, 2007, 09:46:35 AM
Bought SIGA at 3.78.  Stop: 3.59.  Risk: a loss of 5%.

Sold SIGA at 3.65.  Loss: 3.4%

This has been a "coulda...shoulda...woulda."

I "shoulda" sold this the day that I "paid up" for it, when it didn't do anything.

I "shoulda" sold it a couple of times after that,  at a break even, when I had the chance.

The 3.62 - 3.64 lows just broke, so I sold on a little bounce here.  It "could" work out okay, but it also "could" go down and fill that gap at 3.41.  :P

I took the hit.

SIGA currently is BID 3.64...ASK 3.65.

New CEO appointed.

There was also a brief news on the wire about initial human safety data (which I thought were completed last year). I don't know whether that was a mistake or what.

I called the company. Yes, the last paragraph was a mistake on the wire. The CFO seemed really upbeat about the hiring of the new CEO! Eric Rose was the heart surgeon for Bill Clinton two years ago. He is apparently very well connected and is capable of bringing in the big dough for the company using his influence. He has taken a two year leave of absence from Columbia to take this post. The CFO joked about how after two years, the company will be doing so well that they should be gobbled up by a bigger firm and Dr. Rose will not be needed anymore.

Bullish engulfing candlestick posted today. We really need a few up days to consolidate the PPS at a higher base before the next news event. I really don't think it is good for the stock to keep drifting downward.

Nice run today! Let's see whether we can hold these gains this time. This is one of those stocks is due for an extended uptrend instead of monster moves followed by pullbacks. It'd be nice for a change to see green for a few days in a row.

Nice setup for next week. It would have been nicer if it had closed over 4. But, considering the steady downward drip that has been seen over the last few months, a few white candlesticks in a row are an extremely good sign!

SIGA's chart is getting interesting again... time to make some moolah again! ;D :D

Yes you are right, but I would like to see a little more volume before
getting in.

Quote from: jorgegr on February 09, 2007, 06:10:11 PM
Yes you are right, but I would like to see a little more volume before
getting in.

Volume only comes out big time when news come out, next thing you know it's already up 100 percent and traders starts selling their shares. ;)

Actually, the volume was even greater today than Oct. 17 & Dec. 19 from last year, before the day the news came out.

Based on the current chart, a positive news about their Smallpox Drug (SIGA-246) this thing will rocket again.. IMHO ;) :D

Great work Terliso, Applaud
I am still holding some SIGA
Have a great weekend.
SMTX may have a news or earnings run as well
Cheers joe

Quote from: Melf Elf on January 26, 2007, 04:19:35 PM

In the short-term hourly chart, we now have the chance of a little "W"-bottom breakout with a print next week of 3.84, that would put 4.03 IN PLAY.

Math:

3.83 - Middle, or "pivot" of the "W"

3.63 - Lows (I use the more conservative of the 3.62 - 3.63)

3.83 - 3.63 - 0.20 + 3.83 = Target 4.03.

4.38 still is IN PLAY from last Friday's Symmetrical Triangle "Gap To Crap" breakout, so we've got a chance at seeing the 4.00s again.

Good luck to us next week!  ;)

Target 1 made, target 2 almost made ...  :)

No plans of selling here, waiting for the big jump!  ;)

Quote from: Se7en on February 12, 2007, 10:38:29 AM

Target 1 made, target 2 almost made ...  :)

No plans of selling here, waiting for the big jump!  ;)

Se7en,

Target #2: 4.38 just MADE.  Nice going!  ;)

SIGA caught my attention today.
I'm not sure if we're allowed to post the suspected AX here at 3SOF.
Just waiting for planets to align and to see a block trade to support the stock. If this thing goes, shorts could be in hot water.
What I'm counting on in here is:
1) The strength of the trend
2) Shorts buying to cover
3) Buying from regular investors and
4) Institutional buying interest to come in.
but there's still no guarantee and it's good to have a stop loss.

Volume doesn't look that great yet but is higher than the previous day's.
May pick up at the shakeout.
StockScores currently at 98/85.(Another school that could be looking at this)

Quote from: jorgegr on February 09, 2007, 06:10:11 PM
Yes you are right, but I would like to see a little more volume before
getting in.

Now, we got more volume, are you IN?

Still waiting for a  green block. May pass up on this if there's none.
I'd like to see that 4.60 resistance broken by blocks of green.
It looks like this stock is moving in 25 cent increments.
Target: 4.85
Resistance: 4.60
Support: 4.35
Support: 4.10

Quote from: Terliso on February 12, 2007, 01:34:13 PM

Quote from: jorgegr on February 09, 2007, 06:10:11 PM
Yes you are right, but I would like to see a little more volume before
getting in.

Now, we got more volume, are you IN?

Bought @ 4,25 - good luck to all

Deleted

Sell the news?!  >:(


SIGA Begins Second Human Safety Trial of Its Lead Smallpox Drug
Tuesday February 13, 2:45 pm ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of SIGA-246, its lead smallpox drug. The study will examine the safety and pharmacokinetics of SIGA-246 at three different dosages in healthy volunteers when taken once a day for 21 days.

"This is one more milestone in the path to FDA approval," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "This important study we believe will confirm the safety findings of an earlier human study and establish the likely human dose of SIGA-246."

The trial is being conducted at the Orlando Clinical Research Center in Orlando, FL, and is overseen by Dr. Thomas Marbury in collaboration with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The study is a double-blind, randomized, placebo-controlled, ascending multiple-dose study.

SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. SIGA-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has already demonstrated significant antiviral activity in various animal trials, including the complete protection against human smallpox virus in primates as well as complete protection in two primate trials against high doses of monkeypox.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

http://biz.yahoo.com/bw/070213/20070213006285.html?.v=1 (http://biz.yahoo.com/bw/070213/20070213006285.html?.v=1)

(http://stockcharts.com/c-sc/sc?s=SIGA&p=D&b=5&g=0&i=t68303711613&r=8123)

On the verge of a major MA crossover.

Wow! Nice action again!

Quote from: wontfindaname on March 08, 2007, 04:19:46 PM
Wow! Nice action again!

I guess it was some short covering or maybe someone knows something, actually it doesn't matter, as long as we go up! :)

Still holding long and strong!

There have been some developments in the complaint filed by Pharmathene. The motion to stay discovery filed by Siga was granted. This info is available in LexisNexis file and serve. Also, a lot of promising developments on the government front: Siga recently made a presentation to NIAID in which there was a hint that an emergency stockpile fund application may be made in Q1 2007. If that is granted, I see this stock going through the roof. We could see as much as 10 by then. Also, if the Pharmathene complaint is dismissed, we could see some M/A activity.

Quote from: wontfindaname on March 12, 2007, 11:31:15 AM
The motion to stay discovery filed by Siga was granted.

Hm, my English is not that great, what does it exactly mean? thx

Well, it's legal motion. Pharmathene filed a complaint against Siga. Siga filed a motion to dismiss the complaint. They also filed a motion to stay discovery, which means that they want Pharmathene to stop gathering any further evidence to support their complaint. That motion was granted. That is a very positive signal usually.

this news could be explosive for SIGA soon:  ??? watch next week IMO

'US child in hospital after father has smallpox jab
The child has been treated with immune globulin, an antiviral drug called cidofovir, and an experimental antiviral made by Siga Technologies (SIGA.O: Quote, Profile , Research) called SIGA-246, Damon said.

"We are cautiously optimistic that the child is improving," Damon said.'

http://yahoo.reuters.com/news/articlehybrid.aspx?type=comktNews&storyID=urn:newsml:reuters.com:20070317:MTFH27966_2007-03-17_05-00-27_N16213321&pageNumber=1&imageid=&cap=&sz=&WTModLoc=HybArt-C1-ArticlePage1

This is indeed very positive news for Siga (and hopefully the child becomes better too). Unfortunately I'm going to be on vacation from tomorrow till the middle of the week. So I'll have to login to my brokerage from my phone to keep tabs on the stock price. I hope it doubles!!!

definitely has double potential shortterm and much more longterm ;D

but that just my opinion

Great news!!!


Dad's smallpox shot infects son, 2
Experimental drugs bring Ind. boy back from brink of death

March 18, 2007
BY DAVE NEWBART Staff Reporter
A 2-year-old boy stricken with a rare infection from the smallpox vaccine is improving but remained in critical condition Saturday at the Comer Children's Hospital at the University of Chicago.

The boy was infected by his father, a U.S. soldier who was vaccinated in January in preparation for service in Iraq. But his deployment was delayed, and he returned home to Indiana late last month. His son, who suffers from skin lesions known as eczema, then became infected by vaccinia, a virus similar to smallpox and used in the vaccine against it.

The boy is the first person to suffer from the severe infection, known as eczema vaccinatum, since the U.S. military began inoculating troops in 2002. But his condition is so uncommon that U. of C. experts said they could not find reports of any cases in the United States since before 1972, when routine vaccinations for smallpox were halted.

Only seen in photos
"This is something that is new to us," said Kenneth Alexander, head of pediatric infectious disease at U. of C.

The boy, whose name was not released, was sent to U. of C. from a northwest Indiana hospital March 3 after he developed a severe rash. He didn't improve after treatment, and by March 7, a dermatologist noticed his lesions resembled those caused by smallpox -- something doctors had only seen in photos because the disease was eradicated.

Doctors contacted the federal Centers for Disease Control and Prevention, which agreed to fly in a treatment never used on a child, vaccinia immune globulin (VIG). The drug was hand-delivered by U.S. marshals.

The boy's condition continued to worsen, and last weekend, his lungs and kidneys began to fail. "He was near death," said Madelyn Kahana, chief of pediatric critical care medicine. Painful skin lesions covered most of his body.

'He is slowly improving'
The CDC then asked the Food and Drug Administration to grant emergency permission to try ST-246, an experimental drug being developed to fight smallpox. It had been effective in treating mice and monkeys infected with the virus, said U. of C. pediatrician John Marcinak, who is spearheading the boy's treatment. But it had never been used on a sick person.

That, combined with VIG and another drug, seems to be working. Since he first got the drug March 11, "he is slowly improving," Marcinak said.

The boy's mother contracted a milder form of the vaccinia virus from the boy and has been quarantined in the boy's room but is recovering well, officials said.

She has cried some days but in general has been "very strong and optimistic," said Surabhi Vora, a U. of C. fellow who has been assisting in the boy's treatment.

'Military has to be careful'
Doctors said the father -- who has since returned from his deployment at the hospital's urging -- had no idea he should stay away from his son after receiving the vaccine.

Kahana said the "military has to be careful" in making sure soldiers understand the risks and that they stay away from high-risk populations, such as people with eczema.

"They are trying to figure out where the misstep was," she said of the military. A military spokesman could not be reached Saturday.

The boy has two siblings, but no one else appears to have been infected, doctors said. The hospital has taken extreme precautions in treating the boy -- including keeping him in a room where the air only flows inward. Officials say the general public is not at risk because the infection is only transmitted through close physical contact.

Now doctors are just hoping the boy will make a full recovery. Before the infection worsened, the boy was fairly cooperative and talkative, saying "cup, cup, cup" when he was thirsty, Vora recalled. But since then, the boy has been sedated and is on a ventilator.

"I'm looking forward to seeing him awake and talking," she said.

http://www.suntimes.com/news/metro/302333,CST-NWS-VACCINE18.article (http://www.suntimes.com/news/metro/302333,CST-NWS-VACCINE18.article)

HALTED gonna gap and run :o :o :o :o :o
this trial by fire is better than a pr

Of course I didn't buy this but I wonder after this gaps up, if waiting for a bit to see if this will be a good entry point within the first hour...maybe too big of a gap to buy in.

Get fully loaded in this if your not already.BUY ON ANY WEAKNESS THIS MORNING. tALK TO SIGA THEY SAID GOVT/CDC WAS KEEPING A TIGHT LIP ON THIS FOR NOW.Once boy is better this will be on every major news source around the world.SIGA ceo Dr.Rose will be on every news interview. GET N Alot of news to follow.

Siga in the midst of a major breakout. I've been in this for 6 months already. Looks like it's paying off big-time!!

SIGA looked real good today - we've had 3 straight days of positive gains, and today we got a gap up above previous short term resistance.  That level (at $5.30) was tested early on, but SIGA rallied right at the close to finish at the HOD.  And it is up AH too.  Very nice.  Good to see some sustained strength in SIGA, and Looking for it to test te $6.00 level shortly.

Quote from: wontfindaname on April 09, 2007, 04:09:13 PM
Siga in the midst of a major breakout. I've been in this for 6 months already. Looks like it's paying off big-time!!

me2, still holding ...  :)

New 6 year high close for SIGA!  :)

If news will come out about a possible contract/testing results that are finished/'lawsuit'/ or an official release from SIGA/FDA about the boy's improved health, this could see the double digit's soon imo!


http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070413:MTFH80014_2007-04-13_19-13-54_N13208796&type=comktNews&rpc=44 (http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070413:MTFH80014_2007-04-13_19-13-54_N13208796&type=comktNews&rpc=44)
UPDATE 1-New treatment aids U.S. toddler with rare ailment
Fri Apr 13, 2007 3:14pm ET16



(http://img160.imageshack.us/img160/6779/sigarc2.png)

Anyone still watching this one? Major breakdown recently. Trading at less than 50% of high made in April on no real negative news. Could be a good entry point.

Quote from: wontfindaname on July 18, 2007, 02:32:35 PM
Anyone still watching this one? Major breakdown recently. Trading at less than 50% of high made in April on no real negative news. Could be a good entry point.

Only watching at the moment but no position anymore!

You got lucky. You avoided the big drop, huh?

Broke the channel. Should be headed further up soon.

wontfindaname ,from looking at the chart you posted.
Looks like a text book,
Falling Wedge (reversal) Pattern.......What say you ?

Applaud the update....... ;)  ;D

• SIGA Technologies Selected to Join the Russell Microcap Index
Business Wire (Tue, Jun 19) 


52wk Range: 1.00 - 6.04
Volume: 713,302
Avg Vol (3m): 290,438

Technicals
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
6.88%above 13-day MA
-5.78%below 50-day MA
RS Rating: 4 

Fundamentals
Key Data:
Market Cap (M): $95.45 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/09/2007
Last Analyst Rating: N/A


Falling Wedge (Reversal) Pattern :

The falling wedge is a bullish pattern that begins wide at the top and contracts as prices move lower. This price action forms a cone that slopes down as the reaction highs and reaction lows converge. In contrast to symmetrical triangles, which have no definitive slope and no bias, falling wedges definitely slope down and have a bullish bias. However, this bullish bias cannot be realized until a resistance breakout.

The falling wedge can also fit into the continuation category. As a continuation pattern, the falling wedge will still slope down, but the slope will be against the prevailing uptrend. As a reversal pattern, the falling wedge slopes down and with the prevailing trend. Regardless of the type (reversal or continuation), falling wedges are regarded as bullish patterns.

As with rising wedges, the falling wedge can be one of the most difficult chart patterns to accurately recognize and trade. When lower highs and lower lows form, as in a falling wedge, a security remains in a downtrend. The falling wedge is designed to spot a decrease in downside momentum and alert technicians to a potential trend reversal. Even though selling pressure may be diminishing, demand does not win out until resistance is broken. As with most patterns, it is important to wait for a breakout and combine other aspects of technical analysis to confirm signals.

Yes, I think you nailed the pattern. Now, it's time to wait for the real breakout.

Just a small update. SIGA seems to be nicely following through after the falling wedge reversal breakout.

Yep!

This one is looking good.  Looks like a 3 week ascending triangle breakout that's been forming since the wedge break.   Volume has been picking up.  Probably needs a close at least above 3.5 on strong volume to continue.

Quote from: setravis on July 25, 2007, 09:31:21 PM
wontfindaname ,from looking at the chart you posted.
Looks like a text book,
Falling Wedge (reversal) Pattern.......What say you ?

Applaud the update....... ;)  ;D

Quote from: wontfindaname on July 27, 2007, 03:48:08 PM

Quote from: wontfindaname on July 27, 2007, 03:48:08 PM
Yes, I think you nailed the pattern. Now, it's time to wait for the real breakout.

Quote from: wontfindaname on August 10, 2007, 04:28:04 PM
Just a small update. SIGA seems to be nicely following through after the falling wedge reversal breakout.

Quote from: mitchjas on August 13, 2007, 02:21:09 PM
Yep!

This one is looking good.  Looks like a 3 week ascending triangle breakout that's been forming since the wedge break.   Volume has been picking up.  Probably needs a close at least above 3.5 on strong volume to continue.

SIGA is a buy...
Broke through (back above) the 50-day MA

52wk Range: 2.52 - 6.04
Volume: 287,810
Avg Vol (3m): 203,330

Technicals
Closed Friday above the 50-day MA

Last Price Quote is:
15.45%above 13-day MA
9.31%above 50-day MA
RS Rating: 32 

Fundamentals
Earnings Expected on Aug 13

Key Data:
Market Cap (M): $113.87 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/07/2007
Last Analyst Rating: N/A

Shares Get Boost on Successful
Human Trial of Smallpox Drug Candidate
Shares of SIGA Technologies Inc (SIGA) got a boost on Thursday after
the successful completion of a "Phase I" human clinical trial of its lead
drug candidate for smallpox, ST-246. Preliminary results indicate that
the drug is safe and well-tolerated at all tested doses when administered
orally for 21 days to healthy human volunteers. In addition, blood
level exposures were dose-dependent, and the drug's half-life was sufficient
to support once-a-day dosing. "The data obtained here will be an
important and helpful part of our full submission for FDA approval," said
Dr. Eric A. Rose, Chief Executive Officer of SIGA. ST-246 has demonstrated
significant antiviral activity in various animal models of poxvirus
disease, including the complete protection of primates from lethal doses
of monkeypox and smallpox virus. In December 2005, the FDA granted
"fast-track" status to ST-246. In December 2006, the FDA granted to
ST-246 an orphan drug designation. This project has been funded in
whole or in part with Federal funds from the Biomedical Advanced Research
and Development Authority, Department of Health and Human
Services, in conjunction with the National Institute of Allergy and Infectious
Disease, National Institutes of Health, Department of Health and
Human Services. In addition to smallpox, SIGA has antiviral programs
targeting other Category A pathogens, including arenaviruses (Lassa
fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis),
dengue virus, and the filoviruses (Ebola and Marburg). "In the near
future, we will work diligently to complete the regulatory work needed to
initiate federal government procurement efforts and ultimately sell ST-
246 to federal, local, and international agencies charged with protecting
populations from bioterrorism. We also believe that private industry
will purchase our drug to protect their employees and their businesses
from the potentially calamitous impact of a bioterrorist attack," stated
Dr. Rose.

Dear Friends of SIGA Technologies,
It is with great pleasure that we announce the initiation of analyst coverage of SIGA Technologies by the firm of Ladenburg Thalman.

Front page highlight statements includes:

* "Initiating coverage of SIGA with a Buy rating and $5.45 price target"
* "SIGA is well positioned to capture a material portion of the 17-fold increase in federal funding for biodefence since FY 2001"
* "We expect SIGA to receive a $100 million procurement contract for ST-246 under Project BioShield as early as Q4 2008"
* "We expect an initial BioShield award to trigger other purchases of ST-246."

While SIGA will not redistribute the report on behalf of Ladenburg, you should note that overall the report does an excellent job of encapsulating the SIGA value proposition.  An excerpt from the report regarding the $5.45 price target is as follows:

"We are modeling revenue and earnings, respectively, of $7.1 million and $(0.22) in FY 2007, $8.1million and $(0.18) in FY 2008, $15.6 million and $(0.35) in FY 2009. We have not modeled a potential procurement award for ST246 into our FY 2008 or FY 2009 revenue projections, however, since the amount awarded would be recorded initially on the balance sheet as deferred revenue until delivery of ST246 is made. SIGA could initially draw down 50% of the award to fund manufacturing scaleup; subsequent draw downs would be based on the achievement of specified milestones.

In our view, SIGA's current $98 million market cap significantly undervalues the near and long term revenue potential of ST246 and affords little to no value to the Company's other product candidates in development. As noted above, we expect SIGA to receive a $100 million procurement contract for ST246 under Project BioShield as early as Q4 2008. Our initial twelve month price target of $5.45 is based on SIGA achieving a trailing P/S multiple of 25x, inline with a basket of small cap peers that also specialize in treatments for infectious disease. Notably, our target of $5.45 equates to a sales multiple of less than 2x the anticipated $100 million contract for ST246."

SIGA update:
SIGA: Manufacturing of Lead Smallpox Antiviral ST-246 to Begin
Friday , April 04, 2008 09:28ET

By Fain Hughes, [email protected]

SIGA Technologies, Inc. (SIGA) has initiated the activities necessary to produce the NDA registration batches of its lead smallpox antiviral, ST-246. In recent months, SIGA selected, following consultation with the FDA, the final chemical formulation for large-scale production. SIGA has also finalized the market image and packaging of the commercial material.

SIGA has contracted with Albemarle Corporation (ALB) to provide its scale-up and manufacturing services to produce three registration batches in anticipation of the upcoming pivotal safety clinical trial. In order to obtain FDA marketing approval, SIGA must manufacture "registration batches," which are commercial amounts of ST-246 produced in accordance with the FDA's current standards for good manufacturing practices, sometimes called "cGMP."

&

SIGA Advances ST-246 Smallpox Antiviral Development in Europe
Tuesday , April 15, 2008 08:00ET

NEW YORK, Apr 15, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a 'small and medium-sized enterprise' (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a smallpox antiviral and SIGA's lead product candidate. SIGA has also initiated the process for obtaining Marketing Authorization with ST-246 with the EMEA, which is the European equivalent of the United States Food and Drug Administration.

The European Agency for the Evaluation of Medicinal Products (EMEA) established SME as a dedicated office in 2005 to provide special assistance to small and medium-sized enterprises. SME provides qualified companies with scientific advice and protocol assistance in the development of new medical products. SME status also entitles SIGA to certain fee reductions or deferrals, including reduced fees for scientific advice and certain administrative services of the EMEA, and a deferral of the fee payable for an application for marketing authorization.

"Obtaining SME status is a significant achievement in our pursuit of European regulatory approval for ST-246. The SME Office works with small companies like SIGA to assist and provide support throughout the application process. We now have access to advice from the EMEA on the approval process for ST-246 that will allow us to expedite many of the procedures during the approval path. SIGA will continue to work closely with the EMEA in the coming months as it moves forward in its efforts to obtain marketing authorization in Europe for ST-246," Dr. Eric A. Rose, Chief Executive Officer of SIGA Technologies, stated.

In addition, SIGA engaged the SME Office in a pre-submission meeting to discuss development of ST-246 in Europe. The pre-submission meeting with the SME office provided regulatory guidance with respect to the approval process for ST-246 in Europe. SIGA is in the process of scheduling a Scientific Advice Working Party (SAWP) meeting with the EMEA to discuss the development path for ST-246.

Dr. Rose added, "The SAWP meeting will help SIGA construct an appropriate development pathway for ST-246 in Europe since there is currently no European guidance available on development of a drug that cannot be tested for efficacy in human beings due to the lack of a naturally infected population."

chart bullish:

BO Alert:

SIGA: Volume Spike; 61% > 20-adsv, Stock +11.45%
Thursday , April 17, 2008 15:20ET

This is the 1st VOLUME alert for SIGA in the past 7 calendar days.

Trading for SIGA Technologies Inc (NASDAQ SC: SIGA) has been heavier than usual in today's session. By 15:20 ET, the stock had already traded 236,807 shares via 600 trades. The cumulative volume is 61.16% above its 20-day average of 146,937. Normally the stock experiences around 322 individual trades per session.

So far, today's volume surge has caused a net rise in SIGA's stock price. At the time of this alert, the stock was trading at $3.310, up $0.340 (+11.45%).

One year ago, the Company's shares closed at $5.292. The price has declined more than 37 percent since then.

Over the last 10 trading session SIGA has traded in a range between $2.120 and $3.060 and is currently trading 39.71% below its 52-week high of $5.490 set on April 19,2007 and 85.96% above its 52-week low of $1.780 from March 17,2008.

In the previous 3 sessions, SIGA trading has displayed a positive trend. Closing results have been as follows:

April 16, 2008 --- closed at $2.970 up $0.070 (+2.41%) on 138,300 shares
April 15, 2008 --- closed at $2.900 up $0.056 (+1.97%) on 130,700 shares
April 14, 2008 --- closed at $2.844 up $0.084 (+3.04%) on 85,400 shares

The Company last released news on April 15, 2008:

"SIGA Advances ST-246 Smallpox Antiviral Development in Europe"

NEW YORK, Apr 18, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that its Chief Scientific Officer, Dr. Dennis E. Hruby, is presenting a Distinguished Lecture at the Centers for Disease Control and Prevention (CDC) in Atlanta on Wednesday, April 23, 2008. Dr. Hruby's presentation, entitled "Discovery and Development of a Smallpox Antiviral Drug," outlines the progression of SIGA's anti-orthopoxvirus drug, ST-246, from its discovery in the laboratory through SIGA's recent filing with the U.S. Food and Drug Administration (FDA) in support of an Emergency Use Authorization (EUA) application for the drug.

Commenting on the CDC presentation, Dr. Hruby stated, "We look forward to having a platform such as this to provide an update on the progress we have made with our ST-246 antiviral. We have recently achieved several milestones that are of significant importance, including the submission of our application supporting an EUA, the completion of our multiple ascending dose human clinical trial and initiating the process of obtaining marketing authorization in Europe. The CDC has a very intimate understanding of the seriousness of the smallpox virus and the threat that it poses to global health safety. We think that this forum will provide those attending with a better understanding of how far we have come in the development of ST-246 and the drug's capabilities in the event of a smallpox virus release."

Dr. Hruby will also meet with CDC colleagues to discuss a series of smallpox virus challenge studies in nonhuman primates designed to further define the window of protective efficacy of ST-246. In the past, ST-246 has demonstrated significant antiviral activity against both the monkeypox virus and smallpox virus in primate models of disease.

Dr. Hruby specializes in virology and microbial pathogenesis research, and the use of viral and bacterial vectors to produce recombinant vaccines. He is a member of the American Society of Virology, the American Society for Microbiology and a fellow of the American Academy of Microbiology.

The upcoming smallpox virus challenge studies are of special interest to the CDC and SIGA due to the successful effort by SIGA at CDC's request to help save the life of a 28-month toddler who had contracted a severe case of eczema vaccinatum (CID, 2008:46), which had arisen as a complication from smallpox vaccine administration. The FDA's issuance of a compassionate emergency usage approval at CDC's request allowed the child, who was near death and on the ninth day of hospitalization, to receive ST-246. The child's prompt recovery suggests that the therapeutic window for ST-246 use may extend beyond the onset of disease symptoms.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

SOURCE: SIGA Technologies, Inc.


KCSA Strategic Communications 
Todd Fromer, 212-896-1215 
[email protected] 
or 
Marybeth Csaby, 212-896-1236 
[email protected] 
or 
David Burke, 212-896-1258 
[email protected] 

Copyright Business Wire 2008

The Company recognized revenues from grants and contracts of $1.7 million for the quarter ended June 30, 2008, an increase of approximately 19% compared to same quarter of the prior year. Operating loss for the quarter was $2.1 million, essentially unchanged from the loss incurred in the prior year period. The recognition of a non-cash loss of $1.1 million reflecting an increase of the fair market value of certain rights and warrants to purchase common shares of the Company resulted in a loss per share, on a fully diluted basis, of $0.09 as compared to income of $0.02 for the same period last year.

For the six months ended June 30, 2008, the Company reported revenue of $3.7 million, an increase of approximately 12% as compared to the $3.3 million reported for the six months ended June 30, 2007. Operating loss for the period was $4.1 million, an increase of approximately 6% from the prior year six month period. Net loss per share for the periods ending June 30, 2008 and 2007 were $0.12 and $0.08, respectively. Included in net income was a non-cash gain of approximately $1 million in 2007, reflecting changes in the fair value of rights and warrants to purchase common shares.

Total cash and equivalents and short-term investments at June 30, 2008 totaled $5.4 million as compared to $6.8 million at December 31, 2007.

again up on good volume  8)

The Next Million-Dollar Penny Stock
Penny stocks can make you rich. Need proof? Every one of these multi-baggers was, at one time, a penny stock:

Dynamic Materials (Nasdaq: BOOM)
$10.13...Recent Price
553.5%...Five-Year Return


Meridian Bioscience (Nasdaq: VIVO)
$16.90...Recent Price
310.2%...Five-Year Return


True Religion (Nasdaq: TRLG)
$12.16...Recent Price
1,047.2%...Five-Year Return


Sterling Construction
$19.38...Recent Price
396.9%...Five-Year Return


SIGA Technologies (Nasdaq: SIGA)
$4.87...Recent Price
160.4%...Five-Year Return


Video on siga website
have you seen the this video(global impact & Defense)
http://www.siga.com/index.php?ID=72
The average person has no clue what this could do to the the world if this ever happened...


52wk Range: 1.94 - 5.86
Volume: 511,670
Avg Vol (3m): 178,527

Technicals
Last Price Quote is:
11.49%above 13-day MA
21.59%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $184.38 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2009
Last Analyst Rating: N/A

Below the 10 year chart.......

SIGA - Momentum.......

SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases.

Buy any weakness...pull back...dip

52wk Range: 1.94 - 6.33
Volume: 547,192
Avg Vol (3m): 194,379

Technicals
Record Price High

Last Price Quote is:
15.21%above 13-day MA
28.68%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $208.87 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2009
Last Analyst Rating: N/A

A pop this morning...

SIGA Technologies Inc.(NasdaqGM: SIGA)

Real Time 11.88  3.32 (38.79%) 10:31AM EDT

Last Trade: 11.60
Trade Time: 10:16AM EDT
Change:  3.04 (35.51%)
Prev Close: 8.56
Open: 12.21
Bid: 11.55 x 100
Ask: 11.62 x 500
1y Target Est: 10.88
Day's Range: 11.11 - 12.34
52wk Range: 4.83 - 12.34
Volume: 3,459,305
Avg Vol (3m): 280,174
Market Cap: 530.60M
P/E (ttm): N/A
EPS (ttm): -0.25
Div & Yield: N/A (N/A)


•InPlay: SIGA Technologies selected for the procurement of smallpox antiviral drug for the strategic national stockpile; responds to small business size protestBriefing.com(Wed 8:34AM EDT)

8:34AM SIGA Technologies selected for the procurement of smallpox antiviral drug for the strategic national stockpile; responds to small business size protest (SIGA) 8.56 : Co announces that the U.S. Department of Health and Human Services has announced its intention to make an award to co of a contract to deliver 1.7 mln courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to co's status with the Small Business Administration. The base contract is expected to generate revs of ~$500 mln, and the entire contract is expected to generate revs of ~$2.8 bln. The Small Business Administration issues derive from HHS notification to co that Chimerix has filed a small business size protest against co after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. Co intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

.•UPDATE - SIGA says to get $2.8 bln US drug contract; shares jumpat Reuters(Wed 9:44AM EDT)

Wed Oct 13, 2010 9:44am EDT

* Says Dept of Health & Human Services to give contract

* Contract to supply 1.7 mln courses of smallpox drug

* Contract pending small business protest by rival bidder

* Shares jump 44 pct

Oct 13 (Reuters) - Drugmaker SIGA Technologies Inc (SIGA.O) said it expects to get a U.S. government contract worth upto $2.8 billion if all options are exercised, to supply 1.7 million courses of its smallpox antiviral drug for the strategic national stockpile.

SIGA shares jumped 44 percent to a life-time high of $12.34 in early trading Wednesday on Nasdaq.

The contract from the U.S. Department of Health and Human Services is subject to pending resolution of certain issues as a rival bidder has filed a small business size protest against SIGA, the company said in a statement.

The base contract for the drug, codenamed ST-246, is expected to generate about $500 million in revenue, said SIGA, which develops products for use in defense against biological warfare agents.

SIGA also said it was "appropriately qualified" as a small business concern for this procurement, responding to a small business size protest filed by Chimerix Inc, an unsuccessful bidder.

The company said it intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

The drug works by blocking the ability of the virus to spread to other cells. It was given the fast-track status by the U.S. health regulators, according to SIGA website.

SIGA's shares, which have risen 25 percent since it completed successful human safety trial on the drug in June, were up $3.39 at $11.95 in morning trade. (Reporting by Shravya Jain in Bangalore; Editing by Gopakumar Warrier)

SIGA  SIGA Selected for the Procurement of Smallpox Antiviral... 


NEW YORK, Oct 13, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. (SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the U.S. Department of Health and Human Services (HHS) has announced HHS's intention to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to SIGA's status with the Small Business Administration. The award relates to a Request for Proposal issued by HHS's Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35). The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.

The Small Business Administration issues noted above derive from HHS notification to SIGA that Chimerix, Inc. (Chimerix) has filed a small business size protest against SIGA after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. HHS designated the proposed contract as a small business set-aside at the time of the original solicitation in March 2009. SIGA intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, stated, "We are very proud that HHS has selected our groundbreaking drug, ST-246(R), for this important acquisition and believe that SIGA appropriately qualified as a small business concern for this procurement."

Details of HHS's March 11, 2009 request for proposal and subsequent amendments can be found on the Federal Business Opportunities website at www.fbo.gov/index?s=opportunity&mode=form&id=61e7acbe316f2c52bfe0cc8c4b4852fd&tab=core&_cview=1 . SIGA expects the proposed contract to be executed following resolution of the Chimerix protest; however, there can be no assurance concerning the outcome of the small business size protest.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/ .

The SIGA Technologies, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding SIGA's ability to offer its products for sale to the U.S. government and statements regarding execution of the contract described above or the timing or outcome of the pending protest. Statements other than statements of historical fact are forward-looking statements, and may be identified by, among other things, forward-looking language such as the words or phrases "expect," "intend," "believe," "anticipate," "estimate," "may," "project," "scheduled to," "seek," "should," "would," "will be," "will continue," "will likely result," "targeted," or the negative of those terms, or other similar words and phrases or by discussions of intentions or plans. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete the procurement set forth in its solicitation for the acquisition of smallpox antiviral for the strategic national stockpile, or may complete it on different terms, (ix) the risk that the pending protest or another future protest may cause a contract award to us through the RFP process to be delayed or overturned, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, and (xi) the effect of federal, state, and foreign regulation on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at http://www.sec.gov . Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.


CONTACT:  KCSA Strategic Communications
Todd Fromer
212-896-1215
[email protected]
Marybeth Csaby
212-896-1236
[email protected]

SIGA Tech - biotech focusing on defense against biological warfare agents. Above the 50-day. MACD bottoming.


Technicals
Record Price High !!!
Most Actives
Record Price Break Out !!!
Gap Up
Percentage Gainer
Price Gainer

Last Price Quote is:
41.19%above 13-day MA
44.98%above 50-day MA
RS Rating: 93 

SIGA soars on government contract...

SIGA, three days ago received a contract from the government that could be worth conceivably up to $2.8bb for its smallpox antiviral product.

This potentially $2.8bb contract for SIGA is very significant for PIP, which is engaged in a lawsuit with SIGA that could be worth billions to PIP. SIGA produces the smallpox antiviral ST-246, which was just awarded the government contract. SIGA and PIP were at one point, back in 2006, planning on merging. As part of the merger agreement, it was determined that if the merger did not go through that PIP would be able to exclusively license development and marketing rights for ST-246. The merger did not go through, BUT PIP never got the license agreement. Hence, PIP sued SIGA. In my original article I asserted that this was a catalyst for PIP to go higher but it was hard to quantify that catalyst since we didn't know what sorts of revenues ST-246 could generate.

Well, now we can quantify it. Potential revenues are $2.8bb. Pharmathene is a $70mm market cap company. On the basis of this contract alone, Pharmathene would potentially make up to a billion dollars in cash earnings. So what is going on with the lawsuit ?

In July a judge reviewed SIGA's motion to dismiss the case. Note, this is the same judge that rejected an earlier motion to dismiss in January, 2008. The judge is expected to rule on the motion by the end of this month and then the court is expected to go to trial in January. I've thoroughly reviewed the transcript from July. The basic point that SIGA was making in court is that they had no idea how good (or bad) ST-246 was going to do so there was no way to assign a number to damages. The judge, though, basically made the point (I am paraphrasing) that if that were the case then anyone could walk away from any contract if the future potential of that contract was still unknown. He then implied that should the trial go forward and SIGA were to lose then he, the judge, would have the power to determine what the damages were.

However, lets forget that he said all of that. Because we now know what potential damages could be. And the number is in the billions for a $70mm market cap company.

Can the judge dismiss the case? I don't think he will. Specifically he said, "Everybody should proceed on the assumption that there is no way that I am changing the trial date." He then set a trial date for January 3, 2011.

Given that the trial is probably going through and that there is a very reasonable chance SIGA could lose (and lose billions in revenues as a result), the best result for SIGA would be to settle the case before a trial. My guess is they will settle by January. In every scenario, a settlement would benefit shares of PIP.

I have no idea what sorts of terms PIP would accept but here are some possible settlements:

A) A cash settlement between $100-400mm. Since PIP has a market cap of $70mm, this would create anywhere from a $5 to $10 per share value for PIP.

B) An ongoing royalty of 20-30% on sales of ST-246. Again, this would instantly catapult the stock up to $10+.

Most likely a settlement would be some combination of the above two (e.g. $150mm in cash, 5% royalty, etc).

On this one catalyst I think PIP is potentially a $7 - $12 stock, particularly given the two events that have occurred since my article first appeared: the court appearance, and the contract award for ST-246.

While I think this catalyst alone is enough to quadruple the stock price I don't think its the main fundamental catalyst for the company.

The main catalyst is the product that Pharmathene produces, a next-generation vaccine for Anthrax. According to this report on a military website Anthrax is considered the "DOD's Number one biological threat". The US is required to have a stockpile of 75 million doses of vaccine. Right now, the only approved supplier of doses of vaccine is EBS, which has a long-approved first-generation vaccine that requires 5 doses over 18 months and costs $120 per dose. PIP's second-generation vaccine requires 3 doses over 60 days and costs about $45 a dose, according to Eric Richman, the CEO of Pharmathene. EBS's vaccine uses live anthrax to make the vaccine, which increases the cost of and loses scalability versus a second-generation version. There are many problems with the older generation (35 years old) Anthrax vaccine from EBS which is why the government has recently approved $80mm in funding for Pharmathene to continue their work (EBS tried to protest this funding but BARDA threw out their protest).

What is the fundamental value of this vaccine? I'll quote my earlier article: "Assuming Pharmathene can build out the manufacturing processes in three years and their experimental studies continue to produce good results, a dose would cost $45. Since the only customer is the government, this essentially eliminates sales and marketing costs as well as research and development costs. Most biotech firms (think: DNDN, GENZ, GILD, HGSI) enjoy 85% margins on their products because they have to absorb those costs. PIP won't have to — although it is beholden to a single customer. Let's assume 20% net margins, or approximately $10 per dose. Let's assume the government buys 25 million of its 75 million dose requirement from PIP (remember, there is only one other competitor). That means $250 million in earnings in three years.

This alone could easily justify a stock jump to the $7-10 level, or even significantly higher. Also, once the U.S. starts buying, there will be demand from outside the country. This does not factor in significant government funding for several other products including Protexia, a nerve gas vaccine." Note that PIP does not need FDA approvals to start selling the to the government but that they have already tested for safety (no issues) and efficacy in animals (depending on the test, they are 85-100% effective).

So $5-10 in value from the SIGA lawsuit and another $7-10 from their Anthrax vaccine leaves PIP with a $14-$22 stock from these levels, much how SIGA has gone from below $2 to $13 in the past 4 years and EBS has gone from $5 to 20 in the past 3 years. Given these two completely separate catalysts I also think downside is minimal.

Disclosure: Long PIP

Another pop for SIGA.......
not really sure of the numbers, but with a contract, and projections of anywhere from $500 million to $2.8 billion, the game has changed quite a bit.

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
32.19%above 13-day MA
57.53%above 50-day MA
RS Rating: 96 

Quote from: setravis on April 10, 2009, 08:50:39 PM
The Next Million-Dollar Penny Stock
Penny stocks can make you rich. Need proof? Every one of these multi-baggers was, at one time, a penny stock:

Dynamic Materials (Nasdaq: BOOM)
$10.13...Recent Price
553.5%...Five-Year Return


Meridian Bioscience (Nasdaq: VIVO)
$16.90...Recent Price
310.2%...Five-Year Return


True Religion (Nasdaq: TRLG)
$12.16...Recent Price
1,047.2%...Five-Year Return


Sterling Construction
$19.38...Recent Price
396.9%...Five-Year Return


SIGA Technologies (Nasdaq: SIGA)
$4.87...Recent Price
160.4%...Five-Year Return


Video on siga website
have you seen the this video(global impact & Defense)
http://www.siga.com/index.php?ID=72
The average person has no clue what this could do to the the world if this ever happened...

SIGA SIGA to Discuss Third Quarter Results of Operations on Novem... 


NEW YORK, Oct 29, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. (SIGA, Trade ), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report third quarter 2010 results on Tuesday, November 2, 2010.

Management will host a conference call and simultaneous webcast to discuss the results of operations and provide an update on recent business developments at 4:30 P.M. ET on Tuesday, November 2, 2010. Participants should call (877) 564-1219 (United States/Canada) or (973) 638-3429 (International) and request the SIGA call or provide confirmation code 22244336. A live broadcast of the call will be available on the Company's website at www.SIGA.com under the 'Events & Presentations' tab in the Investor Relations section.

A replay of the call will be available approximately two hours after the call and will be accessible until 11:59 p.m. on Tuesday, November 9, 2010. To listen to the replay, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter the pass code 22244336. The webcast of the event will also be archived on the Company's website for one year under the 'Events & Presentations' tab in the Investor Relations section.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/ .

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.


CONTACT:  KCSA Strategic Communications
Todd Fromer
212-896-1215
[email protected]
Marybeth Csaby
212-896-1236
[email protected]

SIGA  New Smallpox Antiviral Procurement Commenced 
by GlobeNewswire  Feb 21 2011 9:35PM

NEW YORK, Feb 21, 2011 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. (SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, has advised that it is issuing a new Request for Proposal, number 11-100-SOL-00007, seeking to procure 1.7 million courses of a smallpox antiviral. The Request for Proposal also proposes that the contract would contain an option to procure up to 12 million additional courses. BARDA's previous Request for Proposal on this subject, number 09-35, has been cancelled. Responses to the new Request for Proposal are due February 28, 2011.

Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, noted, "This new Request for Proposal confirms the Government's commitment to a robust biodefense and the procurement of meaningful, new medical countermeasures against the most serious biothreats. SIGA intends to respond to this Request for Proposal, and we believe that we are well positioned to meet the Government's needs."

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/ .

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain "forward-looking statements"' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding possible terms of procurement of a smallpox antiviral and SIGA's ability to offer its products for sale to the U.S. government. Statements other than statements of historical fact are forward-looking statements, and may be identified by, among other things, forward-looking language such as the words or phrases "expect," "intend," "believe," "anticipate," "estimate," "may," "project," "scheduled to," "seek," "should," "would," "will be," "will continue," "will likely result," "targeted," or the negative of those terms, or other similar words and phrases or by discussions of intentions or plans. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete a procurement of a smallpox antiviral for the strategic national stockpile, or may complete it on terms other than those announced to date, (ix) the risk that any contractual award SIGA may receive to supply a smallpox antiviral may be subject to one or more protests, which may cause such contract award to be delayed or denied, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, and (xi) the effect of federal, state, and foreign regulation on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at http://www.sec.gov . Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.


CONTACT: KCSA Strategic Communications
Todd Fromer / Marybeth Csaby
212-896-1215 / 1236
[email protected] / [email protected]

SIGA Technologies (SIGA) announced that the Biomedical Advanced Research and Development Authority
has advised that it is issuing a new Request for Proposal seeking to procure 1.7 million courses of a smallpox antiviral. The Request for Proposal also proposes that the contract would contain an option to procure up to 12 million additional courses.  Responses to the new Request for Proposal are due February 28, 2011.

Day's Range: 13.12 - 14.34
52wk Range: 6.03 - 14.38
Volume: 1,427,620
Avg Vol (3m): 356,967
Market Cap: 659.26M
P/E (ttm): N/A
EPS (ttm): -0.28
Div & Yield: N/A (N/A)

Technicals
Gap Up
Percentage Gainer

Last Price Quote is:
19.90%above 13-day EMA
13.64%above 50-day EMA
RS Rating: 73